Rank	NCT Number	Title	Recruitment	Study Results	Conditions	Interventions	Sponsor/Collaborators	Gender	Age Groups	Phases	Enrollment	Funded Bys	Study Types	Study Designs	Other IDs	First Received	Start Date	Completion Date	Last Updated	Last Verified	Results First Received	Acronym	Primary Completion Date	Outcome Measures	URL
1	NCT02571972	Dorzolamide-timolol Eye Drops Given With Eye Injections to Treat Age-related Macular Degeneration	Completed	No Results Available	Wet Macular Degeneration|Age-related Macular Degeneration	Drug: Dorzolamide-timolol	Wills Eye|J. Arch McNamara Research Fund|Mid Atlantic Retina	Both	Adult|Senior	Phase 2	15	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	IRB#14-435	October 6, 2015	October 2014	September 2015	October 6, 2015	October 2015	No Study Results Posted	null	September 2015	Mean central macular thickness (CMT)|Visual acuity|Maximum subretinal fluid height|Maximum pigment epithelial detachment height	https://ClinicalTrials.gov/show/NCT02571972
2	NCT01773954	Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration	Active, not recruiting	No Results Available	Age-Related Macular Degeneration|Macular Degeneration	Drug: Intravitreal Aflibercept Injection More|Drug: Intravitreal Aflibercept Injection Less	Brian Burke, MPH|Regeneron Pharmaceuticals|Wills Eye	Both	Adult|Senior		40	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ATLAS|20122054	January 17, 2013	December 2012	November 2014	May 27, 2014	May 2014	No Study Results Posted	ATLAS	November 2014	Mean change in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) letter score|Percentage of eyes with complete resolution of macular fluid on OCT	https://ClinicalTrials.gov/show/NCT01773954
3	NCT02140151	Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration	Recruiting	No Results Available	Age-related Macular Degeneration	Drug: Ranibizumab 0.5mg	Southern California Desert Retina Consultants, MC	Both	Adult|Senior	Phase 1|Phase 2	100	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor)	ML29258	April 25, 2014	September 2014	September 2017	May 22, 2015	May 2015	No Study Results Posted	PREVENT	September 2017	Development of exudative AMD|Vision change|Vision loss|Number of injections|Baseline predictive factors|Development of geographic atrophy (GA)|Ocular adverse events|Systemic adverse events	https://ClinicalTrials.gov/show/NCT02140151
4	NCT02204683	A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).	Recruiting	No Results Available	Neovascular Macular Degeneration	Drug: Aflibercept	University of Nebraska|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 1	15	Other|Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label	334-14-FB	July 28, 2014	July 2014	July 2017	August 11, 2015	August 2015	No Study Results Posted	DRAW	July 2016	Pharmacokinetic (PK) aflibercept aqueous|PK Aflibercept plasma	https://ClinicalTrials.gov/show/NCT02204683
5	NCT02541084	Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan	Recruiting	No Results Available	Wet Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Bayer	Both	Child|Adult|Senior		200	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	17945	August 5, 2015	August 2015	January 2016	October 8, 2015	October 2015	No Study Results Posted	null	December 2015	Burden Index of Caregivers (BIC-11)|Co-relation between score of BIC11 and the number of Medical Visits|Frequency of medical visits by caregivers|Time spent by accompanying caregivers for a clinic visit for wAMD management (minutes)|Estimated costs spent by accompanying caregivers on hospital visits for wAMD management|Center for Epidemiologic Studies Depression Scale (CES-D) Score|Types of treatments for wAMD|Frequency of treatments|Length of treatment|Dosing schedule	https://ClinicalTrials.gov/show/NCT02541084
6	NCT02222207	Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration	Completed	No Results Available	Macular Degeneration	Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506)|Procedure: Sham IVT|Drug: Ranibizumab|Drug: Placebo	Bayer	Both	Adult|Senior	Phase 2	52	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	15984|2012-003763-22	August 20, 2014	October 2014	June 2015	August 14, 2015	August 2015	No Study Results Posted	DREAM	May 2015	Change in BCVA (Best corrected visual acuity) from baseline to week 4 for study part A|Change in BCVA from baseline to week 12 for study part A|Change in BCVA from baseline to week 4 for study part B|Change in BCVA from baseline to week 12 for study part B|Proportion of subjects with individual changes in BCVA of ≥ 0 letters of vision for study part A|Proportion of subjects with a loss of ≥ 10 letters for study part A|Proportion of subjects with individual changes in BCVA of ≥ 0 letters of vision for study part B|Proportion of subjects with a loss of ≥ 10 letters for study part B	https://ClinicalTrials.gov/show/NCT02222207
7	NCT02060604	Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration	Completed	No Results Available	Wet Macular Degeneration	Drug: Ketorolac + Ranibizumab|Drug: Ranibizumab	Università degli Studi di Brescia	Both	Adult|Senior	Phase 4	60	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	NSAIDs_01	February 8, 2014	December 2012	January 2014	February 8, 2014	February 2014	No Study Results Posted	null	January 2014	mean change in study eye visual acuity as measured by the best-corrected ETDRS letter score|mean change in central macular thickness|mean number of intravitreal injections over the 12-month period|adverse ocular events at 12 months	https://ClinicalTrials.gov/show/NCT02060604
8	NCT02540954	Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)	Not yet recruiting	No Results Available	Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Bayer	Both	Adult|Senior	Phase 3	330	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	16598|2013-000120-33	September 2, 2015	September 2015	June 2018	September 30, 2015	September 2015	No Study Results Posted	null	June 2018	Change in Early Treatment Diabetic Retinopathy Study best corrected visual acuity (EDTRS BCVA) letter score for the study eye|Number of participants with adverse events as measure of safety and tolerability|Proportion of subjects maintaining vision (i.e. loss of < 15 letters) in the study eye|Proportion of subjects who gained from baseline ≥ 5 letters in the study eye|Mean change from baseline in central retinal thickness (CRT) in the study eye|Mean change from baseline in choroidal neovascularization (CNV) area in the study eye|Proportion of subjects who lost ≥ 30 letters|Mean change from baseline in total score for National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25)	https://ClinicalTrials.gov/show/NCT02540954
9	NCT02305238	Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration	Recruiting	No Results Available	Wet Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Bayer|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 4	250	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	17668	November 28, 2014	December 2014	December 2017	October 8, 2015	October 2015	No Study Results Posted	ALTAIR	December 2016	Mean change from baseline in best-corrected visual acuity (BCVA) as measured by Early Treatment Diabetic Retinopathy Study(ETDRS) letter score at week 52|Proportion of subjects who maintain vision at Week 52|Proportion of subjects who gain at least 15 letters of vision compared to baseline at Week 52|Mean change in Central Retinal Thickness (CRT) from baseline at Week 52|Proportion of subjects without fluid on Optical coherence tomography (OCT) at Week 52|Number of participants with adverse events as a measure of safety and tolerability	https://ClinicalTrials.gov/show/NCT02305238
10	NCT02348359	X-82 to Treat Age-related Macular Degeneration	Recruiting	No Results Available	Age-Related Macular Degeneration (AMD)|Macular Degeneration|Exudative Age-related Macular Degeneration|AMD|Macular Degeneration, Age-related, 10|Eye Diseases|Retinal Degeneration|Retinal Diseases	Drug: X-82|Drug: Aflibercept|Drug: Placebo	Tyrogenex	Both	Adult|Senior	Phase 2	132	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	X82-OPH-201	January 21, 2015	March 2015	November 2016	May 15, 2015	May 2015	No Study Results Posted	null	October 2016	Mean Change in Visual Acuity Score From Day -1 to Week52	https://ClinicalTrials.gov/show/NCT02348359
11	NCT01835067	Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration	Recruiting	No Results Available	Exudative Macular Degeneration|Retinal Hemorrhage	Drug: Ranibizumab|Drug: C3F8 Gas|Drug: tPA	King's College Hospital NHS Trust	Both	Adult|Senior	Phase 2|Phase 3	55	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	EudraCT Number: 2012-004078-24	April 16, 2013	September 2013	November 2017	August 14, 2015	July 2015	No Study Results Posted	TAPAS	November 2017	Mean ETDRS visual acuity|Percentage patients 15 letters or greater improvement in ETDRS visual acuity|Percentage patients 0 letters or greater improvement in ETDRS visual acuity|Percentage patients 15 letters or greater loss in ETDRS visual acuity|Mean total area of macular haemorrhage on colour fundus photography|Greatest linear dimension of macular haemorrhage on colour fundus photography|Presence of subfoveal blood on colour fundus photography	https://ClinicalTrials.gov/show/NCT01835067
12	NCT02157077	Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration	Active, not recruiting	No Results Available	Macular Degeneration|Wet Macular Degeneration|Retinal Degeneration|Retinal Diseases|Eye Diseases	Drug: Aflibercept	Centre Hospitalier Intercommunal Creteil|Bayer	Both	Adult|Senior	Phase 3	90	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CHIC-ARI2|2013-002869-19	March 2, 2014	December 2013	December 2015	September 21, 2015	September 2015	No Study Results Posted	ARI2	December 2015	Change from baseline in maximal height of pigment epithelium detachment (PED) at 12 weeks|Change from baseline in central retinal thickness by SD OCT at 12 weeks|Change from Baseline in visual acuity at 12 weeks|Change from Baseline in volume of pigment epithelium detachment at 12 weeks|Association with genes involved in AMD history|Number of participants with adverse events from baseline to 32 weeks|Change from Baseline in pigment epithelium detachment height at 12 weeks|Change from baseline in central retinal thickness at 32 weeks|Change from Baseline in pigment epithelium detachment height at 32 weeks|Change from Baseline in visual acuity at 32 weeks|Change from Baseline in volume of pigment epithelium detachment at 32 weeks	https://ClinicalTrials.gov/show/NCT02157077
13	NCT02540369	Study to Assess the Treatment Patterns of Physicians Prescribing Eylea to Treat Wet Age-related Macular Degeneration and Diabetic Macular Edema in Clinics Across Canada	Not yet recruiting	No Results Available	Wet Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Bayer	Both	Adult|Senior		2000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	17995	August 5, 2015	October 2015	May 2018	September 28, 2015	September 2015	No Study Results Posted	PEGASUS	September 2017	Mean change of visual acuity|Mean change in Retinal thickness|Treatment patterns used in routine clinical practice setting|Number of injections at 12 months|Time to achieve stability|Presence/absence of pigment epithelial detachment (PED) (Y/N)|Proportion of patients with no fluid determined by Optical coherence tomography (OCT) at 4 months and 12 months|Maximum treatment interval|Mean time between injections|Number of participants with adverse events as a measure of safety and tolerability|In the switch subpopulation duration of previous treatments|In the switch subpopulation reason to switch to Eylea|Number of patients require adjunctive therapies|Number of injections in a year to acheive stability|In the switch subpopulation type of previous treatments	https://ClinicalTrials.gov/show/NCT02540369
14	NCT02555306	A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: DE-122	Santen Inc.	Both	Adult|Senior	Phase 1|Phase 2	12	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	36-001	September 13, 2015	September 2015	August 2016	October 6, 2015	October 2015	No Study Results Posted	null	August 2016	Number of subjects with adverse events|Change from Baseline in central subfield thickness (CST)|Change from Baseline in macular volume|Change from Baseline in Best Corrected Visual Acuity	https://ClinicalTrials.gov/show/NCT02555306
15	NCT01833325	Proton Radiation Therapy for Macular Degeneration	Recruiting	No Results Available	Age-Related Macular Degeneration	Radiation: Proton radiation	University of Florida	Both	Adult|Senior	Phase 1	10	Other	Interventional	Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	UFPTI 1206-EY01	March 27, 2013	May 2013	March 2018	October 14, 2015	October 2015	No Study Results Posted	null	March 2018	Number of participants with acute and late morbidity of the eye as a measure of safety|Number of participants with cessation of growth of neovascular membranes.|Visual acuity per comprehensive eye exam|Frequency of intravitreal injections following radiation treatment	https://ClinicalTrials.gov/show/NCT01833325
16	NCT02530918	Study of DS-7080a for the Treatment of Neovascular Age-Related Macular Degeneration	Recruiting	No Results Available	Neovascular Age-Related Macular Degeneration	Drug: DS-7080a|Drug: Ranibizumab	Daiichi Sankyo Inc.	Both	Adult|Senior	Phase 1	45	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	DS7080-A-U101	August 17, 2015	July 2015	June 2017	August 24, 2015	August 2015	No Study Results Posted	null	March 2017	Number and severity of adverse events|Best Corrected Visual Acuity (BCVA) score|DS-7080a reduction in retinal thickness and volume|DS-7080a reduction in retinal leakage|DS-7080a plasma concentrations	https://ClinicalTrials.gov/show/NCT02530918
17	NCT02564978	Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration	Recruiting	No Results Available	Age- Related Macular Degeneration	Drug: Minocycline|Other: Placebo	National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)	Both	Adult|Senior	Phase 2	66	NIH	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	150202|15-EI-0202	September 30, 2015	September 2015	March 2019	September 30, 2015	September 2015	No Study Results Posted	null	June 2017	Rate of change in area of GA based on masked grading by an external Reading Center of fundus autofluorescence (FAF) images in the assigned study eye.|Number and severity of adverse events (AEs).|Ocular safety outcomes will be indicated by changes in VA, ocular surface changes, intraocular inflammation and any other ocular changes not consistent with the natural progression of GA.|Changes in best-corrected visual acuity (BCVA), changes in low-luminance VA, rate of change in area of GA based on fundus photography, development of exudative AMD ascertained using optical coherence tomography (OCT), and changes in macular sens...	https://ClinicalTrials.gov/show/NCT02564978
18	NCT02355028	LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration	Recruiting	No Results Available	Exudative Age-Related Macular Degeneration	Drug: LHA510 ophthalmic suspension|Drug: LHA510 vehicle|Drug: Ranibizumab ophthalmic solution	Alcon, a Novartis Company|Alcon Research	Both	Adult|Senior	Phase 2	60	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	LHA510-2201	January 28, 2015	March 2015	April 2016	September 25, 2015	September 2015	No Study Results Posted	null	April 2016	Number of patients requiring Lucentis® retreatment before or at Day 84|Time to first injection of Lucentis® required up to Day 84|Number of Lucentis® injections required up to Day 84|Change from Eligibility (Day -1) in central subfield thickness total (CSFTtot) at each visit|Change from Eligibility (Day -1) in Best Corrected Visual Acuity (BCVA) at each visit|Change from Eligibility (Day -1) in central retinal lesion thickness (CRLT) at each visit|Change from Eligibility (Day -1) in lesion thickness at each visit|Change from Eligibility (Day -1) in subretinal fluid - foveal involvement (SRFfi) thickness at each visit|Change from Eligibility (Day -1) in pigment epithelial detachment - foveal involvement (PEDfi) thickness at each visit|Change from Eligibility (Day -1) in total lesion size at each visit|Change from Eligibility (Day -1) in CNV size at each visit|The observed maximum plasma (or serum or blood) concentration following drug administration [mass / volume] (Cmax)	https://ClinicalTrials.gov/show/NCT02355028
19	NCT01918878	Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.	Active, not recruiting	No Results Available	Neovascular Age-related Macular Degeneration	Drug: Aflibercept (EYLEA)	Hadassah Medical Organization|Bayer	Both	Adult|Senior	Phase 4	48	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CHO123-HMO-CTIL	August 7, 2013	October 2013	December 2015	September 20, 2015	September 2015	No Study Results Posted	null	December 2015	Central macular thickness change|change in best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity and Change in CNV size	https://ClinicalTrials.gov/show/NCT01918878
20	NCT02224963	Macular Degeneration and Aging Study	Active, not recruiting	No Results Available	Age-related Macular Degeneration	Behavioral: Preventive Problem-Solving Training|Behavioral: Life and Health Review	University of Rochester|Dartmouth-Hitchcock Medical Center|Association for the Blind and Visually Impaired	Both	Adult|Senior		250	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Outcomes Assessor)	AG 032032	July 3, 2014	May 2009	June 2017	December 2, 2014	December 2014	No Study Results Posted	MADAS	June 2016	Psychological Well-being|Change in Preparation for Future Care|Preparation for Future Care	https://ClinicalTrials.gov/show/NCT02224963
21	NCT01831947	Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.	Completed	No Results Available	Macular Degeneration	Biological: Ranibizumab	Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|Novartis Pharmaceuticals|University Medical Center Goettingen	Both	Adult|Senior	Phase 4	40	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	CRFB002ADE09T	April 11, 2013	April 2010	March 2013	April 11, 2013	April 2013	No Study Results Posted	RABIMO	March 2013	best-corrected visual acuity|Fluoresceinangiography|Photography|optical coherence tomography (OCT)|number of injections|quality of life	https://ClinicalTrials.gov/show/NCT01831947
22	NCT01782352	Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)	Active, not recruiting	No Results Available	Age-related Macular Degeneration	Drug: Omega-3 fatty acids (fish oil)|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin D3 placebo|Dietary Supplement: Fish oil placebo	Brigham and Women's Hospital|National Eye Institute (NEI)	Both	Adult|Senior		25875	Other|NIH	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	2012P001797|R01EY021900|2012P000724	January 31, 2013	July 2010	October 2017	May 29, 2014	May 2014	No Study Results Posted	null	October 2017	Age-related macular degeneration	https://ClinicalTrials.gov/show/NCT01782352
23	NCT02452840	Photodynamic Therapy for PDA in NV AMD	Recruiting	No Results Available	Neovascular Age-related Macular Degeneration|Macular Degeneration	Other: No Intervention	Duke University|Bausch & Lomb Incorporated	Both	Adult|Senior		100	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	Pro00057705	May 21, 2015	October 2014	October 2021	May 21, 2015	May 2015	No Study Results Posted	null	October 2016	Percentage of subjects with resolution of PDA|Mean change in best-corrected ETDRS visual acuity from baseline|Percentage of subjects with 2-line ETDRS visual acuity gain from baseline|Percentage of subjects with 2-line ETDRS visual acuity loss from baseline|Mean change in central foveal thickness by SD-OCT from baseline|Mean change in choroidal neovascularization lesion size by fluorescein angiography from baseline	https://ClinicalTrials.gov/show/NCT02452840
24	NCT02024269	Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration	Withdrawn	No Results Available	Dry Macular Degeneration	Biological: Adipose Derived Stem Cells	Bioheart, Inc.	Both	Adult|Senior		0	Industry	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ADI-US-AMD-001	December 17, 2013	December 2013	June 2017	September 15, 2015	September 2015	No Study Results Posted	null	December 2016	frequency and nature of adverse events|Visual Field analysis (10-2)|Visual Acuity Measurements|Intraocular pressure	https://ClinicalTrials.gov/show/NCT02024269
25	NCT02036723	Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration	Not yet recruiting	No Results Available	Wet Age-related Macular Degeneration	Drug: Bevacizumab|Drug: Ranibizumab	Biocad	Both	Adult|Senior	Phase 3	108	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	GALATIR/BCD-021-3|GALATIR	January 13, 2014	December 2015	February 2017	February 5, 2015	February 2015	No Study Results Posted	GALATIR	December 2016	• Proportion of patients losing fewer than 15 letters on EDTRS chart at month 12|• Frequency of ocular and systemic adverse events (AE) and serious adverse events (SAE) that are related, in Investigator's opinion, to AMD therapy|• Frequency of AE and SAE with toxicity level of 3-4 that are related, in Investigator's opinion, to AMD therapy|• Number of cases of early withdrawal from the study caused by AE or SAE|• Number of patients who have binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12|• The mean titer of binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12|• Mean change in VA score, measured on the EDTRS scale at month 12|• Average number of injections and time before re-injection|• Lesion size at month 6 and month 12 (by angiography)|• Lesion leakage at month 6 and month 12|• Change in fluid and foveal thickness on OCT during the study|• Retinal sensitivity measured by microperimetry at screening, at month 6 and month 12|• Timing of visual improvement after initiation of therapy	https://ClinicalTrials.gov/show/NCT02036723
26	NCT02261194	Effect of a Self-care Intervention on Depression in People With Age-related Macular Degeneration	Recruiting	No Results Available	Depression|Age-related Macular Degeneration	Behavioral: Self-Care Tools	Maisonneuve-Rosemont Hospital|Fonds de la Recherche en Santé du Québec|Fondation Antoine Turmel	Both	Adult|Senior		68	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	Réseau Vision Freeman	October 2, 2014	October 2014	null	February 20, 2015	February 2015	No Study Results Posted	null	August 2016	Change in depressive symptoms|Change in general health status|Change in severity of anxiety symptoms|Change in self-efficacy|Change in life space|Change in social and leisure-time activities|Change in medication adherence	https://ClinicalTrials.gov/show/NCT02261194
27	NCT02314299	A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration	Recruiting	No Results Available	Diabetic Macular Edema|Age-related Macular Degeneration	Drug: MTP-131	Stealth BioTherapeutics Inc.	Both	Adult|Senior	Phase 1|Phase 2	21	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment|Masking: Open Label	SPIOC-101	December 2, 2014	November 2014	July 2015	December 10, 2014	December 2014	No Study Results Posted	SPIOC-101	May 2015	Incidence and severity of systemic and ocular adverse events|Change from Baseline in vital sign measurements|Change from Baseline in best corrected visual acuity (BCVA) as measured with the early treatment diabetic retinopathy study (ETDRS) scale|Change from Baseline in slit lamp examinations|Change from Baseline in intraocular pressure|Change from Baseline in dilated fundoscopic examinations|Change from Baseline in central subfield thickness|Change in central subfield thickness|Change from Baseline in widefield angiography|Change from Baseline in fundus autofluorescence pattern including the occurrence of and aggregate size of areas of macular atrophy	https://ClinicalTrials.gov/show/NCT02314299
28	NCT02022501	A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration	Active, not recruiting	No Results Available	Age-Related Macular Degeneration	Drug: DE-120	Santen Inc.	Both	Adult|Senior	Phase 1|Phase 2	9	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	35-001	December 20, 2013	January 2014	June 2016	January 14, 2015	January 2014	No Study Results Posted	null	June 2016	Number of subjects with adverse events|Change from Baseline in central subfield thickness (CST)|Change from Baseline in macular volume|Drug concentration in plasma over time after a single injection of DE-120|Change from Baseline in ocular signs and symptoms	https://ClinicalTrials.gov/show/NCT02022501
29	NCT02401945	A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: DE-120|Drug: Aflibercept	Santen Inc.	Both	Adult|Senior	Phase 2	30	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	35-002	March 20, 2015	April 2015	September 2016	May 18, 2015	May 2015	No Study Results Posted	VAPOR1	May 2016	Mean change from baseline in BCVA at Month 8|Change from baseline in total lesion area at Month 8|Change from baseline in greatest linear dimension of the area of leakage at Month 8|Change in Central Subfield Thickness at Month 8	https://ClinicalTrials.gov/show/NCT02401945
30	NCT01835015	Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration	Completed	No Results Available	Age-related Macular Degeneration	Drug: CLG561	Alcon Research	Both	Adult|Senior	Phase 1	50	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label	C-12-074	April 16, 2013	May 2013	November 2014	November 11, 2014	November 2014	No Study Results Posted	null	November 2014	Change from Baseline in Best Corrected Visual Acuity (BCVA)|Intra-Ocular Pressure (IOP)|Change from Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to Baseline Assessment|Change from Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Baseline Assessment|Area under the serum concentration-time curve from time zero to infinity [AUC(0-∞)]|Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-tlast)]|Area under the serum concentration-time curve from time zero to time "t" where t is a defined time point after administration [AUC(0-t)]|Time to reach the maximum serum concentration after drug administration (Tmax)|Dose normalized observed maximum serum concentration following drug administration (Cmax/D)|Dose-normalized area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUC/D)|Terminal elimination half-life (T½)|The apparent volume of distribution during the terminal elimination phase following extravascular administration (Vz/F)|Apparent systemic (or total body) clearance from serum following extravascular administration (CL/F)	https://ClinicalTrials.gov/show/NCT01835015
31	NCT02002377	Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Monthly Ranibizumab Injections	Recruiting	No Results Available	Age Related Macular Degeneration	Drug: Aflibercept	St. Michael's Hospital, Toronto	Both	Adult|Senior	Phase 4	200	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	01	November 29, 2013	April 2014	December 2017	July 30, 2015	July 2015	No Study Results Posted	SHIFT-2	December 2015	'OCT defined success' defined by no presence of intra or sub retinal fluid on SDOCT|Change in central retinal thickness (CRT)|Change in Early Treatment Diabetic Retinopathy Study best-corrected visual acuity	https://ClinicalTrials.gov/show/NCT02002377
32	NCT02076919	First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration	Completed	Has Results	Age-Related Macular Degeneration	Drug: LHA510 Ophthalmic Suspension|Drug: LHA510 Vehicle	Alcon Research	Both	Adult|Senior	Phase 1	110	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)	C-13-007	February 28, 2014	February 2014	June 2014	August 5, 2015	August 2015	June 30, 2015	null	June 2014	Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 1|Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 2|Number of Subjects Experiencing a Non-serious Adverse Event, Part I|Number of Subjects Experiencing a Non-serious Adverse Event, Part 2|The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration [Mass / Volume] (Cmax), Part 2|The Time to Reach the Maximum Concentration After Drug Administration [Time] (Tmax), Part 2|The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [Mass x Time/Volume] (AUClast), Part 2|The Terminal Elimination Half-life [Time] (T1/2), Part 2|Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 1|Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 1|Change From Baseline in Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 1|Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 2|Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 2|Change From Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 2	https://ClinicalTrials.gov/show/NCT02076919
33	NCT01899963	Time to Treatment Utilizing a Tele-Retinal Referral System for Wet Age Related Macular Degeneration and Diabetic Macular Edema: A Pilot Study	Recruiting	No Results Available	Wet Age Related Macular Degeneration|Diabetic Macular Edema		McMaster University	Both	Adult|Senior		165	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Tele-retinal Referral T.T.T.	July 9, 2013	November 2013	April 2015	November 15, 2013	November 2013	No Study Results Posted	null	December 2014	Time to Treatment|Maximum wait time|Minimum Wait Time|Mean wait time|Travel time|Travel Distance	https://ClinicalTrials.gov/show/NCT01899963
34	NCT01914380	Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration	Active, not recruiting	No Results Available	Wet Age-related Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Bayer	Both	Child|Adult|Senior		988	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	16623|EY1313DE	July 23, 2013	July 2013	June 2017	August 13, 2015	August 2015	No Study Results Posted	PERSEUS	March 2017	Mean change of visual acuity for the total patient population|Mean change of visual acuity for the subgroup of pretreated patients|Mean change of visual acuity for the subgroup of non-pretreated patients|Monitoring of disease activity|Monitoring of treatment patterns|Mean time from indication of Eylea-treatment by the treating physician to start of treatment	https://ClinicalTrials.gov/show/NCT01914380
35	NCT02005133	A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics	Recruiting	No Results Available	Wet Age-related Macular Degeneration		Novartis Pharmaceuticals|Novartis	Both	Adult|Senior		200	Industry	Observational	Time Perspective: Prospective	CRFB002AGB16	December 3, 2013	November 2013	April 2016	June 2, 2015	June 2015	No Study Results Posted	null	April 2016	Frequency of aflibercept administration|Frequency of clinic visits|Aflibercept Administration|Changes in visual acuity from baseline|Change in central retinal thickness from baseline	https://ClinicalTrials.gov/show/NCT02005133
36	NCT02395757	Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD)	Not yet recruiting	No Results Available	Stage 3 Age Related Macular Degeneration (AREDS Classification)	Device: MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)	Hospices Civils de Lyon|Novartis	Both	Adult|Senior		300	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	2014.862	February 20, 2015	March 2015	March 2018	March 23, 2015	March 2015	No Study Results Posted	PREVISION	March 2017	The sensitivity of the microperimetric parameter(s) and combination(s) of parameters according to patient status at final assessment.|The specificity of the microperimetric parameter or combination of parameters with the highest level of sensitivity|The positive predictive value of the microperimetric parameter or combination of parameters with the highest level of sensitivity|The negative predictive value of the microperimetric parameter or combination of parameters with the highest level of sensitivity|The sensitivity of the microperimetric parameters associated with the parameters from other ophthalmological examinations.|The specificity of the microperimetric parameters associated with the parameters from other ophthalmological examinations.|The sensitivity of the microperimetric parameters or combinations of parameters for the sub-group of eyes presenting reticular pseudodrusen at inclusion.|The specificity of the microperimetric parameters or combinations of parameters for the sub-group of eyes presenting reticular pseudodrusen at inclusion.	https://ClinicalTrials.gov/show/NCT02395757
37	NCT02142296	Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)	Not yet recruiting	No Results Available	Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration	Drug: Eylea	Lawson Health Research Institute	Both	Adult|Senior	Phase 4	48	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Bayer-001-PED	May 16, 2014	May 2014	May 2017	May 19, 2014	May 2014	No Study Results Posted	null	May 2017	efficacy of Eylea in patients with RPED|safety and tolerability of repeated Eylea injection|effect of repeated Eylea injections of Central Subfield Thickness , Central Subfield Volume and PED height and volume|effect of repeated Eyle injections on vision related quality of life	https://ClinicalTrials.gov/show/NCT02142296
38	NCT02121522	A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration	Completed	No Results Available	Wet Macular Degeneration	Drug: BI 144807	Boehringer Ingelheim	Both	Adult|Senior	Phase 2	14	Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	1313.20|2013-004567-30	April 22, 2014	June 2014	April 2015	May 10, 2015	May 2015	No Study Results Posted	null	March 2015	Change from baseline in 1mm central retinal thickness as measured by SD-OCT|Change in neovascular leakage by fluorescein angiography from baseline	https://ClinicalTrials.gov/show/NCT02121522
39	NCT02289924	Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy	Recruiting	No Results Available	Wet Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Bayer	Both	Child|Adult|Senior		800	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	17634|EY1415IT	November 10, 2014	January 2015	August 2018	October 9, 2015	October 2015	No Study Results Posted	PERSEUS-IT	December 2017	Mean change of visual acuity from baseline to 12 months|Mean change of visual acuity from baseline to 24 months.|Number of clinical visits (visits for injections)|Number of monitoring visits (visits only for diagnostic purposes, but without injections)|Number of combined visits (visits for monitoring and injection)|Number of post-injection monitoring visits (visits only for safety checks after injection)|Number of visits outside the study center after 12 and 24 months|Number of optical coherence tomography (OCT) assessments per patient|Number of visual acuity tests|Number of fundoscopy examinations|Mean time between the injections and visits|Mean time between the first symptoms and diagnosis|Mean time from indication of the Eylea treatment by the treating physician to treatment|Proportion of patients with no fluid|Mean change in retinal thickness from baseline	https://ClinicalTrials.gov/show/NCT02289924
40	NCT01896284	Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor	Not yet recruiting	No Results Available	Wet Macular Degeneration	Drug: 0.5mg aflibercept	Barcelona Macula Foundation|TFS Trial Form Support|Bayer	Both	Adult|Senior	Phase 4	43	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	BMF-AFLI-2013-01|2013-000848-26	July 8, 2013	July 2013	March 2015	July 10, 2013	July 2013	No Study Results Posted	MACBETH	March 2014	Percentage of patients with no fluid on Optical Coherence Tomography (OCT) after loading dose of aflibercept|Changes in best corrected visual acuity (BCVA)after loading dose|Changes in OCT central foveal thickness after loading dose|Anatomic and Visual Acuity outcomes maintained during (every 8 weeks) treatment.|Determine the time to resolution of any intra/sub retinal fluid on OCT|Describe safety of this cohort of patients	https://ClinicalTrials.gov/show/NCT01896284
41	NCT02511613	Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: Squalamine Lactate Ophthalmic Solution, 0.2%|Drug: Placebo Ophthalmic Solution|Drug: ranibizumab	Ohr Pharmaceutical Inc.	Both	Adult|Senior	Phase 2	20	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	OHR-1501	July 27, 2015	July 2015	April 2016	July 28, 2015	July 2015	No Study Results Posted	null	April 2016	Effect of combination therapy of ranibizumab monthly intravitreal injections with Squalamine Lactate Ophthalmic Solution, 0.2% on anatomy and function as assessed by retinal imaging and ETDRS BCVA in subjects with Age-Related Macular Degeneration	https://ClinicalTrials.gov/show/NCT02511613
42	NCT02398500	Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration	Recruiting	No Results Available	Age-related Macular Degeneration (AMD)	Biological: LMG324|Biological: Ranibizumab 0.5 mg|Biological: Sham	Alcon Research|Novartis Institutes for BioMedical Research (NIBR)	Both	Adult|Senior	Phase 1|Phase 2	106	Industry|Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	LMG324-2201|2014‐005214‐37	March 20, 2015	July 2015	February 2017	October 13, 2015	October 2015	No Study Results Posted	null	February 2017	Mean change from baseline in best corrected visual acuity (BCVA) at Day 85|Percentage of LMG324-treated subjects with no identified SoC treatment need up to and including Day 85|Best Corrected Visual Acuity (BCVA)|Central subfield thickness total (CSFTtot)|Central subfield thickness neuro-retina (CFSTnr)|Lesion thickness|Subretinal fluid with foveal involvement (SRFfi) thickness|Retinal pigment epithelial detachment with foveal involvement (PEDfi) thickness|Area of lesion (associated with CNV)|Area of CNV within a lesion|Area under the plasma concentration-time curve from time zero to infinity (AUCinf)|Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Area under the plasma concentration-time curve from time zero to time 't' where t is a defined time point after administration (AUC0-t)|Maximum observed maximum plasma concentration (Cmax)|Time to reach the maximum observed plasma concentration (Tmax)|Observed maximum plasma concentration following drug administration, by dose (Cmax/D)|Area under the plasma concentration-time curve divided by dose (AUC/D)|Frequency of subjects with anti-LMG324 antibodies	https://ClinicalTrials.gov/show/NCT02398500
43	NCT02089503	Monocentric Retrospective Observational Study on Patients With Macular Degeneration	Not yet recruiting	No Results Available	Exudative Age-Related Macular Degeneration	Other: intravitreal injections of Lucentis	Hospital St. Joseph, Marseille, France	Both	Child|Adult|Senior		250	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	ELOUAN HSJ 2014	March 14, 2014	March 2014	December 2014	March 17, 2014	March 2014	No Study Results Posted	ELOUAN	May 2014	Best Corrected Visual Acuity (BCVA), measured at 24 months (± 4 weeks).|the mean change of the BCVA throughout the 24 months of follow-up (FU),	https://ClinicalTrials.gov/show/NCT02089503
44	NCT02507388	Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration	Recruiting	No Results Available	Neovascular Age-Related Macular Degeneration	Drug: RTH258 Lower Dose|Drug: RTH258 Higher Dose	Alcon Research	Both	Adult|Senior	Phase 2	65	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)	RTH258-E003	July 22, 2015	August 2015	November 2016	August 25, 2015	August 2015	No Study Results Posted	null	November 2016	Maximum observed concentration [Cmax (ng/mL)]|Time to reach maximum concentration [Tmax (h)]|Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [AUC0-last (ng*h/mL)]|Area under the concentration-time curve from 0 to infinity [AUC0-inf (ng*h/mL)]|Terminal elimination half-life [t1/2 (h)]|Concentration of RTH258 24 hours after dosing (C24hr)|Number of subjects with positive anti-drug antibody (ADA) test	https://ClinicalTrials.gov/show/NCT02507388
45	NCT01863199	Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)	Recruiting	No Results Available	Neovascular Age Related Macular Degeneration	Drug: Lucentis (Treat and extend)|Drug: Lucentis every 4 weeks|Drug: Lucentis every 12 weeks	Retinal Consultants of Arizona|Genentech, Inc.	Both	Adult|Senior	Phase 4	60	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ML28727	May 20, 2013	May 2013	May 2015	January 7, 2014	January 2014	No Study Results Posted	Liberty	November 2014	Best corrected visual acuity|Central foveal thickness	https://ClinicalTrials.gov/show/NCT01863199
46	NCT02328209	Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration	Recruiting	No Results Available	Exudative Age-related Macular Degeneration	Drug: ranibizumab	Mie University	Both	Adult|Senior		50	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	UMIN000014056	December 19, 2014	June 2014	December 2016	December 26, 2014	December 2014	No Study Results Posted	null	December 2016	A change from baselines best corrected visual acuity at 24 months|A drop-out rate of the 3 and 12 months|A treatment continuance rate until 24 months|A change of best corrected visual acuity at 12 months|A change from baselines central retinal thickness measured by spectral domain optical coherence tomography at 12 and 24 months	https://ClinicalTrials.gov/show/NCT02328209
47	NCT02418754	Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)	Recruiting	No Results Available	Neovascular Age-Related Macular Degeneration	Drug: REGN2176-3|Drug: Intravitreal Aflibercept Injection (IAI)	Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 2	500	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	R2176-3-AMD-1417	April 13, 2015	April 2015	April 2017	April 30, 2015	April 2015	No Study Results Posted	null	June 2016	Change in Best corrected visual acuity (BCVA)|Change in central retinal lesion thickness as measured by 0ptical coherence tomography (OCT)|Proportion of patients with complete resolution of intraretinal and subretinal fluid as measured by OCT|Change in choroidal neovascularization (CNV) area as measured by Fluorescein angiography (FA)|Change in lesion size as measured by Optical coherence tomography (OCT)|Proportion of patients who gain ≥15 letters in BCVA as measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)|Change in subretinal hyperreflectivity material (SHM) as measured by OCT|Incidence of Treatment-emergent adverse event (TEAEs)	https://ClinicalTrials.gov/show/NCT02418754
48	NCT02450981	Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration	Not yet recruiting	No Results Available	Neovascular Age-related Macular Degeneration	Drug: Bevacizumab (BCD-021)	Biocad	Both	Adult|Senior	Phase 1	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: Open Label	BCD-021-1	May 19, 2015	null	null	May 22, 2015	May 2015	No Study Results Posted	null	September 2016	Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to BCD-021 and appeared after the first, the second and the third intravitreal injection of BCD-021|Frequency of ocular and systemic AEs and SAEs related to age-related macular degeneration (AMD) therapy, appeared within the whole study period|Number of cases of early withdrawal from the study caused by AE or SAE|Area under the plasma concentration-time curve from zero (0) hours to 28 days, maximum concentration and half life of bevacizumab after the first administration of BCD-021|Area under the plasma concentration-time curve from 56 days to 84 days, maximum concentration and half life of bevacizumab after the third administration of BCD-021|Minimum concentration of bevacizumab between the first and the third administration of BCD-021|Number of patients who have binding and neutralizing antibodies to BCD-021 in serum at screening, after 3 intravitreal injections and after 12 intravitreal injections of BCD-021|Mean change in visual acuity score, measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale at month 12|Change in fluid and foveal thickness on OCT during the study|Timing of visual improvement after initiation of therapy	https://ClinicalTrials.gov/show/NCT02450981
49	NCT02569892	Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration	Recruiting	No Results Available	Macular Degeneration|Retinal Drusen	Device: Non-damaging thermal laser treatment|Device: Sham macular laser treatment	Stanford University|Bascom Palmer Eye Institute	Both	Adult|Senior		56	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)	IRB-33991	October 5, 2015	September 2015	December 2018	October 6, 2015	October 2015	No Study Results Posted	null	September 2018	Change in macular drusen volume|Change in visual acuity|Development of GA or CNV	https://ClinicalTrials.gov/show/NCT02569892
50	NCT01780935	Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration	Completed	No Results Available	Neovascular Age-related Macular Degeneration	Drug: Ranibizumab	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 3	674	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)	CRFB002A2405|2011-004959-39	January 29, 2013	June 2013	July 2015	October 9, 2015	October 2015	No Study Results Posted	OCTAVE	July 2015	Change in Average Visual Acuity|Change from Baseline in Visual Acuity (Letters) of the Study Eye over time|Gain of equal or more than 1, 5, 10, or 15 letters in Visual Acuity of the Study Eye from Baseline, at Month 12 and 24|Loss of less than 5, 10, and 15 letters in Visual Acuity in the Study Eye from Baseline, at Month 12 and 24|Visual Acuity of 73 letters or more in the Study Eye at Month 12 and 24|Average Visual Acuity change from Month 3 to Month 4 through Month 24 in the Study Eye|Average Visual Acuity change from baseline to Month 1 through Month 12 and 24 in the Study Eye|Change from Baseline in Central Sub-Field Thickness (CSFT) and Central Sub-Field Volume (CSFV) of the Study Eye over time|Dry retina in the Study Eye on OCT at Month 12 and 24|Change from Baseline in lesion size and morphology based on fluorescein angiography at Month 12 and 24|Treatment patterns over time in both treatment arms|Change from Baseline in the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) scores over time|Frequency and severity of ocular and non-ocular adverse events over time	https://ClinicalTrials.gov/show/NCT01780935
51	NCT01941082	A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration	Completed	No Results Available	Macular Degeneration	Drug: RO6867461	Hoffmann-La Roche	Both	Adult|Senior	Phase 1	24	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	BP28936|2013-001972-40	September 3, 2013	December 2013	June 2015	October 1, 2015	October 2015	No Study Results Posted	null	June 2015	Ocular safety, assessed by BCVA (EDTRS chart), slitlamp examination, ophthalmoscopy, IOP, fundus photography, SD-OCT, angiography|Safety: Incidence of adverse events|Pharmacokinetics: Area under the concentration time curve (AUC)|Pharmacokinetics: Maximum plasma concentration (Cmax)	https://ClinicalTrials.gov/show/NCT01941082
52	NCT01933152	Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration	Completed	No Results Available	Macular Degeneration	Drug: Ranibizumab	Bayer	Both	Adult|Senior		137	Industry	Observational	Observational Model: Cohort|Time Perspective: Retrospective	16378	July 29, 2013	August 2012	April 2013	September 30, 2014	September 2014	No Study Results Posted	REVIEW	April 2013	Changes in visual acuity after start of Anti vascular endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard|Demographic characteristics of patients included in the study (Age, Sex, Race)|Mean time from first clinical presentation to diagnosis|Mean time from diagnosis to treatment|Mean time from diagnosis to end of follow-up|Mean change of visual acuity, from diagnosis to end of follow-up, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chart|Mean change of retinal thickness from diagnosis to end of follow-up, assessed by Optical Coherence Tomography (OCT)|Mean change of lesion size from diagnosis to end of follow-up, assessed by Fluorescein Angiography (FA)|Average number of treatments given from diagnosis to end of follow-up	https://ClinicalTrials.gov/show/NCT01933152
53	NCT02304068	The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity	Completed	No Results Available	Acute Macular Degeneration	Other: Home monitoring|Other: Hospital assessment	The Leeds Teaching Hospitals NHS Trust|Biomedical Health Research Centre	Both	Adult|Senior		null	Other	Interventional		OP12/10204|12/YH/0195	November 4, 2014	April 2012	October 2012	November 25, 2014	November 2014	No Study Results Posted	null	October 2012	Monitor disease activity at home using near reading chart	https://ClinicalTrials.gov/show/NCT02304068
54	NCT01996215	Brain Connectivity in Age-Related Macular Degeneration	Recruiting	No Results Available	Age-Related Macular Degeneration		Duke University|National Institute on Aging (NIA)	Both	Adult|Senior		240	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	Pro00046073|R01AG043438	November 22, 2013	April 2014	December 2018	August 3, 2015	August 2015	No Study Results Posted	null	December 2018	Cognitive Changes and Brain Connectivity in Age-Related Macular Degeneration	https://ClinicalTrials.gov/show/NCT01996215
55	NCT02122159	Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration	Not yet recruiting	No Results Available	Myopic Macular Degeneration	Biological: MA09-hRPE Cellular Therapy	University of California, Los Angeles|Ocata Therapeutics	Both	Adult|Senior	Phase 1|Phase 2	null	Other|Industry	Interventional		JSEI MA09-hRPE MMD	April 1, 2014	null	null	April 22, 2014	April 2014	No Study Results Posted	null	April 2015	Safety of hESC-derived RPE cells|Evidence of successful engraftment|Evidence of rejection	https://ClinicalTrials.gov/show/NCT02122159
56	NCT01822873	Study on Visual Function Impairments in Dry Age-related Macular Degeneration	Recruiting	No Results Available	Age Related Macular Degeneration		Duke University|Hoffmann-La Roche	Both	Adult|Senior		210	Other|Industry	Observational	Time Perspective: Prospective	Pro00036248	March 28, 2013	March 2013	null	August 3, 2015	August 2015	No Study Results Posted	null	December 2017	Change in low luminance visual acuity|Change in cone specific contrast sensitivity|Change in contrast sensitivity|Change in macular sensitivity on microperimetry	https://ClinicalTrials.gov/show/NCT01822873
57	NCT02567604	Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective	Not yet recruiting	No Results Available	Age Related Macular Degeneration	Behavioral: Focus Groups	Queen's University, Belfast	Both	Adult|Senior		24	Other	Observational	Time Perspective: Prospective	B15/31	September 11, 2015	October 2015	September 2016	October 1, 2015	October 2015	No Study Results Posted	null	September 2016	Number of potential COS (core outcome set) elements for AMD randomised controlled trials as assessed by the focus group discussions.	https://ClinicalTrials.gov/show/NCT02567604
58	NCT02438111	The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)	Recruiting	No Results Available	Age Related Macular Degeneration	Genetic: metagenome	University Hospital Inselspital, Berne	Both	Adult|Senior		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	KEK BE 205/13	April 28, 2015	November 2013	November 2019	May 5, 2015	May 2015	No Study Results Posted	null	November 2016	taxonomic and functional characterization of gut microbiota|Gut-microbiota-based AMD classification|AMD-associated gut microbial markers	https://ClinicalTrials.gov/show/NCT02438111
59	NCT01790802	Laser Intervention in Early Age-Related Macular Degeneration Study	Active, not recruiting	No Results Available	Age-related Macular Degeneration	Device: 2RT nanosecond laser	Center for Eye Research Australia	Both	Adult|Senior		250	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Outcomes Assessor)	CERA201201|ACTRN12612000704897|CTN Number130/2012	February 12, 2013	November 2011	June 2018	June 16, 2015	June 2015	No Study Results Posted	LEAD	June 2018	progression to advanced Age-related Macular Degeneration (AMD) in the treated eye|progression to advanced AMD in the untreated eye	https://ClinicalTrials.gov/show/NCT01790802
60	NCT01918553	Cohort Study on the Age-related Macular Degeneration: Incidence and Research for Predisposing Factors	Recruiting	No Results Available	Elderly French Population|Age-related Macular Degeneration	Other: clinical parameters|Other: visual acuity exams|Other: retinophotography|Other: SD-OCT|Other: Intra ocular Pressure (IOP)|Other: retinal imaging (OPTOMAP)|Other: axial length (IOL master)	University Hospital, Bordeaux	Both	Child|Adult|Senior		700	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	CHUBX2012/31	July 8, 2013	July 2013	September 2017	November 13, 2014	November 2014	No Study Results Posted	ECLAIR	July 2015	8-year incidence of late AMD (neovascular and/or atrophic)|best-corrected visual acuity (ETDRS methodology) measured in visit 1 and 2 years later with ETDRS methodology	https://ClinicalTrials.gov/show/NCT01918553
61	NCT01824225	Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration	Completed	No Results Available	Age-related Macular Degeneration	Drug: Aflibercept	Nihon University	Both	Adult|Senior	Phase 4	100	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	NihonU-2	March 31, 2013	March 2013	March 2015	October 5, 2015	October 2015	No Study Results Posted	null	March 2014	Visual acuity after treatment by PRN or 2 months intravitreal Aflibercept	https://ClinicalTrials.gov/show/NCT01824225
62	NCT02540148	Transpalpebral Micro Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration	Not yet recruiting	No Results Available	Age-related Macular Degeneration	Device: Nova Oculus™ Micro-current electrical stimulation|Device: Nova Oculus™ Micro-current electrical stimulation - Sham treatment	The Eye Machine Canada Inc.	Both	Adult|Senior		30	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	NO001C	September 1, 2015	null	null	September 2, 2015	September 2015	No Study Results Posted	null	September 2016	The primary outcome will be the mean change in visual acuity at the six week visit of the study group versus the control group.	https://ClinicalTrials.gov/show/NCT02540148
63	NCT02422160	Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration	Recruiting	No Results Available	Age-Related Macular Degeneration	Other: No interventions are planned	Stanford University	Both	Adult|Senior		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	33624	April 16, 2015	April 2015	null	April 20, 2015	April 2015	No Study Results Posted	null	December 2017	Visual Acuity	https://ClinicalTrials.gov/show/NCT02422160
64	NCT02302989	Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration	Not yet recruiting	No Results Available	Age-related Macular Degeneration	Drug: Ranibizumab 0.5mg	Leonard Feiner, MD, PhD|NJ Retina (Retina Associates of New Jersey)	Both	Adult|Senior	Phase 1|Phase 2	88	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Outcomes Assessor)	ML29346	November 25, 2014	November 2014	November 2017	November 26, 2014	November 2014	No Study Results Posted	PROTECT	November 2017	Conversion to neovascular AMD. (CNV leakage on FA and evidence of any fluid on SD-OCT)	https://ClinicalTrials.gov/show/NCT02302989
65	NCT02016508	Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration	Recruiting	No Results Available	Age Related Macular Degeneration	Drug: autologous bone marrow derived stem cells	Al-Azhar University|Hassan , Hosny , M.D. M.Sc|Samour , Hany  M.D. M.Sc|Ismail , Mahmoud  M.D. M.Sc|Higazy , Hasan  M.D. M.Sc|Abou el kheir, Wael, M.D. M.Sc.|Gabr, Hala , M.D. M.Sc.|Bakry, Sayed , phD. M.Sc.	Both	Adult|Senior	Phase 1|Phase 2	1	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	NCT 4619792013|4619792013	May 18, 2013	March 2013	June 2015	December 20, 2013	December 2013	No Study Results Posted	null	April 2015	number of subjects with adverse events|Assessment of visual function changes from the base line	https://ClinicalTrials.gov/show/NCT02016508
66	NCT02130531	Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration	Active, not recruiting	No Results Available	Geographic Atrophy|Age-Related Macular Degeneration	Drug: Emixustat HCl Tablet|Other: Placebo Tablet	Acucela Inc.	Both	Adult|Senior	Phase 1	26	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	4429-101	May 1, 2014	April 2014	December 2015	July 16, 2015	July 2015	No Study Results Posted	null	September 2015	Area Under the Concentration-Time Curve from time zero to 24 hours [(AUC(0-24h)]|Degree of suppression of the ERG b-wave response post-photobleaching.	https://ClinicalTrials.gov/show/NCT02130531
67	NCT02286089	Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration	Recruiting	No Results Available	Age-related Macular Degeneration	Biological: OpRegen	Cell Cure Neurosciences Ltd.	Both	Adult|Senior	Phase 1|Phase 2	15	Industry	Interventional	Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CCN_CT02	November 2, 2014	April 2015	August 2017	April 13, 2015	April 2015	No Study Results Posted	null	August 2016	Safety and tolerability of OpRegen|Duration of graft survival|Efficacy of the graft	https://ClinicalTrials.gov/show/NCT02286089
68	NCT02296567	Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients	Recruiting	No Results Available	Age Related Macular Degeneration	Drug: Ranibizumab|Drug: Bevacizumab|Drug: Aflibercept|Drug: Ranibizumab|Drug: Bevacizumab|Drug: Aflibercept|Drug: Ranibizumab|Drug: Bevacizumab|Drug: Aflibercept|Other: Control Group	East Florida Eye Institute|Genentech, Inc.	Both	Adult|Senior	Phase 2|Phase 3	80	Other|Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label	ML29189	November 5, 2014	December 2014	July 2016	August 7, 2015	August 2015	No Study Results Posted	null	July 2016	Change in serum and plasma levels of free Vascular Endothelial Growth Factor|Change in Serum drug levels in nanomoles (nM) units following treatment|Amount of fluid (cubic mm) as measured by Ocular Coherence Tomography in the contralateral eye will be correlated with systemic Vascular Endothelial Growth Factor levels	https://ClinicalTrials.gov/show/NCT02296567
69	NCT02358889	Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Recruiting	No Results Available	Choroidal Neovascularization|Age-related Macular Degeneration	Biological: hI-con1|Biological: ranibizumab|Other: Sham injection	Iconic Therapeutics, Inc.	Both	Adult|Senior	Phase 2	90	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	IT-002	February 4, 2015	February 2015	null	October 8, 2015	October 2015	No Study Results Posted	EMERGE	June 2016	Change from baseline in best corrected visual acuity (BCVA) in the study eye at Month 3|Change from baseline in central retinal subfield thickness (CST) in the study eye at Month 3|Change from baseline in BCVA in the study eye at Month 6|Change from baseline in CST in the study eye at Month 6	https://ClinicalTrials.gov/show/NCT02358889
70	NCT02137915	Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration	Enrolling by invitation	No Results Available	Age-Related Macular Degeneration|Geographic Atrophy	Biological: Human Central Nervous System Stem Cells	StemCells, Inc.	Both	Adult|Senior		8	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	CL-N02-AMD	May 12, 2014	April 2014	June 2019	May 18, 2015	May 2015	No Study Results Posted	null	June 2019	Frequency and types of serious adverse events|Frequency and types of adverse events	https://ClinicalTrials.gov/show/NCT02137915
71	NCT02257632	Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: Ranibizumab|Drug: Aflibercept	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	40	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	CRFB002ADE27	October 2, 2014	April 2015	May 2016	June 2, 2015	June 2015	No Study Results Posted	TIDE AMD	May 2016	Systemic VEGF-A protein levels|Systemic VEGF-A levels	https://ClinicalTrials.gov/show/NCT02257632
72	NCT02484690	AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)	Recruiting	No Results Available	Macular Degeneration, Choroidal Neovascularization	Drug: RG7716|Drug: Ranibizumab	Hoffmann-La Roche	Both	Adult|Senior	Phase 2	271	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	BP29647	June 12, 2015	August 2015	April 2017	September 9, 2015	September 2015	No Study Results Posted	null	April 2017	Change from Baseline in BCVA letter score|Percentage of participants gaining at least 15 letters from Baseline in BCVA letter score|Percentage of participants with BCVA letter score 20/40 or better|Percentage of participants with BCVA letter score 20/200 or worse|Change from Baseline in foveal center point thickness|Change from Baseline in central subfield thickness|Percentage of participants with no intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment|Change from Baseline in total area of CNV|Change from Baseline in total area of CNV component|Change from Baseline in total area of leakage|Incidence of adverse events|Clearance of RG7716|Volume of distribution of RG7716	https://ClinicalTrials.gov/show/NCT02484690
73	NCT02127463	Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration	Recruiting	No Results Available	Non-Exudative Age Related Macular Degeneration	Drug: MC-1101|Drug: MC-1101 Vehicle	MacuCLEAR, Inc.	Both	Adult|Senior	Phase 2|Phase 3	60	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	MC-1101-003	April 25, 2014	April 2014	April 2016	April 29, 2014	April 2014	No Study Results Posted	McCP2/3	April 2016	Visual Function|Safety and tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia)	https://ClinicalTrials.gov/show/NCT02127463
74	NCT02022540	Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD	Recruiting	No Results Available	Age-Related Macular Degeneration (AMD)	Drug: PAN-90806 Ophthalmic Solution|Drug: Lucentis	PanOptica, Inc.	Both	Adult|Senior	Phase 1	50	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	PAN-01-101	December 20, 2013	February 2014	May 2016	October 19, 2015	October 2015	No Study Results Posted	null	March 2016	Safety	https://ClinicalTrials.gov/show/NCT02022540
75	NCT02098720	An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)	Active, not recruiting	No Results Available	Very Low Vision Secondary to Wet Age-related Macular Degeneration	Drug: Conbercept	Chengdu Kanghong Biotech Co.,Ltd.	Both	Adult|Senior	Phase 2	30	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	KHSWKH902009	March 25, 2014	December 2011	null	July 21, 2014	July 2014	No Study Results Posted	LAMP	March 2014	percentage of patients with best corrected visual acuity (BCVA ) ≥19 letters gain|mean change in BCVA from baseline|change from baseline of macular area thickness and other anatomy results|safety of Conbercept therapy	https://ClinicalTrials.gov/show/NCT02098720
76	NCT02457026	Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD	Not yet recruiting	No Results Available	Neovascular Age-related Macular Degeneration	Drug: Aflibercept|Drug: Triamcinolone Acetonide|Drug: Verteporfin	Duke University|Bausch & Lomb Incorporated	Both	Adult|Senior		200	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	Pro00063930	May 21, 2015	July 2015	July 2018	May 28, 2015	May 2015	No Study Results Posted	null	July 2018	Percentage of individuals with resolution or major reduction in PDA|Percentage of individuals with sustained visual acuity|Average number of aflibercept injections|Frequency of case with progressive disease on therapy|Mean change in choroidal neovascularization lesion size by fluorescein angiography from baseline|Mean change in central foveal thickness by SD-OCT|Mean change in best-corrected ETDRS visual acuity from baseline|Percentage of participants with 2-line ETDRS visual acuity gain|Percentage of participants with 2-line ETDRS visual acuity loss	https://ClinicalTrials.gov/show/NCT02457026
77	NCT02279537	Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD	Active, not recruiting	No Results Available	Wet Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Bayer	Both	Adult|Senior		600	Industry	Observational	Observational Model: Cohort	17374|EY1411FR	October 29, 2014	October 2014	April 2019	September 28, 2015	September 2015	No Study Results Posted	RAINBOW	April 2019	Change in the measurement of best-corrected visual acuity (BCVA) from baseline to 12 months.|Change in Best Corrected Visual Acuity (BCVA) during the second year and until the fourth year of treatment versus the initial visit|Percentage of patients who experienced a gain in BCVA, from initial visit to each follow-up visit (letter score of ≥ 0 letters, ≥ 5 letters, ≥ 10 letters, ≥ 15 letters)|Percentage of patients losing fewer than 15 letters from the initial visit visual acuity at each follow-up visit	https://ClinicalTrials.gov/show/NCT02279537
78	NCT02510885	SD-OCT Angiography	Recruiting	No Results Available	Neovascular Age-related Macular Degeneration|Age-related Macular Degeneration|Diabetic Retinopathy|Retinal Vein Occlusion|Diabetic Macular Edema	Device: AngioVue SD-OCT	Duke University|Optovue	Both	Adult|Senior		100	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: Open Label	Pro00063777	July 28, 2015	July 2015	December 2016	July 28, 2015	July 2015	No Study Results Posted	null	December 2015	Image Quality	https://ClinicalTrials.gov/show/NCT02510885
79	NCT02228304	Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)	Recruiting	No Results Available	Macular Degeneration	Drug: NT-503-3 ECT implantation|Drug: Eylea® injected intravitreally administered every 8 weeks	Neurotech Pharmaceuticals	Both	Adult|Senior	Phase 1|Phase 2	170	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)	NT-503-3-AMD-001	August 27, 2014	September 2014	March 2018	August 27, 2015	August 2015	No Study Results Posted	null	December 2017	Percentage of patients with less than a 3-line loss of BCVA in ETDRS letters|Change from baseline in best corrected visual acuity (BCVA)|Change from baseline in macular thickness as determined by Spectral Domain Optical Coherence Tomography (sdOCT)|Mean (median) number of Eylea® injections and number of patients requiring Eylea® injections for rescue therapy	https://ClinicalTrials.gov/show/NCT02228304
80	NCT01810042	Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab	Completed	Has Results	Exudative Age-related Macular Degeneration	Drug: ranibizumab	Pusan National University Hospital|Novartis	Both	Adult|Senior	Phase 4	49	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	임상20120178	March 11, 2013	October 2010	February 2013	March 9, 2014	March 2014	January 27, 2014	null	February 2013	Caliber of Choroidal New Vessel (CNV)|Lesion Size of CNV|Visual Acuity|Visual Acuity Changes	https://ClinicalTrials.gov/show/NCT01810042
81	NCT02367365	Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD	Recruiting	No Results Available	Neovascular Age-Related Macular Degeneration	Other: No Intervention|Other: No Intervention	Duke University|Bausch & Lomb Incorporated	Both	Adult|Senior		200	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	Pro00055232	February 13, 2015	December 2014	December 2015	February 13, 2015	February 2015	No Study Results Posted	null	December 2015	Frequency of ICG neovascular subtypes|Percentage of each neovascular subtype exhibiting persistent disease activity	https://ClinicalTrials.gov/show/NCT02367365
82	NCT02321839	Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.	Recruiting	No Results Available	Neovascular Age-related Macular Degeneration	Drug: Intraviteal Ranibizumab 0.5mg	Nagoya City University|Novartis	Both	Adult|Senior	Phase 4	100	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	TAENCU001	December 17, 2014	January 2014	December 2018	October 5, 2015	October 2015	No Study Results Posted	null	March 2018	Visual acuity|central foveal thickness	https://ClinicalTrials.gov/show/NCT02321839
83	NCT01796964	Efficacy and Safety Study of ESBA1008 Versus EYLEA®	Completed	No Results Available	Exudative Age-Related Macular Degeneration	Drug: ESBA1008 solution|Drug: Aflibercept	Alcon Research	Both	Adult|Senior	Phase 2	173	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	C-12-006	February 20, 2013	March 2013	August 2014	September 9, 2014	September 2014	No Study Results Posted	null	October 2013	Change from Baseline in Visual Acuity at Week 12|Change from Baseline in Visual Acuity at Week 16|Change from Baseline in Visual Acuity, Up to Week 56|Change from Baseline in Central Subfield (CSF) Thickness by Visit	https://ClinicalTrials.gov/show/NCT01796964
84	NCT01849692	ESBA1008 Microvolume Study	Completed	No Results Available	Exudative Age-Related Macular Degeneration	Drug: ESBA1008 solution|Drug: Ranibizumab	Alcon Research	Both	Adult|Senior	Phase 2	107	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	C-13-001	May 6, 2013	June 2013	January 2015	February 11, 2015	February 2015	No Study Results Posted	null	January 2015	Response based upon central subfield thickness (CSFT) and best-corrected visual acuity (BCVA) outcomes at Day 14 and Day 28|Change from baseline in Best Corrected Visual Acuity (BCVA)|Change from baseline in Central Subfield Thickness (CSFT)	https://ClinicalTrials.gov/show/NCT01849692
85	NCT02251366	NVAMD Satellite Study	Recruiting	No Results Available	Neovascular Age Related Macular Degeneration	Procedure: Physician-guided diagnostic	Johns Hopkins University	Both	Adult|Senior		200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Single Blind (Outcomes Assessor)	NA_00088759	September 9, 2014	October 2014	null	September 7, 2015	May 2015	No Study Results Posted	null	June 2016	Change in visual acuity from baseline|Change in OCT CSF from baseline|total encounter time for each arm	https://ClinicalTrials.gov/show/NCT02251366
86	NCT02121353	Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration	Active, not recruiting	No Results Available	Age Related Macular Degeneration (AMD)	Drug: Lucentis|Drug: PF582	Pfenex, Inc	Both	Adult|Senior	Phase 1|Phase 2	24	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	PF582-CLIN-001	April 17, 2014	November 2013	December 2015	February 27, 2015	February 2015	No Study Results Posted	null	December 2015	To evaluate the safety and tolerability of PF582|To demonstrate the biosimiliarity between PF582 and Lucentis based on PK|To demonstrate biosimilarity between PF582 and reference compound (Lucentis)	https://ClinicalTrials.gov/show/NCT02121353
87	NCT02118831	Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF	Completed	No Results Available	Age-related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion	Drug: Aflibercept|Drug: Bevacizumab|Drug: Ranibizumab	California Retina Consultants	Both	Child|Adult|Senior	Phase 1|Phase 2	145	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label	ML28032	April 15, 2014	March 2012	April 2014	April 17, 2014	April 2014	No Study Results Posted	null	February 2014	Change in Serum Pharmacokinetics Following Treatment|Change in serum and plasma levels of free vascular endothelial growth factor	https://ClinicalTrials.gov/show/NCT02118831
88	NCT02218177	Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD	Recruiting	No Results Available	Age Related Macular Degeneration	Drug: Aflibercept|Drug: Ranibizumab|Procedure: Combination Photodynamic Therapy	University Health Network, Toronto	Both	Adult|Senior		30	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	VEGF wAMD cytokine study	August 13, 2014	August 2014	null	August 13, 2014	August 2014	No Study Results Posted	null	August 2016	Aqueous Humour Cytokine Levels|Demographic Data|Number of anti-VEGF injections before developing non-responder characteristics|History of Previous Treatment|Optical Coherence Tomography (OCT) results|Fluorescein Angiography Results and Indocyanine Green Angiography Results	https://ClinicalTrials.gov/show/NCT02218177
89	NCT01943396	Treatment of AMD With Rheohemapheresis /RHF/	Recruiting	No Results Available	Age Related Macular Degeneration	Procedure: rheohemapheresis	University Hospital Hradec Kralove	Both	Child|Adult|Senior	Phase 4	36	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	FNHK2013/01|IGA-NT14037-4/2013	June 20, 2013	September 2013	March 2016	May 29, 2014	May 2014	No Study Results Posted	TARHF	November 2015	Electroretinography|immunologic parameters changes	https://ClinicalTrials.gov/show/NCT01943396
90	NCT02173496	Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)	Recruiting	No Results Available	Age Related Macular Degeneration	Other: Colour Contrast Sensitivity	Aston University|The Dunhill Medical Trust	Both	Adult|Senior		210	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	CEDAR001|14/WM/0035	March 20, 2014	October 2014	March 2017	January 13, 2015	January 2015	No Study Results Posted	CEDAR	March 2017	Capability of evaluated techniques detecting asymptomatic wet ARMD|Improve understanding of the disease process in wet ARMD	https://ClinicalTrials.gov/show/NCT02173496
91	NCT01799564	Micropulse Laser for Geographic Atrophy	Recruiting	No Results Available	Geographic Atrophy|Age-related Macular Degeneration	Procedure: Micropulse	Institut de la Macula y la Retina	Both	Adult|Senior	Phase 1	15	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Caregiver, Outcomes Assessor)	MPL4DRY	February 25, 2013	August 2012	June 2017	March 23, 2015	March 2015	No Study Results Posted	MPL4DRY	December 2016	Change in area of atrophy as measured with fundus autofluorescence	https://ClinicalTrials.gov/show/NCT01799564
92	NCT02248324	Association of Previously Verified Gene Polymorphisms With AMD in Turkish Population	Recruiting	No Results Available	Age-related Macular Degeneration		Kocatepe University|The Scientific and Technological Research Council of Turkey (TUBITAK)	Both	Adult|Senior		5000	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	0112S269	September 20, 2014	November 2012	November 2016	May 13, 2015	May 2015	No Study Results Posted	AMD-SNP	November 2015	rate of homozygous, heterozygous or wild type genotype and allels|Odds ratios for each genotyping in healthy elderly controls and patients with age related macular degeneration	https://ClinicalTrials.gov/show/NCT02248324
93	NCT02130024	A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: Ranibizumab|Drug: Aflibercept	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	278	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	CRFB002AAU17	March 27, 2014	April 2014	October 2017	June 3, 2015	June 2015	No Study Results Posted	RIVAL	October 2017	Proportion of patients with newly developed geographic atrophy as assessed by multimodal imaging|Number of injections|Mean change in Best Corrected Visual Acuity (BCVA) (logMAR)|Mean change in area of existing and newly developed geographic atrophy|Proportion of patients showing geographic atrophy|Mean change in central retinal thickness (CRT)|Proportion of patients showing no intraretinal fluid (IRF)|Proportion of patients showing greater than and equal to a 15 letters gain|Proportion of patients showing less than and equal to a 15 letters loss|Number of times a patient needed to return to monthly treatments|Change in Retinal Nerve Fibre Thickness|Plasma VEGF levels|Ocular and systemic adverse events|Ocular inflammation	https://ClinicalTrials.gov/show/NCT02130024
94	NCT01880788	Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD	Completed	No Results Available	Age Related Macular Degeneration|Choroidal Neovascularization|Central Serous Chorioretinopathy		Sequenom, Inc.|Vitreous -Retina- Macula Consultants of New York	Both	Adult|Senior		152	Industry|Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	SCMM-AMD-107	May 16, 2013	November 2012	August 2015	September 17, 2015	September 2015	No Study Results Posted	null	March 2015	Total genetic burden	https://ClinicalTrials.gov/show/NCT01880788
95	NCT02051998	Directional Spread in Geographic Atrophy	Recruiting	No Results Available	Nonexudative Age-related Macular Degeneration		University Hospital, Bonn	Both	Adult|Senior		130	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	FL 658/4-1	January 8, 2014	June 2013	null	December 2, 2014	December 2014	No Study Results Posted	DSGA	October 2016	Change of geographic atrophy size to baseline|Change in BCVA from baseline	https://ClinicalTrials.gov/show/NCT02051998
96	NCT02253030	OCT Angiography in Wet AMD	Recruiting	No Results Available	Neovascular (Wet) Age-related Macular Degeneration (AMD)	Device: Optical Coherence Tomography	Oregon Health and Science University	Both	Adult|Senior		145	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	IRB#000010535	September 25, 2014	September 2014	null	April 21, 2015	April 2015	No Study Results Posted	null	September 2017	Number of subjects with new blood vessel growth detected using OCT angiography|Number of subjects with reduced choroidal blood flow that develop wet AMD.	https://ClinicalTrials.gov/show/NCT02253030
97	NCT01840683	HELP Therapy for Dry AMD	Active, not recruiting	No Results Available	Non-exudative (Dry) Age-related Macular Degeneration (AMD)	Device: H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)	B.Braun Avitum AG	Both	Adult|Senior		22	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	BA-I-H-1202	April 5, 2013	May 2013	January 2016	November 11, 2014	November 2014	No Study Results Posted	HELPuc	September 2015	To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA) in patients with non-exudative (dry) AMD.|To evaluate the effects of H.E.L.P. therapy on the change in drusen area as assessed by colour photography.|To evaluate the effects of H.E.L.P. therapy in area of abnormal autofluorescence as assessed by Fundus Autofluorescence (FAF).|To evaluate the effects of H.E.L.P. therapy on overall visual functioning as assessed by the Visual Functioning Questionnaire (VFQ)-25 test.|To evaluate the safety of H.E.L.P. therapy by assessing laboratory tests and vital signs.|To evaluate the effects of H.E.L.P. on the integrity of the outer retinal bands as assessed by Optical Coherence Tomography (OCT)|To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA).|To evaluate the effects of H.E.L.P. therapy on the AREDS severity scale as assessed by colour photography.|To evaluate the effects of H.E.L.P. therapy on the incidence and change in area of geographic hypo autofluorescence as assessed by fundus autofluorescence images.|To evaluate the effects of H.E.L.P. on the drusen volume as assessed by Optical Coherence Tomography (OCT)|To evaluate the safety of H.E.L.P. therapy by assessing adverse events (AEs).|To evaluate the safety of H.E.L.P. therapy by physical examination.	https://ClinicalTrials.gov/show/NCT01840683
98	NCT01926977	Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration	Completed	No Results Available	Neovascular Age-Related Macular Degeneration	Drug: Ranibizumab 0.5mg|Drug: Aflibercept 2.0mg	Arshad Khanani|Genentech, Inc.|Sierra Eye Associates	Both	Adult|Senior	Phase 1|Phase 2	100	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	ML28895|20131227	August 19, 2013	September 2013	May 2014	May 22, 2014	May 2014	No Study Results Posted	null	May 2014	Evidence of Anterior chamber inflammation|Post injection pain	https://ClinicalTrials.gov/show/NCT01926977
99	NCT01997164	Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)	Recruiting	No Results Available	Neovascular Age-Related Macular Degeneration|Diabetic Macular Edema	Drug: REGN910-3|Drug: REGN910|Drug: Intravitreal Aflibercept Injection (IAI)	Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 1	20	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label	R910-3-OD-1403	November 22, 2013	November 2014	October 2015	April 2, 2015	April 2015	No Study Results Posted	null	October 2015	Incidence of treatment-emergent adverse events (TEAEs)|Pharmacokinetic (PK) profile|Development of Anti-drug antibodies (ADA) after IVT injection of REGN910-3	https://ClinicalTrials.gov/show/NCT01997164
100	NCT01775124	Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)	Active, not recruiting	No Results Available	Neovascular Age-related Macular Degeneration	Drug: Ranibizumab	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	333	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	CRFB002A2413	January 22, 2013	February 2013	December 2015	June 2, 2015	June 2015	No Study Results Posted	DRAGON	December 2015	Average change in Visual Acuity (Letters) from Month 3 through Month 12|Change from Baseline in Visual Acuity (Letters) of the Study Eye over time|Gain of equal or more than 5, 10, 15, or 30 letters in Visual Acuity of the Study Eye over time|Loss of less than 15 Letters of Visual Acuity in the study eye over time|Visual Acuity of more of 73 letters or more|Average Visual Acuity change (Letters) from Month 3 to Month 4 through Month 24|Average Visual Acuity change (Letters) from baseline to Month 1 through Month 12 (24) ,|Change from Baseline in Central Sub-Field Thickness (CSFT) of the study eye over time|Number of re-treatments and re-treatment patterns over time in patients receiving PRN dosing of ranibizumab 0.5 mg|Frequency and severity of ocular and non-ocular adverse events over time	https://ClinicalTrials.gov/show/NCT01775124
101	NCT02287298	Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment	Active, not recruiting	No Results Available	Exudative Macular Degeneration	Procedure: TRIPLE COMBINATION THERAPY	The Retina Center of St. Louis County, PC	Both	Adult|Senior		400	Other	Observational	Observational Model: Case Control|Time Perspective: Retrospective	14-07-0540	September 19, 2014	August 2014	December 2015	November 5, 2014	September 2014	No Study Results Posted	null	December 2015	BEST CORRECTED VISUAL ACUITY|NUMBER OF COMBINATION TREATMENTS|REDUCTION OF CENTRAL FOVEAL THICKNESS BY OCT MEASUREMENT|DEVELOPMENT OF EXUDATIVE MACULAR DEGENERATION IN THE FELLOW EYE	https://ClinicalTrials.gov/show/NCT02287298
102	NCT02332941	Treatment -Resistant Neovascular Age-Related Macular Degeneration	Completed	No Results Available	Macular Degeneration	Drug: Rituximab	Washington University School of Medicine	Both	Adult|Senior	Phase 1	5	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	201406106	October 28, 2014	August 2014	June 2015	June 1, 2015	June 2015	No Study Results Posted	Rituximab	June 2015	Central Macular Thickness	https://ClinicalTrials.gov/show/NCT02332941
103	NCT01972789	Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment.	Recruiting	No Results Available	Subfoveal Choroidal Neovascularization (CNV) Secondary to Wet Age-related Macular Degeneration (AMD)	Drug: Ranibizumab	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	330	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	CRFB002AAU15	October 24, 2013	October 2013	November 2016	July 22, 2015	July 2015	No Study Results Posted	FLUID	November 2016	Mean change in best-corrected visual acuity (BCVA) from baseline to 24 months.|Mean change in BCVA from baseline to month 12.|Mean change in central retinal thickness (CRT) from baseline to month 12 and 24.|Mean number of injections from baseline to month 12 and 24|Mean change in area of new and existing geographic atrophy from baseline to month 12 and 24.|Proportion of patients showing newly developed geographic atrophy at months 12 and 24|Proportion of patients showing no IRF and SRF at months 2, 12 and 24.|Proportion of patients showing greater than 15 letters Early Treatment Diabetic Retinopathy (ETDRS) gain from baseline to month 12 and 24.|Proportion of patients showing less than 15 letters ETDRS loss from baseline to month 12 and 24.|Determination of genotypes associated with AMD and response to treatment at baseline; correlation with visual acuity (VA) outcome and ability to dry the retina.|Proportion of patients with both SRF and IRF who despite monthly treatment do not resolve their SRF|The number of times a participant needs to return to monthly treatments during the 24 months.|Ocular and systemic adverse events	https://ClinicalTrials.gov/show/NCT01972789
104	NCT02181517	A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration	Completed	No Results Available	Macular Degeneration	Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure	Allergan	Both	Adult|Senior	Phase 2	25	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	150998-003|CYPRESS	July 2, 2014	June 2014	March 2015	April 28, 2015	April 2015	No Study Results Posted	null	February 2015	Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change from Baseline in BCVA in the Study Eye|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Percentage of Patients with a BCVA Gain of ≥10 Letters in the Study Eye on the ETDRS Scale|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye|Serum Levels of Abicipar	https://ClinicalTrials.gov/show/NCT02181517
105	NCT02181504	A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration	Recruiting	No Results Available	Macular Degeneration	Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure	Allergan	Both	Adult|Senior	Phase 2	25	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	150998-002|BAMBOO	July 2, 2014	August 2014	December 2015	September 9, 2015	September 2015	No Study Results Posted	null	December 2015	Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Change from Baseline in BCVA in the Study Eye|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Percentage of Patients with a BCVA Gain of ≥10 Letters in the Study Eye on the ETDRS Scale|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye|Serum Levels of Abicipar	https://ClinicalTrials.gov/show/NCT02181504
106	NCT02462486	Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration	Recruiting	No Results Available	Macular Degeneration	Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure	Allergan	Both	Adult|Senior	Phase 3	900	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	150998-006|2014-004580-20|SEQUOIA	June 2, 2015	June 2015	August 2018	July 31, 2015	July 2015	No Study Results Posted	null	August 2018	Percentage of Patients with Best Corrected Visual Acuity (BCVA) Change from Baseline ≤15 Letters in the Study Eye|Change from Baseline in BCVA in the Study Eye|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Change from Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score	https://ClinicalTrials.gov/show/NCT02462486
107	NCT02462928	A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration	Recruiting	No Results Available	Macular Degeneration	Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure	Allergan	Both	Adult|Senior	Phase 3	900	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	150998-005|2014-004579-22|CEDAR	June 2, 2015	June 2015	August 2018	July 31, 2015	July 2015	No Study Results Posted	CDER	August 2018	Percentage of Patients with Best Corrected Visual Acuity (BCVA) Change from Baseline ≤15 Letters in the Study Eye|Change from Baseline in BCVA in the Study Eye|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Change from Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score	https://ClinicalTrials.gov/show/NCT02462928
108	NCT02087085	A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration	Recruiting	No Results Available	Geographic Atrophy|Macular Degeneration	Drug: 400 µg Brimonidine Implant|Other: Sham	Allergan	Both	Adult|Senior	Phase 2	300	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	190342-038|2013-003320-36	March 12, 2014	May 2014	October 2018	June 30, 2015	June 2015	No Study Results Posted	BEACON	April 2018	Change from Baseline in Atrophic Lesion Area in the Study Eye|Change from Baseline in Low Luminance Best Corrected Visual Acuity (BCVA) in the Study Eye|Change from Baseline in BCVA in the Study Eye	https://ClinicalTrials.gov/show/NCT02087085
109	NCT02510794	Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration	Recruiting	No Results Available	Macular Degeneration	Drug: Ranibizumab ITV injection|Drug: Ranibizumab through RPDS Implant	Genentech, Inc.	Both	Adult|Senior	Phase 2	220	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	GX28228	July 17, 2015	August 2015	January 2017	October 1, 2015	October 2015	No Study Results Posted	null	December 2016	Time until a patient first requires the RPDS Implant refill according to protocol-defined refill criteria|Mean change in BCVA|Mean average change in BCVA|Mean change from baseline in central foveal thickness over time, as assessed on SD-OCT|Incidence of ocular and non-ocular AEs and SAEs|Incidence of AEs of Special Interest	https://ClinicalTrials.gov/show/NCT02510794
110	NCT01961414	Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910	Active, not recruiting	No Results Available	Exudative Age-related Macular Degeneration	Drug: Aflibercept	Palmetto Retina Center, LLC	Both	Child|Adult|Senior	Phase 4	45	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	VGFT-OD-1319	October 9, 2013	October 2013	July 2015	May 2, 2014	May 2014	No Study Results Posted	RANGE	March 2015	Portion of patients who maintain vision (loss of < or = 5 letters ETDRS BCVA) from baseline to Year 1.	https://ClinicalTrials.gov/show/NCT01961414
111	NCT02309281	Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab	Completed	No Results Available	Neovascular Age-related Macular Degeneration	Drug: aflibercept 2mg	Vista Klinik|Bayer	Both	Adult|Senior	Phase 4	33	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Eylea1	November 25, 2014	May 2013	July 2014	December 2, 2014	December 2014	No Study Results Posted	null	May 2014	mean maximum recurrence-free treatment interval (Imax in weeks) with aflibercept treatment during the 24 months study peroid|mean changes in BCVA score at 24 weeks compared to baseline (Δ BCVAscore=BCVAscore 24 weeks - BCVAscore Baseline)|mean changes in CRT (central retinal thickness; in µm) at 24 weeks compared to baseline (Δ CRT=CRT 24 weeks - CRT Baseline)|percentage of patients with a maximum recurrence-free treatment interval of more than 4 weeks at 24 weeks|mean number of treatments needed during the 24 weeks study follow-up|percentage of lesions showing incidence of fluorescein leakage at baseline and 24 weeks.|mean change in total lesion area at 24 weeks compared to baseline (ΔTotalArea=TotalArea 24weeks - TotalArea Baseline)|mean change in area of leakage from CNV at 24 weeks compared to baseline (ΔLeakageArea=LeakageArea 24weeks - LeakageArea Baseline)|change of quality of life scores (VFQ-25, EQ 5D) from baseline to 24 weeks.|number of participants with adverse events (not fullfilling the criteria of serious adverse events) as a measure of safety and tolerability of up to 4weekly dosing of aflibercept in CNV due to AMD|number of participants with serious adverse events as a measure of safety and tolerability of up to 4weekly dosing of aflibercept in CNV due to AMD	https://ClinicalTrials.gov/show/NCT02309281
112	NCT02461771	Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD	Recruiting	No Results Available	Neovascular Age-Related Macular Degeneration	Drug: APL-2	Apellis Pharmaceuticals, Inc.	Both	Adult|Senior	Phase 1	9	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	POT-CP043014	June 2, 2015	January 2015	null	June 2, 2015	May 2015	No Study Results Posted	ASAP II	November 2015	Number and severity of local and systemic adverse events.|Exposure after single APL-2 intravitreal dose (AUC).|Maximum observed serum concentration (Cmax).|Time to maximum measured concentration (Tmax).|Terminal serum elimination half-life (t1/2).	https://ClinicalTrials.gov/show/NCT02461771
113	NCT02125864	Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept	Completed	No Results Available	Exudative Age-related Macular Degeneration	Drug: Aflibercept	Oslo University Hospital	Both	Adult|Senior	Phase 4	16	Other	Interventional	Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label	2014-000103-27	April 24, 2014	April 2014	November 2014	January 19, 2015	January 2015	No Study Results Posted	Eylea-2014	November 2014	Mean change in VEGF plasma concentration (pg/mL)|Mean change in Visual Acuity as measured with the Snellen chart|Central Retinal Thickness as measured by Optical coherence tomography expressed in microns|Number of non-responders	https://ClinicalTrials.gov/show/NCT02125864
114	NCT02307682	Efficacy and Safety of RTH258 Versus Aflibercept	Recruiting	No Results Available	Neovascular Age-Related Macular Degeneration	Drug: RTH258 solution for IVT injection|Drug: Aflibercept solution for IVT injection	Alcon Research	Both	Adult|Senior	Phase 3	1600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)	RTH258-C001|2014-004885-95	November 21, 2014	December 2014	April 2018	August 17, 2015	August 2015	No Study Results Posted	null	June 2017	Change in Best Corrected Visual Acuity (BCVA) from Baseline at Week 48|Average Change in BCVA from Baseline over the Period Week 36 through Week 48|Proportion of patients with positive q12 treatment status up to Week 96|Proportion of patients with positive q12 treatment status at Week 48 within the subjects with no q8 (every 8 weeks) treatment need during the first q12 cycle (Week 16, Week 20)|Change in BCVA from Baseline at Each Postbaseline Visit|Average Change in BCVA from Baseline over the Period Week 4 to Week 48/96|Average Change in BCVA from Baseline over the Period Week 12 to Week 48/96|Average Change in BCVA from Baseline over the Period Week 84 to Week 96|Gain in BCVA of 15/10/5 Letters or More from Baseline to each Postbaseline Visit|Loss in BCVA of 15/10/5 Letters or More from Baseline to each Postbaseline Visit|Change in Central Subfield Thickness (CSFT) from Baseline to each Postbaseline Visit|Change in CNV Lesion Size from Baseline to up to Week 96|Absence of Subretinal Fluid at each Postbaseline Visit|Absence of Intraretinal Fluid at each Postbaseline Visit|Absence of Sub Retinal Pigment Epithelium (RPE) Fluid at each Postbaseline Visit|Percentage of Subjects with q8 Treatment Need Status at Weeks 16, 20, 32, 44, 56, 68, 80, and 92|Change in Patient Reported Outcomes from Baseline up to Week 96|Change in Neurosensory Retinal Thickness from Baseline at Each Postbaseline Visit|Proportion of patients with positive q12 treatment status at Week 96 within the subjects with no q8 need during the first q12 cycle (Week 16, Week 20)	https://ClinicalTrials.gov/show/NCT02307682
115	NCT02434328	Efficacy and Safety of RTH258 Versus Aflibercept - Study 2	Recruiting	No Results Available	Neovascular Age-Related Macular Degeneration	Drug: RTH258 solution for IVT injection|Drug: Aflibercept solution for IVT injection	Alcon Research	Both	Adult|Senior	Phase 3	1200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	RTH258-C002|2014-004886-26	March 27, 2015	July 2015	March 2018	September 11, 2015	September 2015	No Study Results Posted	null	April 2017	Change in Best Corrected Visual Acuity (BCVA) from Baseline at Week 48|Average Change in BCVA from Baseline over the Period Week 36 through Week 48|Proportion of patients with positive q12 treatment status at Week 48|Proportion of patients with positive q12 treatment status at Week 96|Change in BCVA from Baseline at Each Postbaseline Visit|Average Change in BCVA from Baseline over the Period Week 4 to Week 48/96|Average Change in BCVA from Baseline over the Period Week 12 to Week 48/96|Average Change in BCVA from Baseline over the Period Week 84 to Week 96|Gain in BCVA of 15/10/5 Letters or More from Baseline to each Postbaseline Visit|Loss in BCVA of 15/10/5 Letters or More from Baseline to each Postbaseline Visit|Change in Central Subfield Thickness (CSFT) from Baseline to each Postbaseline Visit|Change in CNV Lesion Size from Baseline to up to Week 96|Absence of Subretinal Fluid at each Postbaseline Visit|Absence of Intraretinal Fluid at each Postbaseline Visit|Percentage of Subjects with q8 Treatment Need Status at Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, and 92|Change in Patient Reported Outcomes from Baseline up to Week 96|Change in Neurosensory Retinal Thickness from Baseline at Each Postbaseline Visit|Proportion of patients with positive q12 treatment status at Week 96 within the subjects with no q8 need during the 1st q12 cycle (Week 16, Week 20)	https://ClinicalTrials.gov/show/NCT02434328
116	NCT02445612	Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients	Enrolling by invitation	No Results Available	Stargardt's Macular Dystrophy	Biological: MA09-hRPE	Ocata Therapeutics	Both	Adult|Senior		13	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	ACT MA09-hRPE 001(SMD)LTFU	May 13, 2015	July 2012	December 2030	May 14, 2015	May 2015	No Study Results Posted	null	December 2029	The safety and tolerance of transplantation of hESC-derived RPE cells MA09-hRPE|Evidence of Successful Engraftment of MA09-hRPE Cells|Evidence of Rejection of MA09-hRPE Cells	https://ClinicalTrials.gov/show/NCT02445612
117	NCT02161575	Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD	Recruiting	No Results Available	Neovascular Age-related Macular Degeneration	Drug: Ranibizumab	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	162	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CRFB002AGB17	June 10, 2014	August 2014	October 2016	October 13, 2015	October 2015	No Study Results Posted	SAFARI	October 2016	Change in Central Subfield Retinal Thickness (CSRT) from Baseline to Day 90.|Change in Subfoveal retinal thickness (SRT), central subfield retinal thickness (CSRT) and central subfield retinal volume (CSRV) from Baseline to Day 180|Proportion of patients with Subretinal fluid (SF), intra-retinal cystoid changes (IRC), pigment epithelial detachments (PEDs) or dry retina from baseline to Day 180|Change in size of SF, IRC, PEDs from baseline to Day 180|Change in Best Corrected Visual Acuity (BCVA) from Baseline to Day 180 and between Day 90 and Day 180|Incidence of ocular and systemic adverse events from Baseline to Day 180	https://ClinicalTrials.gov/show/NCT02161575
118	NCT02521142	Non-invasive Optical Angiography in Age-related Macular Degeneration	Not yet recruiting	No Results Available	Age Related Macular Degeneration	Other: Non-invasive OCT based optical angiography|Other: Oxymap T1|Other: Spectralis OCT and Topcon DRI OCT|Other: FLA/ICG angiography	Medical University of Vienna	Both	Child|Adult|Senior		72	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NOAA	August 3, 2015	October 2015	null	August 7, 2015	August 2015	No Study Results Posted	null	December 2015	Differences in visualization of lesion size between non-invasive OCT based optical angiography and FLA/ICG angiography in treatment-naïve and treated patients with CNV due to AMD.|choroidal thickness as assessed with DRI SS-OCT|peripapillarly bloodflow as assessed with Doppler OCT	https://ClinicalTrials.gov/show/NCT02521142
119	NCT02246829	Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START	Recruiting	No Results Available	Neovascular Age-related Macular Degeneration of All Subtypes	Procedure: Intravitreal injection	University Hospital, Bordeaux	Both	Adult|Senior	Phase 4	50	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CHUBX 2013/18	September 11, 2014	September 2014	January 2016	October 22, 2014	September 2014	No Study Results Posted	START	September 2015	Occurence of a Dry SD-OCT 12-week after initiation of a treatment by Aflibercept (EYLEA®) 2mg|Time to get a dry SD-OCT after initiation of a treatment by Aflibercept|Evolution of morphological and visual modification under Aflibercept (EYLEA®)|Occurence of pigment epithelial detachment|Evolution of retinal hemorrhage if any|Evolution in the atrophic lesions|Occurence the central Retinal Thickness	https://ClinicalTrials.gov/show/NCT02246829
120	NCT01914159	Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study	Recruiting	No Results Available	Age Related Macular Degeneration	Drug: Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)	University Hospital, Bonn	Both	Adult|Senior	Phase 2	30	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	N-037.0156	July 28, 2013	February 2013	null	December 2, 2014	December 2014	No Study Results Posted	RIP	February 2016	Best-corrected visual acuity|Retinal morphology|Visual field|Visual function quality of life	https://ClinicalTrials.gov/show/NCT01914159
121	NCT01922128	Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration	Completed	No Results Available	Nonexudative Age-related Macular Degeneration	Drug: MC-1101, Placebo	MacuCLEAR, Inc.	Both	Adult|Senior	Phase 1	20	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	MC-1101-002	August 7, 2013	September 2013	December 2013	April 17, 2014	April 2014	No Study Results Posted	null	November 2013	No significant ocular or systemic adverse events in any of the 20 study subjects	https://ClinicalTrials.gov/show/NCT01922128
122	NCT01830790	Effects of Sildenafil on Choroidal Thickness in AMD	Terminated	Has Results	Age-related Macular Degeneration	Drug: Sildenafil citrate	Duke University	Both	Adult|Senior	Phase 2	10	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Open Label	Pro00042897	April 10, 2013	March 2013	May 2014	May 27, 2015	April 2015	April 29, 2015	null	May 2014	Change in Choroidal Thickness as Assessed on Enhanced-Depth Imaging Optical Coherence Tomography (EDI-OCT)|Change in Central Foveal Thickness as Assessed by Optical Coherence Tomography (OCT)	https://ClinicalTrials.gov/show/NCT01830790
123	NCT02225119	The Focal Electro-Oculogram in Macular Disease	Recruiting	No Results Available	Macular Degeneration|Age-Related Macular Degeneration		National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)	Both	Child|Adult|Senior		130	NIH	Observational	Time Perspective: Cross-Sectional	140171|14-EI-0171	August 23, 2014	August 2014	December 2017	August 5, 2015	June 2015	No Study Results Posted	null	August 2017	Develop method for recording focal EOG|Establish normal range for focal EOG	https://ClinicalTrials.gov/show/NCT02225119
124	NCT01972763	Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.	Recruiting	No Results Available	Recalcitrant Wet Age-related Macular Degeneration	Drug: Ranibizumab	Northern California Retina Vitreous Associates|Genentech, Inc.	Both	Adult|Senior	Phase 1|Phase 2	8	Other|Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ML28904	October 24, 2013	October 2013	null	November 14, 2014	November 2014	No Study Results Posted	RESCUE	September 2015	Mean change in vision|Mean change in BCVA|Mean change in SD-OCT central foveal thickness|Percentage of recalcitrant patients that respond by either OCT or VA to Ranibizumab after not having a complete response to previous therapy|Percentage of patients that need to be escalated to 1 mg therapy	https://ClinicalTrials.gov/show/NCT01972763
125	NCT02090751	Development of a Device to Measure Dark Adaptation	Recruiting	No Results Available	Macular Degeneration|Age-Related Macular Degeneration		University of Manchester	Both	Adult|Senior		40	Other	Observational	Observational Model: Case Control|Time Perspective: Cross-Sectional	II-LB-0712-20001	March 12, 2014	July 2014	April 2015	July 17, 2014	July 2014	No Study Results Posted	null	February 2015	The rate of recovery of the rod phase S2|Lifestyle questionnaire|Participant Experience Questionnaire	https://ClinicalTrials.gov/show/NCT02090751
126	NCT02372916	Geographic Atrophy and Intravitreal Ranibizumab Injections	Recruiting	No Results Available	Age-related Macular Degeneration|Geographic Atrophy	Drug: Ranibizumab	University Health Network, Toronto	Both	Adult|Senior		90	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	14-8235	February 20, 2015	November 2014	null	February 25, 2015	February 2015	No Study Results Posted	null	November 2016	Geographic atrophy area progression|Geographic atrophy morphological characteristics|Concordance of GA enlargement rate between the two eyes	https://ClinicalTrials.gov/show/NCT02372916
127	NCT02291887	Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept	Not yet recruiting	No Results Available	Age-Related Macular Degeneration	Drug: Ranibizumab|Drug: Aflibercept	Associated Retinal Consultants, Michigan|Genentech, Inc.	Both	Adult|Senior		17	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Retrospective	ARCMichigan	November 12, 2014	November 2014	July 2015	November 12, 2014	November 2014	No Study Results Posted	null	July 2015	Genetic characteristics of patients responsive to Ranibizumab but Resistant to Aflibercept	https://ClinicalTrials.gov/show/NCT02291887
128	NCT01846351	Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes	Completed	No Results Available	Epiretinal Membrane|Age Related Macular Degeneration		New England Retina Associates	Both	Adult|Senior		16	Other	Observational	Time Perspective: Retrospective	NAC270608	May 1, 2013	July 2006	February 2010	May 1, 2013	May 2013	No Study Results Posted	null	February 2010	Best corrected visual acuity|Central macular thickness|Fluorescein angiogram	https://ClinicalTrials.gov/show/NCT01846351
129	NCT02467634	Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD	Recruiting	No Results Available	Age-Related Macular Degeneration	Biological: HuCNS-SC sub-retinal transplantation	StemCells, Inc.	Both	Adult|Senior	Phase 2	63	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CL-AMD-201	June 4, 2015	June 2015	December 2017	October 8, 2015	September 2015	No Study Results Posted	RADIANT	December 2017	GA area based on fundus autofluorescence	https://ClinicalTrials.gov/show/NCT02467634
130	NCT02055612	Mobile Clinic - a Cross-sectional Epidemiological Survey	Completed	No Results Available	Age Related Macular Degeneration		Novartis Slovakia, s.r.o.	Both	Adult|Senior		3278	Industry	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	CRFB002ASK01 EPI	February 4, 2014	March 2013	July 2013	February 4, 2014	February 2014	No Study Results Posted	null	May 2013	Aged specific prevalence of aged-related macular degeneration|Social-demography structure of patients with wAMD|Risk factors associated with wAMD (e.g. co-morbidities, nutrition effects)|Relation between home distance of the patients with wAMD from the nearest center and availability of heath care|Other eye diseases during screening process	https://ClinicalTrials.gov/show/NCT02055612
131	NCT02462889	IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD	Not yet recruiting	No Results Available	Age-Related Macular Degeneration	Drug: Eylea|Drug: Placebo	Jeffrey S Heier|Regeneron Pharmaceuticals|Ophthalmic Consultants of Boston	Both	Child|Adult|Senior	Phase 2	128	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject)	VGFTe-AMD-1507	June 2, 2015	June 2015	December 2018	June 3, 2015	June 2015	No Study Results Posted	PRO-CON	December 2018	Proportion of subjects converting to neovascular AMD at 24 months, characterized by the development of choroidal neovascularization (CNV).|Mean change in visual acuity at 24 months compared to baseline|Percentage of subjects losing less than 15 ETDRS letters at 24 months compared to baseline|Incidence and severity of potential ocular side effects including endophthamitis, retinal detachment, cataract, and intraocular inflammation|Incidence and severity of systemic side effects	https://ClinicalTrials.gov/show/NCT02462889
132	NCT02337647	Evaluation of the Distortion Correction Data Collection (DCDC) App Software	Not yet recruiting	No Results Available	Age-related Macular Degeneration	Other: DCDC App	University of Nebraska	Both	Adult|Senior		5	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label	625-14	December 17, 2014	January 2015	June 2015	January 12, 2015	January 2015	No Study Results Posted	null	February 2015	Functionality of the Distortion Correction Data Collection App (DCDC), as measured by successful usage of the app by subjects.	https://ClinicalTrials.gov/show/NCT02337647
133	NCT01920867	Stem Cell Ophthalmology Treatment Study	Recruiting	No Results Available	Retinal Disease|Macular Degeneration|Hereditary Retinal Dystrophy|Optic Nerve Disease|Glaucoma	Procedure: RB (Retrobulbar)|Procedure: ST (Subtenon)|Procedure: IV (Intravenous)|Procedure: IVIT (Intravitreal)|Procedure: IO (Intraocular)	Retina Associates of South Florida|MD Stem Cells	Both	Adult|Senior		300	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ICMS-2013-0019.	August 8, 2013	August 2013	August 2017	October 16, 2015	October 2015	No Study Results Posted	SCOTS	August 2016	Visual acuity|Visual fields	https://ClinicalTrials.gov/show/NCT01920867
134	NCT02464956	Production of iPSC Derived RPE Cells for Transplantation in AMD	Not yet recruiting	No Results Available	Age Related Macular Degeneration (AMD)		Moorfields Eye Hospital NHS Foundation Trust|Medical Research Council	Both	Adult|Senior		10	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	DACL1011	May 14, 2015	July 2015	April 2016	June 3, 2015	May 2015	No Study Results Posted	null	April 2016	Successful production of a Retinal Epithelial (RPE) layer that fulfils Regulatory Regulation for transplantation. This will be confirmed with standard laboratory characterisation of RPE and completed toxicity and safety studies on the cell layer.	https://ClinicalTrials.gov/show/NCT02464956
135	NCT02463344	Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD	Enrolling by invitation	No Results Available	Age-Related Macular Degeneration	Biological: MA09-hRPE	Ocata Therapeutics	Both	Adult|Senior		13	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	ACT MA09-hRPE AMD -001 LTFU	May 13, 2015	July 2012	December 2030	June 2, 2015	June 2015	No Study Results Posted	null	December 2029	Number of patients experiencing a grade 2 or greater adverse event related to the cell product or showed any evidence that the cells were contaminated with an infectious agent or showed any evidence that the cells have tumorigenic potential|Exploratory evaluations for potential efficacy endpoints.|Exploratory evaluation for successful engraftment.	https://ClinicalTrials.gov/show/NCT02463344
136	NCT01944839	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: E10030|Drug: ranibizumab|Drug: E10030 sham intravitreal injection	Ophthotech Corporation	Both	Adult|Senior	Phase 3	622	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	OPH1002	September 9, 2013	August 2013	null	September 8, 2015	September 2015	No Study Results Posted	null	July 2016	Mean Change in Visual Acuity from Baseline at the Month 12 Visit	https://ClinicalTrials.gov/show/NCT01944839
137	NCT01940900	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy	Active, not recruiting	No Results Available	Age-Related Macular Degeneration	Drug: E10030|Drug: ranibizumab|Drug: E10030 sham intravitreal injection	Ophthotech Corporation	Both	Adult|Senior	Phase 3	622	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	OPH1003	September 9, 2013	August 2013	null	September 8, 2015	September 2015	No Study Results Posted	null	July 2016	Mean Change in Visual Acuity from Baseline at the Month 12 Visit.	https://ClinicalTrials.gov/show/NCT01940900
138	NCT01940887	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: E10030|Drug: bevacizumab or aflibercept|Drug: E10030 sham intravitreal injection	Ophthotech Corporation	Both	Adult|Senior	Phase 3	622	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	OPH1004	September 9, 2013	May 2014	null	September 8, 2015	September 2015	No Study Results Posted	null	July 2016	Mean change in visual acuity from baseline at the Month 12 visit.	https://ClinicalTrials.gov/show/NCT01940887
139	NCT02420132	Study to Evaluate Home Vision Testing in Patients Receiving Ranibizumab	Not yet recruiting	No Results Available	Macular Edema, Macular Degeneration	Other: No intervention	Hoffmann-La Roche	Both	Adult|Senior		300	Industry	Observational	Observational Model: Case Control|Time Perspective: Prospective	GE29720	April 14, 2015	April 2015	December 2015	October 1, 2015	October 2015	No Study Results Posted	null	December 2015	Number of "Clicks" on Study Information Advertisements on Patient Advocacy, Digital Media, and Professional Society Websites (main study only)|Percentage of Participants Participating at Specified Milestones in the Recruitment/Enrollment Process (main study only)|Percentage of Participants Performing Self-Testing Two Times per Week Using the Mobile Application|Percentage of Participants Visiting their Ophthalmologist at Least Every 8 Weeks (main study only)|Percentage of Office Visits for Which Visual Acuity Data Were Provided to Scripps Translational Science Institute (STSI) (main study only)|Percentage of Office Visits for Which Optical Coherence Tomography (OCT) Data Were Provided to Scripps Translational Science Institute (STSI) (main study only)|Degree of Correlation between myVisionTrack (mVT) Test Results and Certified Early Treatment Diabetic Retinopathy Study (ETDRS) Protocol Visual Acuity (substudy only)|Degree of Correlation between myVisionTrack (mVT) Test Results and Optical Coherence Tomography (OCT) Characteristics (substudy only)|Association Between myVisionTrack (mVT) Test Results and Routine Visual Acuity Measurements, Measured by Snellen or Other Standard-of-Care Visual Acuity Scores (main study only)|Total Number of Participants in the Enrolled Population (main study only)|Total Number of Participants in the Confirmed Population (main study only)|Differences Between the Participant's and Their Ophthalmologist's Assessments of Eligibility (main study only)|Percentage of Photographed and Transmitted Optical Coherence Tomography OCT Images That are Gradable for Central Subfield Thickness|Percentage of Participants Downloading the myVisionTrack (mVT) Application Who Require Assistance via Human Interaction from the Help Lines|Number of Support Tickets Needed for Technician/Coordinator Interactions with the Participant to Download the myVisionTrack (mVT) Application|Total Support Time as an Average per Participant Needed for Technician/Coordinator Interactions with the Participant to Download the myVisionTrack (mVT) Application|Number of Additional Support (Calls/Interactions) Required by Participants|Incidence of Critical Security Issues Which May Require Reporting|Incidence of Loss of Participant Data Due to Technical Issues|Incidence of Data Processing Issues Occurring During the Study That Are Recoverable, But Require Specific Effort, Indicating a Technical Problem|Score of Participants Survey on Opinions Regarding Self-Monitoring|Percentages of Substudy Optical Coherence Tomography (OCT) Images (Photographs of the OCT Taken Using a Mobile Device), That Are Readable for Qualitative Assessment, Readable for\nQuantitative Assessment, or Indeterminate (substudy only)|Percentage of Actual Substudy Downloaded Optical Coherence Tomography (OCT) Images, That Are Readable for the Presence of Cysts, Sub Retinal Fluid (SRF), and Pigment Epithelial Detachment (PED), or Indeterminate (substudy only)	https://ClinicalTrials.gov/show/NCT02420132
140	NCT01988662	UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-VEGF Effects in Patients With neovascuLar AMD	Recruiting	No Results Available	Neovacular Age-related Macular Degeneration	Procedure: VEGF level assessment	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	204	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	CRFB002A-MAX-IL-01	November 14, 2013	April 2014	September 2015	June 2, 2015	June 2015	No Study Results Posted	UNRAVEL	September 2015	Percent reduction in blood VEGF at month 3 following intravitreal (IVT) injection of anti-VEGF agent|Percent reduction in blood VEGF level overtime|Correlation between blood detected VEGF level and measured concentration of anti-VEGF agent overtime|Mean change from baseline in Best Corrected Visual Acuity (BCVA) of the study eye over time|mean change in central retinal thickness (CRT) of the study eye over time|Number of ocular and systemic Adverse Events	https://ClinicalTrials.gov/show/NCT01988662
141	NCT02243878	Stereotactic Radiotherapy for Wet AMD (STAR)	Recruiting	No Results Available	Neovascular (Wet) Age-related Macular Degeneration (AMD)	Radiation: Stereotactic radiotherapy (16 Gray or Sham)|Drug: 0.5 mg ranibizumab	King's College Hospital NHS Trust|King's College London	Both	Adult|Senior	Phase 3	411	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	Version 1.3 (25.10.2014)|ISRCTN12884465	September 8, 2014	December 2014	October 2022	August 14, 2015	July 2015	No Study Results Posted	STAR	December 2016	Number of as required (prn) ranibizumab injections during the first 24 months|Mean Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) at 24 months.	https://ClinicalTrials.gov/show/NCT02243878
142	NCT02486484	Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection	Recruiting	No Results Available	Neovascularization|Macular Degeneration|Diabetic Retinopathy|Retinal Vein Occlusion|Choroidal Neovascularization|Retinal Neovascularization	Drug: ziv-aflibercept	Rafic Hariri University Hospital	Both	Child|Adult|Senior	Phase 2	100	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	RaficHaririUH	May 24, 2015	March 2015	September 2017	July 1, 2015	July 2015	No Study Results Posted	Zaltrap	May 2017	vision before and after ziv-aflibercept|central macular thickness before and after ziv-aflibercept	https://ClinicalTrials.gov/show/NCT02486484
143	NCT02113254	Study of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine	Completed	No Results Available	Age Macular Degeneration	Other: Corn zeaxanthin	University Hospital, Bordeaux|Vilmorin & Cie	Both	Adult		9	Other	Interventional	Endpoint Classification: Bio-availability Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label	CHUBX 2013/17	April 10, 2014	February 2014	June 2014	October 22, 2014	October 2014	No Study Results Posted	MAIS	June 2014	The primary outcome is the measure of the evolution of the macular pigment density after 10 weeks of supplementation compared with the initial measure.|The measure of the evolution of the plasmatic rate of zeaxanthin after10 weeks of supplementation|The measure of the macular pigment density before supplementation in 3, 6, 8, and 10 weeks of supplementation and after 4 weeks of stop by three methods: the sensibility in colours and two methods of autofluorescence|The measure of plasmatic rate of total cholesterol, HDL-cholesterol, triglycerides, lutein and zeaxanthin, initial and in 6 and 10 weeks of supplementation|In the inclusion, the measure of the visual acuity and the examination of the fundus oculi.|In the inclusion, the measure of the retinal thickness with OCT (Optical Coherence Tomography)	https://ClinicalTrials.gov/show/NCT02113254
144	NCT02402660	Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease	Recruiting	No Results Available	Stargardt Disease|Stargardt Macular Degeneration|Stargardt Macular Dystrophy|Autosomal Recessive Stargardt Disease 1 (ABCA4-related)	Drug: ALK-001|Drug: Placebo	Alkeus Pharmaceuticals, Inc.	Both	Child|Adult	Phase 2	50	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	ALK001-P1002|FDA OOPD	March 9, 2015	August 2015	March 2018	September 16, 2015	September 2015	No Study Results Posted	TEASE	December 2017	Safety and tolerability of 24 months of daily dosing of ALK-001 assessed by Incidence and/or clinically significant changes of a combination of ocular and non-ocular adverse events|Effects of ALK-001 on the progression of Stargardt disease|Pharmacokinetic profile of ALK-001 derived from the concentrations of ALK-001 and metabolites in plasma	https://ClinicalTrials.gov/show/NCT02402660
145	NCT02435940	Inherited Retinal Degenerative Disease Registry	Recruiting	No Results Available	Eye Diseases Hereditary|Retinal Disease|Achromatopsia|Bardet-Biedl Syndrome|Bassen-Kornzweig Syndrome|Batten Disease|Best Disease|Choroidal Dystrophy|Choroideremia|Cone Dystrophy|Cone-Rod Dystrophy|Congenital Stationary Night Blindness|Enhanced S-Cone Syndrome|Fundus Albipunctatus|Goldmann-Favre Syndrome|Gyrate Atrophy|Juvenile Macular Degeneration|Kearns-Sayre Syndrome|Leber Congenital Amaurosis|Refsum Syndrome|Retinitis Pigmentosa|Retinitis Punctata Albescens|Retinoschisis|Rod-Cone Dystrophy|Rod Dystrophy|Rod Monochromacy|Stargardt Disease|Usher Syndrome		Foundation Fighting Blindness Clinical Research Institute	Both	Child|Adult|Senior		20000	Other	Observational	Time Perspective: Prospective	FFB-Registry-01	April 3, 2015	June 2014	June 2034	May 1, 2015	April 2015	No Study Results Posted	null	June 2034	Number of Participants with Rare Diagnoses Within the Inherited Retinal Degenerative Disease Category as Defined by Clinical Evaluation	https://ClinicalTrials.gov/show/NCT02435940
146	NCT02088151	Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina	Recruiting	No Results Available	Macular Edema|Central Serous Chorioretinopathy|Retinal Vein Occlusion|Age-related Macular Degeneration|Retinal Neovascularization	Device: Selective retinal pigment epithelium laser therapy using SRT Vario Laser	University Hospital Inselspital, Berne	Both	Adult|Senior		100	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	003/10|2011-MD-0006	March 6, 2014	June 2010	May 2016	July 15, 2015	July 2015	No Study Results Posted	null	May 2016	Visual Acuity according to ETDRS protocol|Retinal thickness measured by optical coherence tomography|Leakage of fluorescein in fluorescein angiography|Area of absent fundus autofluorescence	https://ClinicalTrials.gov/show/NCT02088151
147	NCT02173873	Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I	Recruiting	No Results Available	Age Related Macular Degeneration|Central Retinal Vein Occlusion	Drug: ziv-aflibercept drug	Rafic Hariri University Hospital	Both	Child|Adult|Senior	Phase 1	100	Other	Interventional	Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	INV 2014-194	June 14, 2014	June 2014	December 2016	June 23, 2014	June 2014	No Study Results Posted	ZIV	September 2016	Ziv-aflibercept in retinal diseases with poor vision: Safety monitoring by OCT and visual acuity|OCT retinal structure	https://ClinicalTrials.gov/show/NCT02173873
148	NCT01778491	AMD Phenotype and Genotype Study	Completed	No Results Available	Age-Related Macular Degeneration|AMD		National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)	Both	Adult|Senior		49	NIH	Observational	Time Perspective: Prospective	130027|13-EI-0027	January 26, 2013	November 2012	September 2015	September 30, 2015	September 2015	No Study Results Posted	null	September 2015	Allow users to assess phenotypes of AMD|Develop and evaluate potential markers and risk|Develop and evaluate an AMD classification scheme(s)|Assess the progression of the disease and investigate that shape it.	https://ClinicalTrials.gov/show/NCT01778491
149	NCT02577107	Head to Head Study of Anti-VEGF Treatment.	Not yet recruiting	No Results Available	Age-related Macular Degeneration	Drug: ranibizumab|Drug: Conbercept	Novartis Pharmaceuticals|Novartis	Both	Child|Adult|Senior	Phase 4	12	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label	CRFB002ACN07	July 30, 2015	December 2015	July 2016	October 13, 2015	October 2015	No Study Results Posted	RELIANCE	July 2016	Change from baseline to 7d post-injection in plasma VEGF concentration after dose 1|Change from baseline to 3h post-injection in plasma VEGF concentration after dose 3|Change from baseline to 1d post-injection in plasma VEGF concentration after dose 3|Change from baseline to 3d post-injection in plasma VEGF concentration after dose 3|Change from baseline to 7d post-injection in plasma VEGF concentration after dose 3|Change from baseline to 28d post-injection in plasma VEGF concentration after dose 3	https://ClinicalTrials.gov/show/NCT02577107
150	NCT02226835	Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198	Recruiting	No Results Available	Age-Related Macular Degeneration|Alzheiner's Disease|AMD		National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)	Both	Adult|Senior		150	NIH	Observational	Time Perspective: Cross-Sectional	140173|14-EI-0173	August 26, 2014	August 2014	October 2015	August 28, 2015	July 2015	No Study Results Posted	null	October 2015	Photographs and images of subjects' eyes|OCT measurement	https://ClinicalTrials.gov/show/NCT02226835
151	NCT01915238	Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study	Completed	No Results Available	AMD|Age- Related Macular Degeneration		National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)	Both	Adult|Senior		52	NIH	Observational	Time Perspective: Prospective	130179|13-EI-0179	July 31, 2013	July 2013	June 2014	August 27, 2015	June 2014	No Study Results Posted	null	June 2014	Vision loss outcome measure is mean change in visual acuity by Early Treatment Diabetic Retinopathy (ETDRS) score.	https://ClinicalTrials.gov/show/NCT01915238
152	NCT01986907	Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye	Active, not recruiting	No Results Available	Wet Age Related Macular Degeneration	Drug: ranibizumab	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	1044	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CRFB002AIT02	November 12, 2013	March 2014	June 2016	October 14, 2015	October 2015	No Study Results Posted	TWEYES	June 2016	Number and type of ocular and systemic drug-related adverse events|Number and frequency of ranibizumab injections|Number and type of systemic and ocular AEs, stratifyed by type of patient|Number and type of AEs by study drug exposure|Number and type of AEs by study drug exposure in presence of possible previous treatment(s)|Number of new onset in the fellow eye with wet AMD diagnosis in patients currently enrolled with unilateral diagnosis.	https://ClinicalTrials.gov/show/NCT01986907
153	NCT01948830	Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD	Active, not recruiting	No Results Available	Age-related Macular Degeneration|Choroidal Neovascularization	Drug: Ranibizumab 0.5mg|Drug: Ranibizumab 0.5mg	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 3	649	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Outcomes Assessor)	CRFB002A2411|2013-002626-23	September 19, 2013	December 2013	November 2015	June 4, 2015	June 2015	No Study Results Posted	TREND	November 2015	BCVA change; by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts|Change in BCVA score from baseline to month 12|Number of visits scheduled|Percentage of patients with Best Corrected Visual Acuity (BCVA) improvements ≥1, ≥5, ≥10, ≥15, and ≥30 letters by visit|Percentage of patients with Best Corrected Visual Acuity (BCVA) loss >=73 letters by visit|Percentage of patients with Best Corrected Visual Acuity (BCVA) loss <5, <10, and <15 letters by visit|BCVA score measured at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts|Average change in BCVA from Baseliine to Month 12|Period (time) between injections|Presence of the disease activity|Change from baseline in central retinal thickness of the study eye over time|Percentage of patients with Choroidal Neovascularization (CNV) leakage in the study eye|Quality of Life|Number of participants with Adverse Events as a measure of Safety and Tolerability	https://ClinicalTrials.gov/show/NCT01948830
154	NCT02379169	Effects of Sea Buckthorn Oil and Lutein on Eye Health	Not yet recruiting	No Results Available	Risk Factors for Age Related Macular Degeneration	Dietary Supplement: Sea buckthorn oil & lutein|Dietary Supplement: Placebo	Turku University Hospital|Aromtech Ltd.	Both	Adult|Senior		90	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	SBEYE	November 7, 2014	February 2015	August 2018	February 26, 2015	November 2014	No Study Results Posted	SBEYE	February 2017	Change in macular pigment optical density from baseline to 6 mo|Change in symptoms of dry eye from baseline to 6 mo|Change in serum lipids (Triglycerides, HDL-cholesterol, LDL-cholesterol, total cholesterol) from baseline to 6 mo|Change in serum markers of inflammation (hs-CRP) from baseline to 6 mo|Change in circulating aminotransferases (ALAT, ASAT) from baseline to 6 mo|Change in contrast sensitivity from baseline to 6 mo|Change in vision aquity from baseline to 6 mo|Change in vision functioning from baseline to 6 mo|Change in tear film osmolarity from baseline to 6 mo	https://ClinicalTrials.gov/show/NCT02379169
155	NCT02321241	Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD	Not yet recruiting	No Results Available	Wet Macular Degeneration	Drug: Aflibercept (EYLEA, BAY-86-5321)	Bayer|Regeneron Pharmaceuticals	Both	Adult|Senior		225	Industry	Observational	Observational Model: Cohort	17405|EY1413FR	December 17, 2014	October 2015	February 2017	September 21, 2015	September 2015	No Study Results Posted	TITAN	December 2016	Treatment success rate (defined as a gain of at least 1 letter in BCVA and/or a diminution of CRT (expressed in µm))|Proportion of patients whose BCVA increases by ≥ 0 letter, ≥ 5 letters, ≥ 10 letters, ≥15 letters|Proportion of patients with less than 15 letters loss|Proportion of patients with dry-OCT|Mean duration of treatment with ranibizumab before initiation of aflibercept|Mean change in Central retinal thickness in µm (OCT)	https://ClinicalTrials.gov/show/NCT02321241
156	NCT02120950	Aflibercept in Polypoidal Choroidal Vasculopathy	Active, not recruiting	No Results Available	Neovascular Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Other: Visudyne	Bayer|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 4	313	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	16995|2013-004464-54	April 10, 2014	May 2014	September 2017	September 14, 2015	September 2015	No Study Results Posted	PLANET	September 2016	Change of ETDRS BCVA (Early Treatment Diabetic Retinopathy Study Best Corrected Visual Acuity)|Number of participants of with a loss of less than 15-letter on BCVA scale	https://ClinicalTrials.gov/show/NCT02120950
157	NCT01942213	Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.	Recruiting	No Results Available	Neovascular Age Related Macular Degeneration		NJ Retina	Both	Adult|Senior		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NJRetina ML28942|NJRetina Observational ML28942	September 10, 2013	December 2013	June 2016	April 20, 2015	April 2015	No Study Results Posted	null	June 2016	To evaluate post-intravitreal injection inflammatory response in patients receiving either ranibizumab or aflibercept.|To evaluate patients 2-3 days post-injection for best corrected visual acuity	https://ClinicalTrials.gov/show/NCT01942213
158	NCT01950741	Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy	Active, not recruiting	No Results Available	Exudative Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy	Drug: aflibercept	Pusan National University Hospital|Bayer	Both	Child|Adult|Senior	Phase 4	48	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	D-1304-013-014	September 23, 2013	September 2013	December 2015	December 17, 2014	December 2014	No Study Results Posted	VAULT	August 2015	Visual acuity reservation|Visual acuity changes|Visual acuity >20/200|Visual acuity >20/40|ICG angiography|Quality of Life	https://ClinicalTrials.gov/show/NCT01950741
159	NCT01819415	Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD	Completed	Has Results	Exudative Age-related Macular Degeneration.	Dietary Supplement: Anti-VEGF plus AREDS-2|Dietary Supplement: Anti-VEGF plus AREDS-1	Maisonneuve-Rosemont Hospital|Centre de Recherche en Ophtalmologie, Université de Montréal|Foundation Fighting Blindness|Retina Foundation of Canada|Insight Instruments|Synergetics Inc|Novartis	Both	Adult|Senior	Phase 1	40	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	HMR-10059	March 24, 2013	February 2011	February 2013	April 28, 2013	April 2013	April 28, 2013	null	August 2011	Vitreal VEGF Levels.|Lipidomics Profile|Central Foveal Thickness	https://ClinicalTrials.gov/show/NCT01819415
160	NCT01983579	TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection	Terminated	No Results Available	Neovascular Age Related Macular Degeneration (AMD)|Open Angle Glaucoma	Procedure: Intraocular anti-VEGF injection|Device: SENSIMED Triggerfish	Sensimed AG	Both	Adult|Senior	Phase 4	4	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label	TF-1304	October 24, 2013	October 2013	February 2014	March 4, 2014	November 2013	No Study Results Posted	null	February 2014	Peak amplitude on SENSIMED Trggerfish (TF) pattern within 2 hours of injection	https://ClinicalTrials.gov/show/NCT01983579
161	NCT02255981	Efficacy of Acupuncture in Macular Diseases	Active, not recruiting	No Results Available	Macular Degeneration	Other: Traditional Chinese Medicine (TCM) Acupuncture	Escuela Neijing	Both	Child|Adult|Senior		33	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Neijing Ophthalmology	September 25, 2014	March 2013	November 2016	October 2, 2014	September 2014	No Study Results Posted	null	May 2016	Improvement and maintenance of gain in visual acuity|Affordability of treatment for Colombian population|Change in macular thickness	https://ClinicalTrials.gov/show/NCT02255981
162	NCT02032173	Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase	Terminated	No Results Available	Macular Edema|Macular Degeneration|Diabetes	Drug: Main group	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 3	31	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CRFB002DFR11	January 8, 2014	May 2014	January 2018	June 10, 2015	June 2015	No Study Results Posted	CONSTELLATION	January 2018	Rate of patients with a stable BCVA at 24 months compared with BCVA at 6 months|Rate of patients will a stable BCVA at 24 months compared with BCVA at 11 months|Rate of patients keeping a BCVA score gain ≥10 letters|Rate of patients keeping a BCVA score gain ≥15 letters|BCVA mean absolute variation from baseline to 24 months|CST evaluation|Effect of follow-up change on CST and BCVA in rescue group|Rate of patients with a BCVA loss ≥15 letters compared with month 6|Number of participants with Adverse Events as a Measure of Safety and Tolerability|Evaluation of the spaced out follow-up on visual functions and quality of life	https://ClinicalTrials.gov/show/NCT02032173
163	NCT01771081	Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy	Completed	No Results Available	Ophthalmology|Macular Edema|Macular Degeneration	Drug: Ranibizumab (or other DME treatment)	Bayer|Regeneron Pharmaceuticals	Both	Child|Adult|Senior		911	Industry	Observational	Observational Model: Cohort	16459|NN1201	January 11, 2013	April 2013	April 2015	May 7, 2015	May 2015	No Study Results Posted	POLARIS	January 2015	Changes in visual acuity, assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) or SNELLEN|Demographic and clinical characteristics (Age, sex, race, employment status, severity of DME)|Mean time from diagnosis to first commencement with an approved anti-VEGF therapy|Changes in retinal thickness, measured by Optical Coherence Tomography (OCT)|Presence of clinically significant macular edema, measured as defined by the ETDRS Research Group|Resource utilization in terms of treatment choices, frequency and duration|Mean change in quality of life score (using the NEI VFQ 25), only in countries where used as part of routine practice	https://ClinicalTrials.gov/show/NCT01771081
164	NCT02067013	Analysis of Aqueous and Vitreous Humor	Not yet recruiting	No Results Available	Proliferative Diabetic Retinopathy|Macular Degeneration|Macular Hole|Neovascular Glaucoma	Drug: Ranibizumab	California Retina Consultants	Both	Adult|Senior	Phase 2	45	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label	ML28894s	February 17, 2014	March 2014	null	February 19, 2014	February 2014	No Study Results Posted	ARK	June 2014	Cytokine Levels|Serum Pharmacokinetics	https://ClinicalTrials.gov/show/NCT02067013
165	NCT02264938	Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation	Completed	No Results Available	Macular Degeneration	Dietary Supplement: Antioxidant	Germans Trias i Pujol Hospital	Both	Adult|Senior		35	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label	AC-11-112	October 9, 2014	January 2013	October 2014	October 9, 2014	October 2014	No Study Results Posted	null	July 2014	Drusen volume change	https://ClinicalTrials.gov/show/NCT02264938
166	NCT02543229	Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD	Recruiting	No Results Available	Eye Diseases|Macular Degeneration|Retinal Diseases|Retinal Degeneration|Neovascularization, Pathologic	Drug: OPT-302|Drug: Lucentis™	Opthea Pty Ltd.	Both	Adult|Senior	Phase 1	50	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	OPT-302-1001	August 25, 2015	July 2015	December 2016	September 3, 2015	September 2015	No Study Results Posted	null	October 2016	Safety (Adverse Events)|Mean change in Best Corrected Visual Acuity (BCVA) from baseline|Mean change in central retinal thickness from baseline|Mean change in Choroidal Neovascularization (CNV) lesion area from baseline|Mean number of retreatment injections of anti-VEGF-A therapy during long term follow-up (week 12 to 24)|Need for 'rescue therapy' with ranibizumab in subjects receiving OPT-302 monotherapy|Assess the Pharmacokinetic profile of OPT-302 alone and in combination with ranibizumab following intravitreal administration|Anti-OPT-302 antibody formation	https://ClinicalTrials.gov/show/NCT02543229
167	NCT02558712	Technology-based Eye Care Services (TECS) Compare	Not yet recruiting	No Results Available	Cataract|Macular Degeneration|Glaucoma	Other: Technology-based Eye Care Services (TECS) Protocol	Emory University	Both	Adult|Senior		600	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	IRB00080630	September 21, 2015	October 2015	September 2017	September 22, 2015	September 2015	No Study Results Posted	null	September 2017	Number of patients with accurate diagnosis of eye diseases from TECS protocol versus face to face eye exam|Number of patients appropriately referred from the TECS protocol|Number of participants with an accurate diagnosis for anterior segment disease|Inter-reader variability of the TECS protocol|Intra-reader variability of the TECS protocol|Compare auto-refraction eyeglass prescriptions with manifest-refraction eyeglass prescriptions	https://ClinicalTrials.gov/show/NCT02558712
168	NCT02555995	Assessment of Scan Quality of Sparse OCT Retina Scanner (MimoStudy01)	Not yet recruiting	No Results Available	Macular Degeneration	Device: OCT scan (as yet unnamed)	University of Bern|University Hospital, Zürich|ISS AG	Both	Adult|Senior		40	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	KEK-ZH-Nr. 2015-0316	September 17, 2015	October 2015	February 2016	September 21, 2015	September 2015	No Study Results Posted	null	February 2016	Distance between ILM and RPE (IPD) measurement successful or not. Successful is defined as a) measurement performed/failed, and if performed, b) value obtained within ±10% of value of reference OCT device.|Patient comfort during examination|Duration of OCT examination with investigational device	https://ClinicalTrials.gov/show/NCT02555995
169	NCT02390245	Improving Glaucoma Detection and Management	Enrolling by invitation	No Results Available	Glaucoma|Glaucoma Suspect|Diabetic Retinopathy|Ocular Hypertension|Cataract|Branch Retinal Vein Occlusion|Branch Retinal Arterial Occlusion|Central Retinal Vein Occlusion|Central Retinal Artery Occlusion|Epi-retinal Membrane|Macular Degeneration|Drusen|Loss of Vision	Other: Use of patient navigation and social worker	Wills Eye|Centers for Disease Control and Prevention|Westat|Public Health Management Corporation|Philadelphia Department of Public Health (PDPH)|The Health Federation of Philadelphia|Crozer-Keystone Health System|Temple Physicians Inc.	Both	Adult|Senior		300	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)	14-441	March 11, 2015	March 2015	December 2019	March 11, 2015	March 2015	No Study Results Posted	null	June 2016	To estimate the positive predictive value (PPV) of the teleophthalmology intervention for diagnosing of glaucoma|Attendance at recommended follow-up visits (Visit 4 and later)	https://ClinicalTrials.gov/show/NCT02390245
170	NCT02313259	The Impact of Ocular Diseases on Driving: a Prospective Study	Active, not recruiting	No Results Available	Macular Degeneration|Glaucoma	Other: Speed discrimination test|Behavioral: Driving simulation	Centre Hospitalier Universitaire de Québec, CHU de Québec	Both	Adult|Senior		60	Other	Observational	Time Perspective: Prospective	2012-1593, DR-002-1370	August 25, 2014	February 2012	February 2016	September 11, 2015	September 2015	No Study Results Posted	null	February 2016	Speed discrimination threshold|Driving performance	https://ClinicalTrials.gov/show/NCT02313259
171	NCT01783925	Eylea Regulatory Post Marketing Surveillance(rPMS)	Recruiting	No Results Available	Macular Degeneration	Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Bayer|Regeneron Pharmaceuticals	Both	Child|Adult|Senior		3600	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	16469|EY1310KR	February 1, 2013	April 2014	December 2018	October 19, 2015	October 2015	No Study Results Posted	null	December 2018	Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs)|Measurement of BCVA (prior to injection and performing other ocular assessments) by eye chart.[BCVA: Best Corrected Visual Acuity]|Central retinal thickness by OCT with or without.[OCT: Optical Coherence Tomography]|Findings of FAG and/or ICAG. [FAG: Fluorescein Angiography|IOP(if performed, before/after injection).[IOP: Intra Ocular Pressure]|Measurement of fundus lesion by fundoscopy	https://ClinicalTrials.gov/show/NCT01783925
172	NCT02162953	Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.	Recruiting	No Results Available	Retinal Disease|Bestrophinopathy|Best Vitelliform Macular Dystrophy|Adult Onset Vitelliform Macular Dystrophy|Autosomal Dominant Vitreoretinalchoroidopathy		Mayo Clinic	Both	Child|Adult|Senior		21	Other	Observational	Time Perspective: Prospective	13-008089	June 11, 2014	February 2014	December 2016	July 13, 2015	July 2015	No Study Results Posted	null	December 2016	Number of iPS cells successfully differentiated into RPE cells	https://ClinicalTrials.gov/show/NCT02162953
173	NCT01991730	Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients	Recruiting	No Results Available	Age Related Macular Degeneration		NJ Retina	Both	Adult|Senior		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NJRetina-ML28942|NJRetina Observational ML28942	November 11, 2013	October 2013	null	April 20, 2015	April 2015	No Study Results Posted	null	June 2016	To evaluate post-intravitreal injection inflammatory response in patients receiving either ranibizumab or aflibercept.|To evaluate patients 2-3 days post-injection for best corrected visual acuity	https://ClinicalTrials.gov/show/NCT01991730
174	NCT01866371	High Resolution Retinal Imaging	Recruiting	No Results Available	Stargardts|Retinitis Pigmentosa|Age-related Macular Degeneration|Choroideremia|Geographic Atrophy	Procedure: Retinal imaging	University of Pennsylvania|National Eye Institute (NEI)	Both	Child|Adult|Senior		600	Other|NIH	Observational	Observational Model: Case Control|Time Perspective: Prospective	817019|R24EY019861	May 28, 2013	May 2013	null	December 12, 2014	December 2014	No Study Results Posted	AOSLO	December 2017	high-resolution images of retina|Cone mosaic parameters	https://ClinicalTrials.gov/show/NCT01866371
175	NCT02563782	Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD	Recruiting	No Results Available	Age-Related Macular Degeneration	Biological: Sub-retinal transplantation of MA09-hRPE cells|Drug: tacrolimus and mycophenolate mofetil|Drug: Placebo tacrolimus and mycophenolate mofetil|Procedure: Sham Surgery	Ocata Therapeutics	Both	Adult|Senior	Phase 2	60	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	MA09-hRPE AMD 02 PORTRAY	September 21, 2015	August 2015	May 2019	September 29, 2015	September 2015	No Study Results Posted	PORTRAY	March 2017	Number of subjects with evidence of graft failure or rejection.|Change in area of geographic atrophy by Optical coherence tomography|Change in area of geographic atrophy by Autofluorescence|Change in average Best Corrected Visual Acuity (BCVA)	https://ClinicalTrials.gov/show/NCT02563782
176	NCT02550002	Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen	Not yet recruiting	No Results Available	Age Related Macular Degeneration	Drug: Aflibercept	University Hospital Inselspital, Berne	Both	Adult|Senior		175	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	TOLERANT	September 1, 2015	November 2015	November 2019	September 11, 2015	September 2015	No Study Results Posted	null	November 2018	Change in best corrected visua acuity (BCVA) from baseline to end of treatment (EOS) at week 104. The primary outcome of the trial is the difference between the two arms in the mean change in BCVA from baseline to EOS.|The difference between the two arms in the mean change in BCVA from baseline to week 52.|The difference between the two arms in the mean change in central retinal thickness (CRT) from baseline to week 52 and to EOS.|The difference between the two arms in the mean number of injections from baseline to week 52 and to EOS.|The difference between the two arms in the proportion of patients showing newly developed geographic atrophy at week 52 and at EOS as compared to baseline.|The difference between the two arms in the mean change in the area of new and existing geographic atrophy from baseline to week 52 and to EOS.|The difference between the two arms in the proportion of patients showing no IRF and no SRF at week 52 and at EOS.|The difference between the two arms in the proportion of patients showing no SRF at week 52 and at EOS.	https://ClinicalTrials.gov/show/NCT02550002
177	NCT02452385	Phase 1 Study of CM082 in Patients With Wet-AMD	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: CM082 tablet	AnewPharma|West China Hospital	Both	Adult|Senior	Phase 1	32	Industry|Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CM082-OPH-101	March 10, 2015	March 2015	December 2016	May 20, 2015	March 2015	No Study Results Posted	null	March 2016	Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area under the plasma concentration versus time curve (AUC) of CM082|Change in best corrected visual acuity (BCVA) (in number of letters)|Change in optical coherence tomography (OCT) (in micron)	https://ClinicalTrials.gov/show/NCT02452385
178	NCT02441816	VITAL - Individualising Therapy for Neovascular AMD With Aflibercept	Recruiting	No Results Available	Age Related Macular Degeneration	Drug: Aflibercept|Other: Extend Treatment	Moorfields Eye Hospital NHS Foundation Trust	Both	Adult|Senior	Phase 4	50	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	2014-002381-73	October 20, 2014	November 2014	November 2017	May 7, 2015	April 2015	No Study Results Posted	VITAL	November 2017	Primary outcome - mean change in visual acuity (Early Treatment of Diabetic Retinopathy Study letter score)	https://ClinicalTrials.gov/show/NCT02441816
179	NCT02387957	An 18 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: Fovista®|Drug: bevacizumab|Drug: ranibizumab|Drug: aflibercept	Ophthotech Corporation	Both	Adult|Senior	Phase 2	60	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	OPH1006	March 9, 2015	February 2015	March 2017	August 10, 2015	August 2015	No Study Results Posted	null	March 2017	To evaluate the safety of Fovista (anti-PDGF BB) when administered in combination with anti-VEGF therapy as assessed by the incidence of test article related adverse events	https://ClinicalTrials.gov/show/NCT02387957
180	NCT02357342	Sirolimus Versus AntiVEGF for Wet AMD	Recruiting	No Results Available	Age-Related Macular Degeneration	Drug: Sirolimus|Drug: Standard of Care intravitreal injections of anti-VEGF	Maturi, Raj K., M.D., P.C.	Both	Adult|Senior	Phase 2	30	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	RKM008	February 2, 2015	April 2015	June 2016	June 25, 2015	June 2015	No Study Results Posted	null	June 2016	Change in edema from baseline to month 6 measured by central subfield thickness on Heidelberg optical coherence topography|visual acuity (best corrected visual acuity)	https://ClinicalTrials.gov/show/NCT02357342
181	NCT02345317	Reticular Pseudodrusen Progression Study	Recruiting	No Results Available	Age-related Macular Degeneration		University Hospital Muenster	Both	Adult|Senior		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	AltenAugenklinik	January 19, 2015	December 2014	null	January 19, 2015	January 2015	No Study Results Posted	null	July 2017	Change of reticular pseudodrusen affected retinal area to baseline	https://ClinicalTrials.gov/show/NCT02345317
182	NCT02332343	Sparing of the Fovea in Geographic Atrophy Progression	Recruiting	No Results Available	Atrophy|Geographic Atrophy|Age-related Macular Degeneration|Eye Diseases	Other: No intervention - Natural history study	University Hospital, Bonn|Genentech, Inc.	Both	Adult|Senior		30	Other|Industry	Observational	Observational Model: Case-Crossover|Time Perspective: Cross-Sectional	173/14	January 4, 2015	October 2014	June 2015	January 17, 2015	January 2015	No Study Results Posted	SIGHT	June 2015	Best corrected visual acuity (BCVA)|Size of Geographic atrophy area as determined by confocal laser scanning ophthalmoscopy (in mm²)|Size of foveal sparing area as determined by confocal laser scanning ophthalmoscopy (in mm²)	https://ClinicalTrials.gov/show/NCT02332343
183	NCT02308215	Retinal Therapy Guided by 3D OCT Image Analysis	Recruiting	No Results Available	Age-Related Macular Degeneration|Choroidal Neovascularization		University of Iowa|National Eye Institute (NEI)	Both	Adult|Senior		200	Other|NIH	Observational	Observational Model: Case-Only|Time Perspective: Prospective	UIowa201003712|1R01EY019112-01A2	November 13, 2014	July 2010	null	December 4, 2014	December 2014	No Study Results Posted	null	November 2019	Measure central retinal layer thickness in µms.|Measure amount of fluid in the retina in µms.	https://ClinicalTrials.gov/show/NCT02308215
184	NCT02230228	Phase 1 Safety Study of ALK-001 in Healthy Volunteers	Completed	No Results Available	Stargardt Disease|Age-related Macular Degeneration|Other Retinal Dystrophies	Drug: ALK-001 (No generic name)	Alkeus Pharmaceuticals, Inc.	Both	Adult|Senior	Phase 1	40	Industry	Interventional	Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label	ALK001-P1001	August 27, 2014	April 2014	February 2015	March 21, 2015	March 2015	No Study Results Posted	null	September 2014	Safety of 4-week daily dosing of ALK-001 in healthy adults.	https://ClinicalTrials.gov/show/NCT02230228
185	NCT02227498	Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol	Recruiting	No Results Available	Age Related Macular Degeneration	Device: Argus II Retinal Prosthesis System	Second Sight Medical Products	Both	Adult|Senior	Phase 1	5	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CP-04-01	August 25, 2014	October 2014	March 2018	January 16, 2015	January 2015	No Study Results Posted	null	March 2016	The number of adverse events in implanted subjects.|Visual function	https://ClinicalTrials.gov/show/NCT02227498
186	NCT02214628	Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD	Active, not recruiting	No Results Available	Age-related Macular Degeneration	Drug: Fovista® (anti-PDGF BB) plus anti-VEGF	Ophthotech Corporation	Both	Adult|Senior	Phase 2	100	Industry	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	OPH1005	August 5, 2014	July 2014	May 2017	July 20, 2015	July 2015	No Study Results Posted	null	May 2017	safety	https://ClinicalTrials.gov/show/NCT02214628
187	NCT02174211	Effect of Vitrectomy and Posterior Vitreous Detachment on Intravitreal Ranibizumab Pharmacokinetics	Recruiting	No Results Available	Age Related Macular Degeneration	Drug: Ranibizumab	King's College Hospital NHS Trust|King's College London	Both	Adult|Senior		120	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	EudraCT Number: 2012-005500-18	June 24, 2014	June 2014	null	August 14, 2015	July 2015	No Study Results Posted	VITCLEAR	December 2015	Ranibizumab half-life	https://ClinicalTrials.gov/show/NCT02174211
188	NCT02126423	Resistance to Antibiotics in Patients Receiving Eye Injections	Completed	No Results Available	Age-Related Macular Degeneration|Retinal Vein Occlusion|Diabetic Retinopathy	Other: Conjunctival and nasopharyngeal swabs	NJ Retina|Genentech, Inc.	Both	Adult|Senior		40	Other|Industry	Observational	Time Perspective: Prospective	1001	April 23, 2014	May 2014	September 2014	April 20, 2015	April 2015	No Study Results Posted	null	September 2014	Kirby Bauer disc diffusion antimicrobial susceptibility	https://ClinicalTrials.gov/show/NCT02126423
189	NCT02102880	The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects	Recruiting	No Results Available	Age-Related Macular Degeneration	Genetic: the polymerase chain reaction (PCR)	Medical University of Vienna	Both	Adult		220	Other	Interventional	Intervention Model: Single Group Assignment|Masking: Open Label	OPHT-040214	March 21, 2014	March 2015	null	September 7, 2015	September 2015	No Study Results Posted	null	December 2016	Choroidal blood flow during isometric exercise (LDF)|Flicker induced vasodilatation, expressed as percent change to baseline (DVA)|Genotyping (PCR)|Retinal vessel calibers and AV- ratio (DVA)	https://ClinicalTrials.gov/show/NCT02102880
190	NCT02035722	Intravitreal Injections-related Anxiety	Completed	No Results Available	Age-related Macular Degeneration	Behavioral: Printed materials|Behavioral: Video	University Health Network, Toronto	Both	Adult|Senior	Phase 2|Phase 3	73	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor)	UHN-110463AE	January 10, 2014	September 2011	June 2014	February 20, 2015	February 2015	No Study Results Posted	null	April 2014	Anxiety|Knowledge of AMD	https://ClinicalTrials.gov/show/NCT02035722
191	NCT01879501	Living Successfully With Chronic Eye Diseases	Recruiting	No Results Available	Chronic Diseases|Low Vision|Diabetic Retinopathy|Glaucoma|Age-related Macular Degeneration	Behavioral: Low Vision Self-Management Program	Singapore Eye Research Institute|Ministry of Health, Singapore|University of Melbourne|Singapore National Eye Centre|Curtin University of Technology	Both	Adult|Senior		160	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Single Blind (Outcomes Assessor)	HSRG11MAY005	April 10, 2013	January 2013	January 2015	June 14, 2013	June 2013	No Study Results Posted	ADAPT-LAH	January 2014	Vision-related quality of life|Perceived self-efficacy, emotional well being, and vision-specific distress	https://ClinicalTrials.gov/show/NCT01879501
192	NCT01876147	Visual and Functional Assessment in Low Vision Patients	Recruiting	No Results Available	Retinitis Pigmentosa|Age-related Macular Degeneration|Optic Nerve Pathology|Inherited Retinal Dystrophies		University of Oxford	Both	Adult|Senior		50	Other	Observational	Observational Model: Case-Crossover|Time Perspective: Prospective	OxfordVA2013	June 10, 2013	June 2013	December 2016	March 10, 2015	June 2013	No Study Results Posted	null	August 2016	Comparison of VA measured with FrACT and BRVT vision tests|Relationship between VA and ability to carry out daily living tasks.	https://ClinicalTrials.gov/show/NCT01876147
193	NCT01859299	Intestinal Bacteria and Ocular Inflammatory Disease	Recruiting	No Results Available	Uveitis|Age-Related Macular Degeneration		National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)	Both	Adult|Senior		65	NIH	Observational	Time Perspective: Prospective	130072|13-EI-0072	May 17, 2013	January 2013	September 2016	October 3, 2015	July 2015	No Study Results Posted	null	September 2016	The primary outcome is principal component analysis using the unweighted UniFrac distance metric of microbial composition; the significance between groups will be tested by the Adonis method	https://ClinicalTrials.gov/show/NCT01859299
194	NCT01830608	Risk Factors for Drusen Progression	Withdrawn	No Results Available	Age-related Macular Degeneration		Medical University of Vienna	Both	Adult|Senior		0	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	OPHT-240912	April 10, 2013	January 2015	March 2015	April 7, 2015	April 2015	No Study Results Posted	null	March 2015	Drusen area and volume as measured using polarization sensitive-OCT|Visual acuity and refraction|Choroidal blood flow|Macular pigment optical density	https://ClinicalTrials.gov/show/NCT01830608
195	NCT02445313	Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device	Not yet recruiting	No Results Available	Age-related Macular Degeneration (AMD)	Device: Nidek MP-3	Doheny Image Reading Center	Both	Child|Adult|Senior		100	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	NIDEKMP3	May 13, 2015	June 2015	June 2016	May 14, 2015	May 2015	No Study Results Posted	null	June 2016	Geographic Atrophy	https://ClinicalTrials.gov/show/NCT02445313
196	NCT01846273	Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy.	Active, not recruiting	No Results Available	Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy (PCV)	Drug: Ranibizumab|Drug: Verteporfin PDT|Drug: Sham PDT	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	321	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	CRFB002A2412	April 29, 2013	August 2013	April 2017	June 2, 2015	June 2015	No Study Results Posted	EVEREST II	April 2017	Change from Baseline in in Visual Acuity (Letters) of the Study Eye to Month 12|Complete polyp regression assessed by ICGA at Month 12|Change from Baseline in Visual Acuity (Letters) of the Study Eye over time|Gain of equal or more than 5, 10, or 15 letters in Visual Acuity of the Study Eye up to Month 24|Loss of less than 5, 10, 15, and 30 letters in Visual Acuity in the Study Eye from baseline to Month 24|Maintenance of Visual Acuity of the Study Eye at Month 12 and 24 compared to the time point of first treatment interruption|Change in Visual Acuity (Letters) of the Study Eye at Month 12 and 24 compared to the timepoint of first treatment interruption|Occurrence of complete polyp regression in the Study Eye as assessed by ICGA at Months 6 and 24|Presence of leakage in the Study Eye based on fluorescein angiography at Months 6, 12 and 24|Change from Baseline in Central Subfield Retinal Thickness (CSRT) of the Study Eye over time|Total number of treatments with ranibizumab in the Study Eye and total number of treatments with verteporfin PDT from baseline to Month 12 and 24|Total number of treatments in the Study Eye with ranibizumab from Month 3 to Month 12 and 24|National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) scores at baseline, Months 3, 12, and 24, and change from baseline over time|Frequency and severity of ocular and non-ocular adverse events over time	https://ClinicalTrials.gov/show/NCT01846273
197	NCT02479386	An Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Proxima A).	Recruiting	No Results Available	Geographic Atrophy		Hoffmann-La Roche	Both	Adult|Senior		360	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	GX29633|2014-003939-19|GX29639	June 19, 2015	August 2015	April 2020	September 3, 2015	September 2015	No Study Results Posted	null	April 2020	Macular functional response as assessed by mesopic microperimetry (MP)|Binocular reading speed as assessed by the Minnesota Low-Vision Reading Test (MNRead) or by Radner Reading Cards|Best Corrected Visual Acuity (BCVA) as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart under low luminance conditions|Change in the Geographic Atrophy (GA) area, as assessed by retinal imaging|Change over time in selected patient-reported outcomes, as assessed by the National Eye Institute Visual Functioning Questionnaire 25-item Version (NEI VFQ-25)	https://ClinicalTrials.gov/show/NCT02479386
198	NCT02399072	An Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Proxima B)	Recruiting	No Results Available	Geographic Atrophy		Hoffmann-La Roche	Both	Adult|Senior		200	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	GX29639|2014-003940-11|GX29633	March 23, 2015	March 2015	February 2021	October 1, 2015	October 2015	No Study Results Posted	null	February 2021	Change in the GA area, as assessed by retinal imaging|Change in additional measures of visual function|Best Corrected Visual Acuity (BCVA) score as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) chart under low luminance conditions	https://ClinicalTrials.gov/show/NCT02399072
199	NCT02247479	A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)	Recruiting	No Results Available	Geographic Atrophy	Drug: Lampalizumab|Other: Sham	Hoffmann-La Roche	Both	Adult|Senior	Phase 3	936	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	GX29176|2014-000107-27	July 15, 2014	September 2014	September 2018	October 1, 2015	October 2015	No Study Results Posted	null	September 2018	Change in GA area, as assessed by retinal imaging|Change in best corrected visual acuity (BCVA)|Change in additional measures of visual function	https://ClinicalTrials.gov/show/NCT02247479
200	NCT02061865	Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD	Completed	No Results Available	Neovascular Wet Age-related Macular Degeneration (AMD)	Drug: REGN2176-3	Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 1	12	Industry	Interventional	Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	R2176-3-AMD-1303	January 28, 2014	February 2014	December 2014	February 9, 2015	February 2015	No Study Results Posted	null	December 2014	Safety	https://ClinicalTrials.gov/show/NCT02061865
201	NCT01782989	Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)	Recruiting	No Results Available	Geographic Atrophy	Drug: ORACEA®|Drug: Placebo	Paul Yates, MD, PhD|MEDARVA Foundation|University of Virginia	Both	Adult|Senior	Phase 2|Phase 3	286	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	16586	January 31, 2013	February 2013	December 2017	June 19, 2015	June 2015	No Study Results Posted	TOGA	July 2017	Rate of enlargement in area of geographic atrophy in the study eye during the treatment period.|Change in Best Corrected Visual Acuity (BCVA)	https://ClinicalTrials.gov/show/NCT01782989
202	NCT02410122	The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy	Recruiting	No Results Available	Stargardt Disease		Johns Hopkins University|The Shulsky Foundation	Both	Child|Adult|Senior		15	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NA_00092688	March 5, 2015	December 2014	March 2018	September 14, 2015	September 2015	No Study Results Posted	ProgStar-4	March 2018	Growth of atrophic lesions as measured by fundus autofluorescence (FAF) imaging|Rate of retinal thinning and photoreceptor loss as measured by spectral domain optical coherence tomography (sd-OCT)|Loss of retinal sensitivity as measured by microperimetry|Change in best-corrected visual acuity by using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol|Correlation of all outcome measures with genetic profile	https://ClinicalTrials.gov/show/NCT02410122
203	NCT02557451	Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications	Not yet recruiting	No Results Available	Subretinal Haematoma Linked to AMD	Other: Surgery|Other: Intravitreal injections of gas|Procedure: injections of an antiangiogenic	Centre Hospitalier Universitaire Dijon	Both	Adult|Senior		90	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label	BRON PHRC I 2013	September 16, 2015	null	null	September 22, 2015	August 2015	No Study Results Posted	STAR	January 2020	Visual acuity measured on the ETDRS scale|Area of the scotoma presented by the patient according to the Amsler grid|Quality of life using the VFQ-25 scale|Number of injections of an antiangiogenic at the end of the 6 months of treatment|Number of patients with macular bleeding|Area of hypoautofluorescence using the autofluorescence technique|Complications rate	https://ClinicalTrials.gov/show/NCT02557451
204	NCT02247531	A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)	Recruiting	No Results Available	Geographic Atrophy	Drug: Lampalizumab|Other: Sham	Hoffmann-La Roche	Both	Adult|Senior	Phase 3	936	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	GX29185|2014-000106-35	July 15, 2014	October 2014	November 2017	October 1, 2015	October 2015	No Study Results Posted	null	November 2017	Change in GA area, as assessed by retinal imaging|Change in best corrected visual acuity (BCVA)|Change in additional measures of visual function	https://ClinicalTrials.gov/show/NCT02247531
205	NCT01802866	Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride	Active, not recruiting	No Results Available	Geographic Atrophy	Drug: ACU-4429|Drug: Placebo	Acucela Inc.|Otsuka Pharmaceutical Co., Ltd.	Both	Adult|Senior	Phase 2|Phase 3	480	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	4429-202	February 28, 2013	February 2013	July 2016	July 16, 2015	July 2015	No Study Results Posted	SEATTLE	July 2016	Change from baseline in the total area of the GA lesion(s)|Change from baseline in BCVA score|Frequency of AEs, discontinuations due to AEs, or dose modifications; severity and seriousness of AEs	https://ClinicalTrials.gov/show/NCT01802866
206	NCT01790958	Microcurrent Stimulation to Treat Macular Degeneration	Completed	No Results Available	Retinal Diseases|Stargardt's Disease|Retinitis Pigmentosa		Retina Institute of Hawaii	Both	Adult|Senior		50	Other	Observational	Observational Model: Case Control|Time Perspective: Retrospective	RIH 1009	February 11, 2013	June 2012	December 2012	February 11, 2013	February 2013	No Study Results Posted	null	December 2012	Measure visual acuity after receiving microcurrent stimulation treatments.	https://ClinicalTrials.gov/show/NCT01790958
207	NCT02158624	Ranibizumab Treatment for Age-Related Macular Degeneretion	Recruiting	No Results Available	Visual Disorder Due to Age-related Macula Degeneration	Drug: Intravitreal Lucentis 0.5mg	Kyushu University|University of Occupational and Environmental Health|Kurume University|Fukuoka University|Clinical Research Support Center Kyush|Novartis	Both	Adult|Senior		100	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	13-E-09	June 5, 2014	December 2013	December 2015	June 5, 2014	June 2014	No Study Results Posted	QUATRO	April 2015	Baseline change of visual acuity and QOL after ranibizumab treatment|To evaluate the correlation between the changes of visual acuity and QOL measurement during one year follow-up observations	https://ClinicalTrials.gov/show/NCT02158624
208	NCT01977846	A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies	Active, not recruiting	No Results Available	Stargardt Disease		Foundation Fighting Blindness Clinical Research Institute|Foundation Fighting Blindness|Department of Defense	Both	Child|Adult|Senior		200	Other|U.S. Fed	Observational	Observational Model: Case-Only	FFBCRI-PROGSTAR-01/02	October 31, 2013	August 2013	January 2017	October 5, 2015	October 2015	No Study Results Posted	ProgSTAR	January 2017	To assess the yearly rate of progression of STGD using the growth of atrophic lesions as measured by fundus autofluorescence (FAF) imaging.|To assess the yearly rate of progression of STGD using spectral-domain optical coherence tomography (sd-OCT) to measure the rates of retinal thinning and the loss of photoreceptors|To assess the yearly rate of loss of retinal sensitivity as measured by microperimetry.|To assess the yearly rate of visual acuity changes as measured by best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol|To correlate the presence and progression of morphological abnormalities in FAF and sd-OCT images with visual function as measured by microperimetry and visual acuity.|To perform exploratory analysis of factors associated with STGD progression, such as participant's use of vitamin A supplementation, and mutations in the ABCA4 gene.|To assess the yearly rate of loss of retinal sensitivity as measured by scotopic microperimetry.	https://ClinicalTrials.gov/show/NCT01977846
209	NCT02136303	Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of AMD-patients	Recruiting	No Results Available	Changes in Macular Pigment Optical Density	Dietary Supplement: S1: Dosage-dependency|Other: S2: Kale extract versus kale purée|Other: S3: Kale extract: AMD-patients	University of Jena	Both	Adult|Senior		90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	BO 1511/8-1	May 6, 2014	February 2015	null	September 24, 2015	September 2015	No Study Results Posted	KALESIGHT	December 2018	changes in macular pigment optical density MPOD [ODU: optical density units]	https://ClinicalTrials.gov/show/NCT02136303
210	NCT02126904	Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept	Recruiting	No Results Available	The Injection Burden	Drug: IVA group	Yokohama City University Medical Center|Novartis Pharmaceuticals	Both	Adult|Senior		200	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Retrospective	1310006	April 27, 2014	January 2012	null	April 28, 2014	April 2014	No Study Results Posted	null	October 2013	Time to recurrence after induction phase	https://ClinicalTrials.gov/show/NCT02126904
211	NCT02338973	Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)	Recruiting	No Results Available	Inherited Ophthalmic Diseases|Inherited Retinal Degeneration	Drug: Interferon gamma-1b	National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)	Both	Child|Adult|Senior	Phase 1|Phase 2	12	NIH	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	150052|15-EI-0052	January 14, 2015	December 2014	null	June 2, 2015	May 2015	No Study Results Posted	null	December 2015	Number and severity of IP-related AEs|Changes in Visual Function	https://ClinicalTrials.gov/show/NCT02338973
212	NCT01958918	Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD	Recruiting	No Results Available	Visual Impairment Due to Neovascular AMD	Drug: Ranibizumab|Drug: Aflibercept	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	500	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	CRFB002ADE23	October 7, 2013	October 2013	August 2016	October 14, 2015	October 2015	No Study Results Posted	SALT	August 2016	Central retinal thikness stability|Functional outcomes	https://ClinicalTrials.gov/show/NCT01958918
213	NCT01787669	Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema	Recruiting	No Results Available	Diabetes|Diabetic Macular Oedema|Diabetic Macular Edema|Diabetic Retinopathy	Drug: Avastin (Bevacizumab)|Drug: Ozurdex (dexamethasone)	University of Sydney|Allergan	Both	Adult|Senior	Phase 2	50	Other|Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	SwitchDMO	February 6, 2013	June 2013	December 2015	June 11, 2014	June 2014	No Study Results Posted	SwitchDMO	October 2014	Proportion of eyes that have central macular thickness <300 microns 6 months after switching|Mean change in central macular thickness (CMT) as measured by OCT.	https://ClinicalTrials.gov/show/NCT01787669
214	NCT01975103	Endpoint Management Software for Photothermal Stimulation of Macular Diseases	Recruiting	No Results Available	Diabetic Macular Edema|Branch Retinal Vein Occlusion|Chronic Central Serous Retinopathy|Macular Telangiectasia	Procedure: Topcon Endpoint Management	Federal University of Rio Grande do Sul	Both	Adult|Senior	Phase 2	null	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	EPM-001	October 28, 2013	March 2013	null	December 1, 2013	December 2013	No Study Results Posted	EPM	November 2014	Best corrected visual acuity|Central macular thickness on OCT	https://ClinicalTrials.gov/show/NCT01975103
215	NCT02169648	Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion	Recruiting	No Results Available	Macular Edema|Branch Retinal Vein Occlusion|Central Retinal Vein Occlusion	Drug: ranibizumab	Tokyo Medical University	Both	Adult|Senior		100	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	H-4	June 13, 2014	December 2013	December 2015	June 18, 2014	June 2014	No Study Results Posted	null	December 2015	Visual function by ranibizumab in macular edema with retnal vein occlusion|Cytokine levels by ranibizumab in macular edema with retnal vein occlusion	https://ClinicalTrials.gov/show/NCT02169648
216	NCT02503540	Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO	Recruiting	No Results Available	Retinal Vein Occlusion|Diabetic Macular Edema|Branch Retinal Vein Occlusion|Central Retinal Vein Occlusion	Drug: Aflibercept	Justis Ehlers|Regeneron Pharmaceuticals|The Cleveland Clinic	Both	Adult|Senior	Phase 4	30	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	15-442	July 17, 2015	August 2015	July 2017	August 26, 2015	August 2015	No Study Results Posted	PERMEATE	July 2017	Mean change in total leakage index|Diabetic retinopathy severity (if applicable)|Amount hemorrhage|Change in ischemic index (defined as the proportion of retinal area with nonperfusion)|Mean absolute change from baseline central subfield thickness|Mean change from baseline in best-corrected visual acuity (BCVA) score|Percentage of subjects that were anatomically 'dry' by SDOCT|Percentage of participants who gained or lost 10 letters or more of vision|Percentage of subjects who gained or lost 15 letters or more of vision|Percentage of patients that are 20/40 or better|Percentage of patients that are 20/200 or worse|Incidence and severity of ocular and non-ocular adverse events (AEs) and serious AEs.	https://ClinicalTrials.gov/show/NCT02503540
217	NCT02229175	Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema	Not yet recruiting	No Results Available	Diabetic Macular Edema	Drug: bevacizumab|Device: PASCAL Endpoint Management (EpM) laser treatment	University of California, San Francisco	Both	Adult|Senior	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)	14-14153	August 14, 2014	July 2015	January 2018	March 4, 2015	March 2015	No Study Results Posted	null	January 2018	Retinal thickness|Visual Acuity|Number of injections of bevacizumab needed	https://ClinicalTrials.gov/show/NCT02229175
218	NCT02181400	Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema	Not yet recruiting	No Results Available	Diabetic Macular Oedema	Device: Ellex Integre NIR laser	University of Sydney	Both	Adult|Senior		21	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	NIRD	June 27, 2014	July 2014	May 2017	July 2, 2014	June 2014	No Study Results Posted	NIRD	February 2016	Change in measurement( in microns) in central macular thickness as measured by Spectral Domain Optical coherence Tomography( OCT)|Change in measurement( in microns) in central macular thickness as measured by Spectral Domain Optical coherence Tomography( OCT|change in total macular volume as measured by Spectral Domain Optical Coherence Tomography (in microns).|Change in total macular volume as measured by Spectral Domain Optical Coherence Tomography|Change in Logmar Best corrected visual acuity (BCVA)|Change in Logmar best corrected visual acuity (BCVA)	https://ClinicalTrials.gov/show/NCT02181400
219	NCT02443012	Topical Nepafenac as Supplement for Diabetic Macular Edema	Completed	No Results Available	Diabetic Macular Edema	Drug: Topical Gutt Nepafenac 0.1%|Procedure: Laser	University of Science Malaysia	Both	Adult|Senior	Phase 4	47	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	NMRR-13-1296-13714|1001/PPSP/812064	April 25, 2015	March 2013	August 2014	May 8, 2015	May 2015	No Study Results Posted	null	August 2014	Changes in Logarithm Best Minimal Angle of Resolution Corrected Visual Acuity (LogMAR BCVA) (Measurement of Visual Acuity)|Changes in central macular thickness (measurement of macular thickness)	https://ClinicalTrials.gov/show/NCT02443012
220	NCT01994291	A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema	Terminated	No Results Available	Macular Edema, Diabetic	Drug: Ranibizumab|Drug: Placebo|Drug: PF-04634817|Drug: Masked Sham Therapy	Pfizer	Both	Adult|Senior	Phase 2	212	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	B1261009|2013-003147-27	November 8, 2013	November 2013	August 2015	October 8, 2015	October 2015	No Study Results Posted	null	August 2015	Mean Change from Baseline in the Best Corrected Visual Acuity Score|Proportion of participants gaining 15 ETDRS letters in BCVA from baseline|Mean changes in central subfield retinal thickness from baseline as assessed by optical coherence tomography (OCT)|Mean changes in the area of fluorescein leakage from baseline by scheduled study visit as assessed by fluorescein angiography (FA)|Mean change in steps of diabetic retinopathy (ETDRS severity scale) from baseline as assessed by digital fundus photography (FP)|The systemic exposure of PF-04634817 in participants with diabetes and macular edema	https://ClinicalTrials.gov/show/NCT01994291
221	NCT01795209	Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision	Recruiting	No Results Available	Branch Retinal Vein Occlusion|Macular Edema	Drug: Ranibizumab|Device: Sham injection|Procedure: Rescue laser	Seoul National University Bundang Hospital|Samsung Medical Center|Novartis	Both	Adult|Senior	Phase 4	40	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	B-1207-162-005	February 18, 2013	January 2013	December 2015	November 19, 2014	November 2014	No Study Results Posted	RVOFV	December 2015	Time to achieve an improvement of 10 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters in best-corrected visual acuity|Mean change from baseline ETDRS letter score over time|Percentage of patients gaining 10 or more letters in ETDRS letter score from baseline BCVA|Percentage of patients gaining < 10 letters in ETDRS letter score from baseline BCVA|Percentage of patients losing < 10 letters in ETDRS letter score from baseline BCVA|Proportion of patients with who at least maintain baseline BCVA|Percentage of patients with central foveal thickness (CFT) of < 300 um|Safety outcomes|Mean change from baseline CFT over time|Mean change from baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) distance activities subscale score|Mean change from baseline in contrast sensitivity|Mean change from baseline in multifocal electroretinogram (mfERG) P1 amplitude|Percentage of patients losing 10 or more letters in ETDRS letter score from baseline BCVA	https://ClinicalTrials.gov/show/NCT01795209
222	NCT02399657	Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema	Recruiting	No Results Available	Diabetes Mellitus|Macular Edema|Retinal Exudates and Deposits	Drug: Intravitreal dexamethasone 0.7mg implant	Inje University|Allergan	Both	Adult|Senior	Phase 4	48	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	EXTINCT	March 18, 2015	February 2015	December 2016	April 2, 2015	April 2015	No Study Results Posted	null	December 2016	The ratio of eyes showing reduced hard exudates in macula (1500 micrometer from foveal center)|The average change in ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity|The Ratio of eyes with central macular thickness under 290 micrometer in OCT (optical coherence tomography)|The Ratio of eyes showing reduced perifoveal capillary leakage in fluorescein angiography|The average change in number of microaneurysm in macula|The progression rate of cataract|Number of eyes having increased intraocular pressure	https://ClinicalTrials.gov/show/NCT02399657
223	NCT02559180	Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab	Not yet recruiting	No Results Available	Diabetic Retinopathy|Macular Edema	Drug: aflibercept	Rishi Singh|Regeneron Pharmaceuticals|The Cleveland Clinic	Both	Adult|Senior	Phase 4	20	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	SwapTwo Study	September 22, 2015	October 2015	February 2017	September 22, 2015	September 2015	No Study Results Posted	SwapTwo	November 2016	Safety and Efficacy|Central Foveal Thickness|Visual Acuity-mean change	https://ClinicalTrials.gov/show/NCT02559180
224	NCT01875783	OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits	Recruiting	No Results Available	Diabetes|Diabetic Macular Edema|Diabetic Retinopathy	Device: OCT imaging	Joslin Diabetes Center|Genentech, Inc.|Juvenile Diabetes Research Foundation|Optovue	Both	Adult|Senior		380	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	2011-17	June 10, 2013	April 2014	January 2016	September 9, 2014	September 2014	No Study Results Posted	DME FOUND	December 2014	Rates of retina care for patients with diabetic macular edema|Retinal referral rates for patients with DME|Rates of retinal treatment for patients with DME|Rates of retinal treatment over 1 year for patients with DME	https://ClinicalTrials.gov/show/NCT01875783
225	NCT02255032	Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis	Active, not recruiting	No Results Available	Uveitis|Macular Edema|Uveitis, Posterior|Uveitis, Anterior|Panuveitis|Uveitis, Intermediate	Drug: 4 mg CLS-TA|Drug: 0.8 mg CLS-TA	Clearside Biomedical, Inc.	Both	Adult|Senior	Phase 2	28	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	CLS1001-201	September 30, 2014	October 2014	null	October 12, 2015	October 2015	No Study Results Posted	DOGWOOD	December 2015	Change from baseline in central subfield thickness, measured using optical coherence tomography, after treatment with CLS-TA in subjects with macular edema following uveitis	https://ClinicalTrials.gov/show/NCT02255032
226	NCT01870440	TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema	Completed	No Results Available	Macular Edema|Uveitis	Drug: Ozurdex Intravitreal Injection (0.7 mg)	Northern California Retina Vitreous Associates|Allergan	Both	Adult|Senior	Phase 4	10	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	NCRVA-2013-Ozurdex-16.2	May 24, 2013	May 2013	February 2015	March 9, 2015	March 2015	No Study Results Posted	null	February 2015	Best Corrected Visual Acuity (using Early Treatment Diabetic Retinopathy Study Protocal)|Central Subfoveal Retinal Thickness|Best Corrected Visual Acuity	https://ClinicalTrials.gov/show/NCT01870440
227	NCT01783886	Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement	Completed	No Results Available	Macular Edema	Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Procedure: Laser photocoagulation	Bayer|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 3	378	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	15161	February 1, 2013	February 2013	March 2015	May 7, 2015	May 2015	No Study Results Posted	VIVID EAST	March 2015	Change in best-corrected visual acuity (BCVA) in ETDRS (Early Treatment Diabetic Retinopathy Study) letter score|Change in retinal thickness|Proportion of subjects who gain a threshold change in visual acuity|Change in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) near activities subscale|Change in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) distance activities subscale	https://ClinicalTrials.gov/show/NCT01783886
228	NCT02485249	Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema	Recruiting	No Results Available	Macular Edema	Drug: Dexamethasone Phosphate Ophthalmic	Eyegate Pharmaceuticals, Inc.	Both	Adult|Senior	Phase 1|Phase 2	20	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	EGP-437-007	June 26, 2015	July 2015	March 2016	August 4, 2015	August 2015	No Study Results Posted	null	December 2015	Anatomic improvement measured as reduction in mean central subfield thickness as evaluated by spectral-domain-optical coherence tomography|Changes in macular volume as evaluated by spectral-domain-optical coherence tomography|Qualitative review of spectral-domain-optical coherence tomography scans|Dilated fundus exam	https://ClinicalTrials.gov/show/NCT02485249
229	NCT02294656	Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide	Recruiting	No Results Available	CYSTOID MACULAR EDEMA	Drug: Ranibizumab,|Drug: Triamcinolone acetonide	Soll Eye|Genentech, Inc.	Both	Adult|Senior	Phase 1	20	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ML27905	November 4, 2014	November 2014	November 2017	June 2, 2015	June 2015	No Study Results Posted	null	November 2016	SAFETY of INTRAVITREAL RANIBIZUMAB VS. TRIAMCINOLONE ACETONIDE FOR ACUTE PSEUDOPHAKIC CYSTOID MACULAR EDEMA TREATMENT (Incidence and severity of ocular adverse events)|Mean change in spectral domain OCT CMT from baseline (microns)|Mean change in ETDRS letters from baseline (letters)|Proportion of patients with 3 line or better ETDRS letter improvement (%)|Time to 3 line ETDRS letter improvement (days)|Mean number of R or T injections (#)|Mean IOP (mm Hg)	https://ClinicalTrials.gov/show/NCT02294656
230	NCT02303184	Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO	Recruiting	No Results Available	Macular Edema|Retinal Vein Occlusion	Drug: suprachoroidal CLS-TA + IVT aflibercept|Drug: suprachoroidal sham + IVT aflibercept	Clearside Biomedical, Inc.	Both	Adult|Senior	Phase 2	40	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)	CLS1003-201	November 25, 2014	January 2015	July 2016	October 12, 2015	October 2015	No Study Results Posted	TANZANITE	July 2016	Total number of times a subject qualifies to be administered IVT aflibercept in each arm	https://ClinicalTrials.gov/show/NCT02303184
231	NCT01982435	Safety and Efficacy of Ranibizumab for Diabetic Macular Edema	Active, not recruiting	No Results Available	Diabetic Macular Edema	Drug: Ranibizumab|Drug: Ranibizumab	Justis Ehlers|Genentech, Inc.|The Cleveland Clinic	Both	Adult|Senior	Phase 1|Phase 2	30	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	REACT Study	October 29, 2013	December 2013	September 2016	August 26, 2015	August 2015	No Study Results Posted	REACT	June 2016	Safety and Tolerability|Central Foveal Thickness	https://ClinicalTrials.gov/show/NCT01982435
232	NCT02309476	Sub-threshold Photocoagulation of Diabetic Macular Oedema	Recruiting	No Results Available	Diabetic Macular Oedema	Device: PASCAL Laser, Green Laser 0.75|Device: PASCAL Laser, Green Laser 1|Device: PASCAL Laser, 70% Yellow Laser 0.75|Device: PASCAL Laser, 70% Yellow Laser 1|Device: PASCAL Laser, 40% Yellow Laser 0.75|Device: PASCAL Laser, 40% Yellow Laser 1	Central Manchester University Hospitals NHS Foundation Trust|Topcon Corporation|Optos, PLC.	Both	Adult|Senior		30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	R03018	September 29, 2014	October 2012	December 2015	December 3, 2014	December 2014	No Study Results Posted	MEM	December 2014	reduction of diabetic macular edema (central retinal thickness) within the 6 arms of the study|Improvement in visual acuity (> 10 letters or two lines in the ETDRS chart)|increase in retinal sensitivity within the 6 arms of the study	https://ClinicalTrials.gov/show/NCT02309476
233	NCT02055911	Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema	Not yet recruiting	No Results Available	Diabetic Macular Edema	Drug: Ranibizumab	Federal University of São Paulo|Novartis	Both	Adult|Senior	Phase 4	30	Other|Industry	Interventional	Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Retinal Ganglion Cell_DME	February 3, 2014	March 2014	July 2015	February 3, 2014	February 2014	No Study Results Posted	null	March 2015	focal macular changes in full-field and photopic negative response (PhRN) amplitude (in µV)|The mean change in BCVA|the mean change in central macular thickness (CMT)	https://ClinicalTrials.gov/show/NCT02055911
234	NCT02457884	Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema	Recruiting	No Results Available	Diabetic Macular Oedema|Parafoveal Scotoma	Other: Temporal Group|Other: Spatial Group|Other: Combined Group	The Hong Kong Polytechnic University|The University of Hong Kong	Both	Adult|Senior		152	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Outcomes Assessor)	12131601	May 25, 2015	May 2015	December 2017	May 28, 2015	May 2015	No Study Results Posted	null	October 2017	Change in visual processing speed|Change in visual span size|Change in reading performance|Change in fixation stability|Change in Chinese version of Impact of Visually Impaired (C-IVI) measure	https://ClinicalTrials.gov/show/NCT02457884
235	NCT02441907	Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema	Not yet recruiting	No Results Available	Diabetic Macular Edema	Drug: aflibercept	St. Michael's Hospital, Toronto	Both	Adult|Senior	Phase 4	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Aflibercept Cytokine DME	May 8, 2015	August 2015	April 2018	May 8, 2015	May 2015	No Study Results Posted	null	August 2017	Change in cytokine levels (picograms per mL) between baseline aflibercept injection and at 1, 2, and 3 months|Relation of baseline aqueous cytokine levels to baseline Snellen BCVA in response to aflibercept	https://ClinicalTrials.gov/show/NCT02441907
236	NCT02221453	Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide	Not yet recruiting	No Results Available	Diabetic Macular Edema	Drug: Triamcinolone Acetonide	St. Michael's Hospital, Toronto	Both	Adult|Senior	Phase 2	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label	PersDMEcytokineTA	August 18, 2014	August 2015	December 2016	May 18, 2015	May 2015	No Study Results Posted	null	December 2016	Change in cytokine levels (picograms per mL) between baseline triamcinolone acetonide injection and 3 months|Change in cytokine levels (picograms per mL) 3 months after 2nd triamcinolone acetonide injection|Change in ocular cytokine levels (picograms per mL) in relation to change in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) in response to steroid treatment|Change in ocular cytokine levels (picograms per mL) in relation to change in central macular thickness (CMT) measured in micrometers (um) from optical coherence tomography	https://ClinicalTrials.gov/show/NCT02221453
237	NCT02002403	Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema	Completed	No Results Available	Diabetic Macular Edema	Drug: Danazol	St. Michael's Hospital, Toronto	Both	Adult|Senior	Phase 2	34	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	DMILS-RX09-001	November 29, 2013	January 2011	April 2012	December 5, 2013	November 2013	No Study Results Posted	null	April 2012	OCT|ETDRS BCVA|Retinal volume	https://ClinicalTrials.gov/show/NCT02002403
238	NCT02329132	Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema	Not yet recruiting	No Results Available	Diabetic Macular Edema	Drug: Ranibizumab	Kagawa University|Novartis Pharmaceuticals	Both	Child|Adult|Senior		30	Other|Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	H26-000	December 26, 2014	September 2015	December 2017	September 1, 2015	September 2015	No Study Results Posted	null	December 2017	The change of retinal oxygen saturation and consumption from baseline at 6 months	https://ClinicalTrials.gov/show/NCT02329132
239	NCT01947881	Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)	Active, not recruiting	No Results Available	Diabetic Macular Edema		Association for Innovation and Biomedical Research on Light and Image	Both	Adult|Senior		70	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	4C-2013-05	September 17, 2013	January 2014	February 2016	October 7, 2015	October 2015	No Study Results Posted	CHARTRES	February 2015	Central Retinal Thickness (Change from screening)|Presence (and location) of cysts in the retinal layers (change from screening)|Presence of OCT diffuse macular edema (without cyst formation) (change from screening)|Presence of neurosensorial retinal detachment. (change from screening)|Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening)|Presence and extension of capillary occlusion (change from screening)|Area of macular leakage (intraretinal fluid volume and retinal thickness) (change frmo screening)|Best Corrected Visual Acuity (BCVA) (Change from screening)|Central Retinal Thickness (change from screening)|Area of macular leakage (intraretinal fluid volume and retinal thickness) (change from screening)|Best Corrected Visual Acuity (change from screening)	https://ClinicalTrials.gov/show/NCT01947881
240	NCT02084576	Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification	Completed	No Results Available	Cystoid Macular Edema|Cataract	Drug: Nepafenac|Drug: Ketorolac	Hospital Oftalmologico de Brasilia	Both	Adult|Senior	Phase 4	40	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)	2014.02|HOB03022014	February 18, 2014	August 2013	February 2014	March 10, 2014	March 2014	No Study Results Posted	null	August 2013	The incidence of CME was evaluated by retinal foveal thickness on optical coherence tomography (OCT)|Postoperative corrected distance visual acuity	https://ClinicalTrials.gov/show/NCT02084576
241	NCT02406157	577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macular Edema	Device: 577-MPL|Device: 532-SLP	Sun Yat-sen University	Both	Adult|Senior		118	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)	ZOC-MPLD	March 11, 2015	January 2015	October 2016	October 17, 2015	October 2015	No Study Results Posted	null	August 2016	Change of Best Corrected Visual Acuity(BCVA)|Change in 10°retinal sensitivity|Change of fundus autofluorescence|Change of Central Retinal Thickness(CRT)	https://ClinicalTrials.gov/show/NCT02406157
242	NCT02088229	Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema	Active, not recruiting	No Results Available	Diabetic Macular Edema		University of Michigan|Juvenile Diabetes Research Foundation	Both	Adult|Senior		50	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	HUM00064483	March 7, 2014	September 2012	null	December 8, 2014	December 2014	No Study Results Posted	null	June 2015	Dark adaptation (AdaptRx)|Optical coherence tomography	https://ClinicalTrials.gov/show/NCT02088229
243	NCT02310295	Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema	Completed	No Results Available	Diabetic Macular Edema	Device: Laser|Drug: Bevacizumab|Drug: Triamcinolone Acetonide	University of Sao Paulo	Both	Adult|Senior		45	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	12029-2008	December 2, 2014	January 2009	December 2012	December 5, 2014	December 2014	No Study Results Posted	IBeTA	December 2011	Central subfield macular thickness|Visual acuity	https://ClinicalTrials.gov/show/NCT02310295
244	NCT02103283	A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Teprotumumab	River Vision Development Corporation	Both	Adult|Senior	Phase 1	10	Industry	Interventional	Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	DME01RV	March 27, 2014	October 2014	October 2015	May 4, 2015	May 2015	No Study Results Posted	null	October 2015	Safety of RV001in subjects with Diabetic Macular Edema	https://ClinicalTrials.gov/show/NCT02103283
245	NCT02121197	Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.	Active, not recruiting	No Results Available	Diabetic Macular Edema	Drug: Ozurdex	Association for Innovation and Biomedical Research on Light and Image	Both	Adult|Senior		321	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	ECR-RET-2014-07	April 22, 2014	August 2014	January 2016	October 7, 2015	October 2015	No Study Results Posted	ARTES	January 2016	Percentage of patients with Best Corrected Visual Acuity (BCVA) from baseline to 4 - 6 months after last injection, with comparison between early (<9 month duration of DME) vs late (≥9 month duration of DME), and naïve vs previously treated patients.	https://ClinicalTrials.gov/show/NCT02121197
246	NCT02281292	A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema	Not yet recruiting	No Results Available	Diabetic Macular Edema	Biological: LKA651 ophthalmic solution|Biological: Ranibizumab ophthalmic solution|Biological: Sham injection	Alcon Research|Novartis Institutes for BioMedical Research (NIBR)	Both	Adult|Senior	Phase 1	72	Industry|Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	LKA651X-2101	October 30, 2014	October 2015	March 2017	September 25, 2015	September 2015	No Study Results Posted	null	March 2017	Number of subjects with a serious adverse event (SAE) that, in the opinion of the investigator, is related to the study drug|Number of subjects experiencing a non-serious adverse event|The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass x time / volume] (AUC(0-tlast))|The area under the serum concentration-time curve from time zero to time 't' where t is a defined time point after administration [mass x time / volume] (AUC (0-t))|The observed maximum serum concentration following drug administration [mass / volume] (Cmax)|The time to reach the maximum serum concentration after drug administration [time] (Tmax)|The dose normalized observed maximum serum concentration following drug administration [mass*dose / volume] (Cmax/D)|The dose-normalized area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass*dose x time / volume] (AUC/D)|Central subfield thickness	https://ClinicalTrials.gov/show/NCT02281292
247	NCT02302079	A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)	Recruiting	No Results Available	Diabetes Mellitus|Diabetic Macular Edema	Drug: ASP8232|Drug: ranibizumab|Drug: Placebo|Other: Sham intravitreal (IVT) injection	Astellas Pharma Europe B.V.|Astellas Pharma Inc	Both	Adult|Senior	Phase 2	84	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	8232-CL-3001	November 24, 2014	January 2015	April 2016	September 29, 2015	September 2015	No Study Results Posted	VIDI	April 2016	Percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence tomography (SD-OCT) at Month 3|Absolute change from baseline in CST in the study eye as assessed by SD-OCT at Month 3|Change from baseline in early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) score in the study eye at Month 3|Absolute and percent change from baseline in excess CST in the study eye as assessed by SD-OCT at Months 1 and 2	https://ClinicalTrials.gov/show/NCT02302079
248	NCT02245516	Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema	Completed	No Results Available	Retinal Vein Occlusion|Diabetic Macular Edema	Drug: KPI-121	Kala Pharmaceuticals, Inc.	Both	Adult|Senior		16	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	KPI-121-C-004	September 4, 2014	July 2014	December 2014	March 30, 2015	March 2015	No Study Results Posted	Molokini	December 2014	Primary Efficacy	https://ClinicalTrials.gov/show/NCT02245516
249	NCT02359526	A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients	Active, not recruiting	No Results Available	Diabetic Macular Edema	Drug: IlUVIEN	Association for Innovation and Biomedical Research on Light and Image	Both	Adult|Senior	Phase 4	12	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	4C-2014-06	February 2, 2015	October 2014	February 2016	October 7, 2015	October 2015	No Study Results Posted	RESPOND	February 2016	Changes in best-corrected visual acuity (BCVA) from baseline to Month-12|Changes in central retinal thickness assessed using spectral domain optical coherence tomography (SD-OCT) from baseline to Month-12|Occurrence of Adverse events, namely cataract and elevated IOP	https://ClinicalTrials.gov/show/NCT02359526
250	NCT02556424	Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema	Not yet recruiting	No Results Available	Inflammatory Macular Edema	Drug: Dexamethasone|Drug: Triamcinolone	Nantes University Hospital	Both	Adult|Senior	Phase 3	142	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	RC 15_0056	May 29, 2015	null	February 2019	September 18, 2015	September 2015	No Study Results Posted	TRIOZ	October 2018	Evaluation of the effectiveness of a subconjunctival injection of triamcinolone on reducing the central macular thickness versus an intravitreal implant of dexamethasone between patient selection and 2 months after treatment|Evaluation of the experience of the injection by a questionnaire (tolerable, unpleasant and very unpleasant) and by EVA (0cm = no pain to 10 cm = extreme pain)|Evaluation of the effectiveness of the studied injection at each visit regarding gain in visual acuity (ETDRS)|Evaluation of the effectiveness of the studied injection at each visit regarding reduction of the anterior flare|Evaluation of the effectiveness of the studied injection at each visit regarding reduction of the vitreous haze|Evaluation of the effectiveness of the studied injection at each visit regarding central macular thickness measured by OCT, allowing the evaluation of the duration of action of the treatment|Evaluation of the effectiveness of the studied injection at each visit regarding local and general tolerance, by collecting all Adverse Events (AEs) / Serious Adverse Events (SAEs)|Evaluation of the effectiveness of the studied injection at each visit regarding patients' quality of life	https://ClinicalTrials.gov/show/NCT02556424
251	NCT01824862	Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema	Completed	No Results Available	Diabetic Retinopathy|Clinically Significant Macular Edema		Hospital Juarez de Mexico	Both	Adult|Senior		60	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	HJM2021/11-B	March 26, 2013	January 2013	July 2013	July 10, 2013	July 2013	No Study Results Posted	null	June 2013	foveal sensitivity|Retinal thickness	https://ClinicalTrials.gov/show/NCT01824862
252	NCT02127684	Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing	Withdrawn	No Results Available	Persistent Diabetic Macular Edema	Drug: ranibizumab|Drug: ranibizumab	Maturi, Raj K., M.D., P.C.	Both	Adult|Senior	Phase 2	0	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	ML29381	April 29, 2014	null	November 2015	July 29, 2014	July 2014	No Study Results Posted	null	August 2015	mean change in optical coherence topography central subfield thickness at 12 weeks and 24 weeks after randomization	https://ClinicalTrials.gov/show/NCT02127684
253	NCT01769352	Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)	Recruiting	No Results Available	Post-surgical Cystoid Macular Edema (PSCME)	Drug: PredA + Kelac	Johns Hopkins University	Both	Adult|Senior	Phase 2|Phase 3	46	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	NA_00074523	January 14, 2013	August 2012	September 2016	April 14, 2015	April 2015	No Study Results Posted	TEMPEST	September 2015	Mean change from baseline in BCVA	https://ClinicalTrials.gov/show/NCT01769352
254	NCT01870427	NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions	Active, not recruiting	No Results Available	Macular Edema With Central Retinal Vein Occlusions	Drug: Aflibercept (2.0 mg)	Northern California Retina Vitreous Associates|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 4	20	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	NCRVA-2013-Newton-4-01	May 25, 2013	June 2013	August 2016	February 16, 2015	February 2015	No Study Results Posted	NEWTON	August 2016	Duration of Intravitreal Aflibercept on Treatment Interval|Change in Visual Acuity|Retinal Thickness|Adverse Events|Number of Treatments	https://ClinicalTrials.gov/show/NCT01870427
255	NCT02217306	Contrast Sensitivity and Diabetic Macular Edema	Completed	No Results Available	DIABETES MELLITUS|DIABETIC RETINOPATHY|MACULAR EDEMA		Hospital Juarez de Mexico	Both	Adult|Senior		132	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	HJM2295/14R	August 6, 2014	January 2014	August 2014	August 13, 2014	August 2014	No Study Results Posted	null	July 2014	Contrast Sensitivity	https://ClinicalTrials.gov/show/NCT02217306
256	NCT01951066	Diabetic Macular Edema Treated With Ozurdex (DMEO)	Active, not recruiting	No Results Available	Diabetic Macular Edema	Drug: OZURDEX	Johns Hopkins University	Both	Adult|Senior	Phase 2	20	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label	DMEO-001	September 20, 2013	October 2013	null	April 1, 2015	April 2015	No Study Results Posted	DMEO	September 2015	change from baseline in aqueous levels of VEGF, SDF-1, and angiopoietin-2	https://ClinicalTrials.gov/show/NCT01951066
257	NCT01774474	PRevention of Macular EDema After Cataract Surgery	Recruiting	No Results Available	Cystoid Macular Edema|Cataract|Diabetes Mellitus	Drug: Bromfenac|Drug: Dexamethasone|Drug: Bevacizumab|Drug: Triamcinolone Acetonide	Maastricht University Medical Center|European Society of Cataract and Refractive Surgeons	Both	Adult|Senior	Phase 3	1350	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)	NL42463.068.12	January 7, 2013	July 2013	October 2016	April 9, 2015	April 2015	No Study Results Posted	PREMED	October 2016	Change in central subfield mean macular thickness as a measurement of efficacy|No. of subjects developing clinically significant macular edema as a measurement of efficacy	https://ClinicalTrials.gov/show/NCT01774474
258	NCT02374060	PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial	Recruiting	No Results Available	Macular Edema|Uveitis	Drug: Periocular triamcinolone 40 mg|Drug: Intravitreal triamcinolone 4 mg|Drug: Dexamethasone intravitreal implant	JHSPH Center for Clinical Trials|National Eye Institute (NEI)	Both	Adult|Senior	Phase 4	267	Other|NIH	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	IRB00006139|1U10EY024527-01	February 18, 2015	March 2015	July 2018	October 2, 2015	October 2015	No Study Results Posted	POINT	July 2018	Percent change in central subfield thickness from the baseline OCT measurement	https://ClinicalTrials.gov/show/NCT02374060
259	NCT01946399	Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF	Recruiting	No Results Available	Retinal Vein Occlusion (RVO)|Macular Edema	Drug: Ozurdex implant	Retina Research Institute, LLC|Retina-Vitreous Associates Medical Group|West Coast Retina Medical Group, Inc.	Both	Adult|Senior		50	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Ozurdex RVO 2013	September 16, 2013	September 2013	December 2017	July 24, 2015	July 2015	No Study Results Posted	null	September 2016	Improvement in best-corrected Snellen visual acuity following initiation of Ozurdex therapy|Anatomic/angiographic improvement in macular edema as evaluated by OCT and fluorescein angiography	https://ClinicalTrials.gov/show/NCT01946399
260	NCT02403128	Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms	Recruiting	No Results Available	Macular Edema|Retinal Artery Macroaneurysm	Drug: aflibercept	Kamal Kishore, MD|Illinois Retina and Eye Associates	Both	Adult|Senior	Phase 1	5	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Kishore_Eylea_RAM	March 23, 2015	May 2015	June 2017	July 5, 2015	July 2015	No Study Results Posted	null	December 2016	Safety profile as demonstrated by the incidence and severity of ocular and systemic adverse events in patients with macular edema caused by retina artery macroaneurysm(s) after intravitreal injection of 2 mg of aflibercept|Change in best-corrected ETDRS visual acuity at 3 and 6 months.|Change in central field macular thickness at 3 and 6 months|Proportion of eyes completely dry by spectral domain OCT|Occlusion of retinal artery macroaneurysm (RAM) at 3 and 6 months by intravenous fluorescein angiography|Number of patients requiring additional treatment beyond baseline and total number of treatments	https://ClinicalTrials.gov/show/NCT02403128
261	NCT01790945	Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography	Not yet recruiting	No Results Available	Mild Nonproliferative Diabetic Retinopathy|Moderate Nonproliferative Diabetic Retinopathy|Severe Nonproliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy|Diabetic Macular Edema		Retina Institute of Hawaii	Both	Adult|Senior		500	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Prospective	DIVER Study	February 11, 2013	February 2013	August 2013	February 12, 2013	February 2013	No Study Results Posted	DIVER	June 2013	% change in Diabetic Retinopahy/Diabetic Macular Edema diagnosis with pre-screening system compared to post-screening system|Change in HgA1C from Primary Care Physician referral to post retinal specialist visit	https://ClinicalTrials.gov/show/NCT01790945
262	NCT01939691	Topical Treatment of Uveitic Macular Edema	Not yet recruiting	No Results Available	Uveitis|Cystoid Macular Edema	Drug: Difluprednate 0.05% ophthalmic emulsion|Drug: Nepafenac 0.1% ophthalmic solution|Drug: Prednisolone acetate 1% ophthalmic suspension	University of California, San Francisco	Both	Child|Adult|Senior	Phase 4	24	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	CMEND	September 6, 2013	December 2015	March 2018	May 26, 2015	May 2015	No Study Results Posted	null	December 2017	Number of patients with improvement and/or resolution of macular edema|number of patients with resolution of macular edema|number of patients with improvement in macular edema defined as 20% or greater reduction in central subfield thickness by OCT but not resolution|number of patients with intraocular pressure increase greater than 10mmHg over baseline|Number of patients in each group with 2-line improvement in visual acuity|Change in macular central subfield thickness by OCT at 2 weeks	https://ClinicalTrials.gov/show/NCT01939691
263	NCT01845844	Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Ranibizumab 0.3mg/0.05cc	Southeast Retina Center, Georgia|Genentech, Inc.	Both	Adult|Senior	Phase 1|Phase 2	30	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ML28713	April 2, 2013	April 2013	January 2015	September 16, 2014	September 2014	No Study Results Posted	ROTATE	January 2015	Incidence of ocular and systemic adverse events will be compared between experimental and active comparator groups|Severity of ocular and systemic adverse events will be compared between experimental and active comparator groups|Efficacy of monthly and monthly followed by PRN dosing of 0.3 mg ranibizumab after persistent DME despite previous bevacizumab therapy	https://ClinicalTrials.gov/show/NCT01845844
264	NCT01934920	Identifying Patients With Unrecognized Treatable Diabetic Macular Edema	Not yet recruiting	No Results Available	Diabetic Macular Edema		Elman Retina Group|Genentech, Inc.	Both	Adult|Senior		500	Other|Industry	Observational	Time Perspective: Prospective	Elman-01	August 30, 2013	November 2015	October 2016	August 4, 2015	August 2015	No Study Results Posted	null	October 2016	Assess the incidence of new and/or undiagnosed diabetic macular edema.|Streamlining and identification of patients at risk of diabetic macular edema	https://ClinicalTrials.gov/show/NCT01934920
265	NCT02556723	Intravitreal Injections of Ziv-aflibercept for Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Intravitreal injections of ziv-aflibercept	Retina Clinic, Sao Paulo, Brazil|Federal University of São Paulo	Both	Adult|Senior		20	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Caregiver)	RetinaCLINIC	September 18, 2015	September 2014	September 2017	September 21, 2015	September 2015	No Study Results Posted	null	September 2015	Multifocal electroretinogram responses at Week 24 and 48|Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Snellen Letter Score at Week 24 and 48|Change From Baseline in Central Retinal Thickness (CRT) at Week 24 and 48 as Assessed on Optical Coherence Tomography (OCT)	https://ClinicalTrials.gov/show/NCT02556723
266	NCT02554747	Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa	Not yet recruiting	No Results Available	Diabetic Macular Oedema	Device: Navigated laser|Device: Conventional laser	Odense University Hospital|Moorfields Eye Hospital NHS Foundation Trust	Both	Adult|Senior	Phase 4	60	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	SDUSF-2015-21-(129)|S-20150077	September 11, 2015	October 2015	October 2018	September 17, 2015	September 2015	No Study Results Posted	ADDENDUM	October 2017	Percentage of eyes that received additional aflibercept injections after laser at month 12 in group A and B|Number of additional aflibercept injections after laser at month 12 in group A and B|Change in ETDRS visual acuity from baseline to month 12 in group A and B|Change in global retinal vessel geometric markers from baseline to month 12 in group A and B|Change in macular retinal vessel geometric markers from baseline to month 12 in group A and B|Change in global oxygen saturation from baseline to month 12 in group A and B|Change in macular oxygen saturation from baseline to month 12 in group A and B|Evaluation of non-invasive retinal risk factors (retinal vascular geometric markers and oxygen saturation) for successful treatment outcome at month 12|Change in level of macular ischemia (area of foveal avascular zone (FAZ)) from baseline to month 12 in group A and B|Evaluation of baseline area of foveal avascular zone (FAZ) as marker of successful treatment outcome at month 12	https://ClinicalTrials.gov/show/NCT02554747
267	NCT01846299	To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema	Completed	No Results Available	Macular Edema (ME)	Other: Sham control|Drug: Ranibizumab	Novartis Pharmaceuticals|Novartis	Both	Child|Adult|Senior	Phase 3	180	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	CRFB002G2302|2012-005418-20	April 30, 2013	October 2013	September 2015	October 14, 2015	October 2015	No Study Results Posted	null	September 2015	Best-corrected visual acuity (BCVA) change from baseline to Month 2 in study eye|BCVA change from baseline by visit up to Month 2 in study eye (ranibizumab as compared to sham treatment)|Change in central subfield thickness (CSFT) and central subfield volume (CSFV) in study eye from baseline over time to Month 2|Presence of intra-/subretinal fluid in study eye at Month 2|Presence of active ME leakage assessed by fluorescein angiography (FA) at Month 2|Requirement for rescue treatment at Month 1|Average BCVA change in study eye from baseline to Month 1 through Month 12|Change from baseline in CSFT and CSFV in study eye by visit|Presence of intra-/subretinal fluid in study eye at Month 2, Month 6, and Month 12 compared to Baseline|Presence of active ME leakage in study eye at Month 2, Month 6, and Mon th 12 compared to Baseline|Proportion of patients with ≥ 1, ≥ 5, ≥ 10 and ≥ 15 letters gain or reaching 84 letters, at Month 2, Month 6 and Month 12|Porportion of patients with > 1, > 5, > 10 and > 15 letters loss at Month 2, Month 6 and Month 12|Number of ranibizumab treatments and re-treatments to study eye by Month 2, Month 6, Month 12|Type, frequency and severity of ocular and non-ocular adverse events in the study eye up Month 2, up to Month 6 and up to Month 12	https://ClinicalTrials.gov/show/NCT01846299
268	NCT02063321	Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic	Enrolling by invitation	No Results Available	Diabetic Macular Edema|Diabetic Retinopathy		Emil Martinka|Novartis Slovakia, s.r.o.|National Institute of Endocrinology and Diabetology, Slovakia	Both	Adult|Senior		762	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	LUB012013	February 11, 2014	December 2012	December 2015	February 12, 2014	February 2014	No Study Results Posted	null	September 2015	Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema|Patient´s structure with DME and clinically significant DME in terms of demography and anamnesis of diabetes|Range of visual deterioration and occurence of blindness in relation to duration of diabetes|Prognostic factors, which determine the occurence of DME using explorative analysis|Range of visual deterioration and occurence of blindness in relation to type of diabetes|Range of visual deterioration and occurence of blindness in relation to general treatment (insulin vs. OAD or combination therapy)	https://ClinicalTrials.gov/show/NCT02063321
269	NCT02096874	Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema	Recruiting	No Results Available	Non-proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy|Diabetic Macular Edema	Drug: Bevacizumab	King Khaled Eye Specialist Hospital	Both	Adult|Senior	Phase 4	50	Other	Interventional	Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	RP 1310	March 24, 2014	June 2013	June 2015	March 25, 2014	March 2014	No Study Results Posted	null	December 2014	Peripheral retinal ischemia	https://ClinicalTrials.gov/show/NCT02096874
270	NCT01928654	Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macular Edema	Device: Micropulse laser treatment|Device: Laser modified ETDRS	Luigi Sacco University Hospital	Both	Adult|Senior		32	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	Lasercomparison	August 21, 2013	July 2013	November 2014	March 18, 2014	March 2014	No Study Results Posted	null	October 2014	Mean change in visual acuity (ETDRS letters)|Mean change in central retinal thickness|Percentage of patients gaining ETDRS lines|Percentage of patients losing ETDRS lines	https://ClinicalTrials.gov/show/NCT01928654
271	NCT02471651	Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Dexamethasone intravitreal implant (0.7 mg)|Drug: Intravitreal anti-VEGF injection	California Retina Consultants|Allergan	Both	Adult|Senior	Phase 4	40	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	CRC2015-02	June 11, 2015	June 2015	September 2016	June 12, 2015	June 2015	No Study Results Posted	DIME	July 2016	Mean change in central 1 mm subfield thickness|Mean change in standardized best-corrected visual acuity|Total number of treatments in each arm	https://ClinicalTrials.gov/show/NCT02471651
272	NCT02308644	Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study	Completed	No Results Available	Diabetic Macular Edema	Drug: intravitreal bevacizumab injection(1.25mg)	University of Sao Paulo	Both	Adult|Senior	Phase 3	41	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	80838792A	November 24, 2014	February 2009	February 2013	December 1, 2014	December 2014	No Study Results Posted	null	December 2011	Contrast sensitivity|Metabolic control	https://ClinicalTrials.gov/show/NCT02308644
273	NCT02363621	Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Ranibizumab 0.3 mg|Drug: Aflibercept 2.0 mg	Arshad Khanani|Genentech, Inc.|Sierra Eye Associates	Both	Adult|Senior	Phase 2	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	ML29634	February 2, 2015	January 2015	January 2016	May 2, 2015	May 2015	No Study Results Posted	null	January 2016	Presence of Intraocular inflammation|Presence of Intraocular Inflammation|Post injection Pain	https://ClinicalTrials.gov/show/NCT02363621
274	NCT02036424	Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema	Active, not recruiting	No Results Available	Diabetic Macular Edema	Drug: Ozurdex|Drug: Bevacizumab	Raj K. Maturi, MD|Allergan|Maturi, Raj K., M.D., P.C.	Both	Adult|Senior	Phase 4	60	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	OA 003	January 13, 2014	January 2014	October 2015	July 21, 2015	May 2015	No Study Results Posted	null	August 2015	Mean visual acuity change	https://ClinicalTrials.gov/show/NCT02036424
275	NCT02227745	Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema	Recruiting	No Results Available	Diabetic Retinopathy|Diabetic Macular Edema	Drug: Dorzolamide hydrochloride (2%)|Drug: Placebo Sodium hyaluronate 4mg	Hospital Juarez de Mexico	Both	Adult|Senior		60	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	HJM 2296/14-R	August 26, 2014	January 2014	December 2015	March 18, 2015	March 2015	No Study Results Posted	null	March 2015	efficiency in visual function with dorzolamide after photocoagulation	https://ClinicalTrials.gov/show/NCT02227745
276	NCT01821677	A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug)in the Treatment of Diabetic Macular Edema	Completed	No Results Available	Diabetic Macular Edema	Drug: Low Dose Danazol|Drug: Placebo	Ampio Pharmaceuticals. Inc.	Both	Adult|Senior	Phase 3	355	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	AP-05-002	March 25, 2013	February 2013	January 2015	August 10, 2015	August 2015	No Study Results Posted	null	June 2014	Improvement in Best Corrected Visual Acuity	https://ClinicalTrials.gov/show/NCT01821677
277	NCT02059772	Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macular Edema	Drug: ranibizumab|Procedure: micropulse diode laser	GWT-TUD GmbH|Novartis	Both	Adult|Senior	Phase 4	50	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ReCaLL-2013	February 10, 2014	April 2014	January 2017	February 24, 2015	February 2015	No Study Results Posted	ReCaLL	June 2016	change in best corrected visual acuity (BCVA)|change in central macular thickness|number of intravitreal Lucentis injections	https://ClinicalTrials.gov/show/NCT02059772
278	NCT02448446	The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates	Recruiting	No Results Available	Diabetic Macular Edema|Hard Lipid Exudates	Drug: ranibizumab 0.3mg	South Coast Retina Center; Carson, McBeath, Boswell, Inc.|Genentech, Inc.|Doheny Image Reading Center|Retina Partners	Both	Adult|Senior	Phase 1|Phase 2	30	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ML259577	March 5, 2015	August 2015	July 2018	August 27, 2015	August 2015	No Study Results Posted	null	October 2017	Best Corrected Visual Acuity as measured by ETDRS at 6 and 12 months|Percentage of patients with improvement of lipid deposits in the central subfield as measured on OCT and fundus photography|Percentage of patients with complete resolution of lipid deposits in the central subfield as measured on OCT and fundus photography|Time to complete resolution of lipid deposits in the central subfield as measured on OCT and fundus photography|Percentage of patients with improvement in lipid deposits throughout the macular grid as measured by OCT and fundus photography|Percentage of patients with complete resolution of lipid deposits throughout the macular grid as measured on OCT and fundus photography|Time to complete resolution of lipid deposits throughout the macular grid as measured by OCT and fundus photography|Incidence and severity of ocular adverse events as a measure of safety and tolerability|Incidence and severity of other adverse events as a measure of safety and tolerability	https://ClinicalTrials.gov/show/NCT02448446
279	NCT01934556	A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema	Active, not recruiting	No Results Available	Diabetic Macular Edema	Drug: Ranibizumab 0.3 mg intravitreal injection|Device: Guided Laser Photocoagulation	Palmetto Retina Center, LLC	Both	Adult|Senior	Phase 1|Phase 2	150	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label	ML28724	August 28, 2013	November 2013	November 2016	January 20, 2015	January 2015	No Study Results Posted	TREX-DME	November 2016	Mean change in vision at 24 months|Incidence and severity of adverse events (ocular and non-ocular).|Number of intravitreal injections|Number of office visits|Change in retinal thickness|Percentage of eyes gaining or losing vision|Percentage of eyes which progress to proliferative diabetic retinopathy|Percentage of patients able to begin extension after 4 treatment visits|Percentage of eyes with a secondary or tertiary baseline retinal thickness|Noninferiority Comparison	https://ClinicalTrials.gov/show/NCT01934556
280	NCT02368756	Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial)	Enrolling by invitation	No Results Available	Diabetic Macular Edema	Drug: Aflibercept	Palmetto Retina Center, LLC|Regeneron Pharmaceuticals|Retina Consultants of Houston	Both	Adult|Senior	Phase 4	25	Other|Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Endurance 2	December 11, 2014	December 2014	December 2016	February 20, 2015	February 2015	No Study Results Posted	null	December 2016	Composite Measurement of the Need for Ongoing Intravitreal Aflibercept Injections in the Management of DME|Composite Measurement of Longer-term Efficacy of Intravitreal Aflibercept Injections in the Management of DME|Measurement of Longer-term Safety of Intravitreal Aflibercept Injections in the Management of DME: Incidence and severity of ocular and systemic adverse events|Composite Measurement of the Role of Focal Laser Treatment in Decreasing the Treatment Burden Among Subjects Who Require Ongoing Aflibercept Treatment in the Management of DME|Composite Evaluation of the Role of (ultrawide-field, if available) Baseline vs 52-Week Fluorescein Angiography-determined Retina Ischemia in Predicting Past and Future Anti-VEGF Treatment Burden, Anatomic and Visual Outcomes.	https://ClinicalTrials.gov/show/NCT02368756
281	NCT02050828	The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema	Completed	No Results Available	Diabetic Macular Edema (DME)	Drug: AKB-9778|Drug: ranibizumab	Aerpio Therapeutics	Both	Adult|Senior	Phase 2	144	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	AKB-9778-CI-2003	January 29, 2014	January 2014	May 2015	August 24, 2015	August 2015	No Study Results Posted	TIME-2	April 2015	Mean change from baseline in spectral domain optical coherence tomography (sdOCT)-measured central subfield thickness (CST)|Mean change from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA)	https://ClinicalTrials.gov/show/NCT02050828
282	NCT02348918	A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Luminate 1.0mg|Drug: Luminate 2.0mg|Drug: Luminate 3.0mg|Drug: Avastin|Device: Focal laser photocoagulation	Allegro Ophthalmics, LLC|Trial Runners, LLC|Duke University	Both	Adult|Senior	Phase 2	150	Industry|Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	DME 202B	January 12, 2015	October 2014	March 2016	January 23, 2015	January 2015	No Study Results Posted	null	December 2015	Change in OCT (Optical coherence tomagraphy) Central Subfield Thickness at Week 24|Change in BCVA at Week 24	https://ClinicalTrials.gov/show/NCT02348918
283	NCT02006147	Phase I/II Trial to Find Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLT) of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)	Recruiting	No Results Available	Macular Edema Due to Retinal Vein Occlusion (RVO)	Drug: TLC399(ProDex)	Taiwan Liposome Company	Both	Adult|Senior	Phase 1|Phase 2	30	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	TLC399.1	November 13, 2013	July 2014	March 2016	June 2, 2015	June 2015	No Study Results Posted	null	March 2016	Part 1: The maximum tolerated dose (MTD) and the type of dose-limiting toxicity(ies) (DLT[s]) of TLC399 (ProDex)|Part 2: Proportion of patients with BCVA gain of 15 or more letters from baseline BCVA in the study eye (Months 1-12)|Part 1: Safety assessment, including AEs, physical examination, vital signs (including Blood Pressure(BP)), clinical chemistry and hematology for up to 1 year|Part 2: Time to achieve a treatment response of gain of 15 or more letters from baseline BCVA to 6 months BCVA|Part 2: Mean change from baseline in Intraocular pressure (IOP)|Part 2: Mean change from baseline in number of letters read correctly (using BCVA) in the study eye|Part 2: Mean change from baseline of retinal thickness (by using Optical Coherence Tomography (OCT))|Part 2: Safety assessment, including AEs, physical examination, vital signs (including BP), clinical chemistry and hematology	https://ClinicalTrials.gov/show/NCT02006147
284	NCT02392364	Variable Interval Versus Set Interval Aflibercept for DME	Not yet recruiting	No Results Available	Cystoid Macular Edema|Diabetic Macular Edema	Drug: Intravitreal Aflibercept Injection	California Retina Consultants|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 4	50	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	2014-01-CRC	March 2, 2015	March 2015	October 2017	March 18, 2015	March 2015	No Study Results Posted	EVADE	October 2017	BCVA Change	https://ClinicalTrials.gov/show/NCT02392364
285	NCT02258009	Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema	Suspended	No Results Available	Visual Impairment Due to Diabetic Macular Edema	Drug: Ranibizumab|Drug: Aflibercept	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	40	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	CRFB002DDE25	October 2, 2014	October 2015	October 2016	October 14, 2015	October 2015	No Study Results Posted	TIDE DME	October 2016	Systemic VEGF-A protein levels|Systemic VEGF-A levels	https://ClinicalTrials.gov/show/NCT02258009
286	NCT01909791	Treatment for CI-DME in Eyes With Very Good VA Study	Recruiting	No Results Available	Diabetic Macular Edema	Procedure: Prompt Laser|Drug: Prompt aflibercept|Procedure: Deferred laser|Drug: Deferred aflibercept	Diabetic Retinopathy Clinical Research Network|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 3	702	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	DRCR.net Protocol V	July 23, 2013	October 2013	March 2017	April 28, 2015	April 2015	No Study Results Posted	Protocol V	March 2017	Percent of eyes that have lost at least 5 letters of visual acuity at 2 years compared with baseline mean visual acuity|Percent of eyes with at least 5, 10 and 15 letter losses in visual acuity from baseline mean visual acuity|Percent of eyes with at least 5 letter gain in visual acuity from baseline mean visual acuity|Mean change in visual acuity, adjusted for baseline mean visual acuity|Visual acuity area under the curve between baseline and annual visits|Mean change in OCT CSF thickness, adjusted for baseline mean thickness|Percent of eyes with at least a 1 and 2 log step increase or decrease on OCT CSF thickness|Percent of eyes with OCT CSF thickness of <250 µm on Stratus OCT (or spectral domain equivalent) and at least a 10% OCT CSF thickness decrease|Number of injections and/or focal/grid photocoagulation sessions performed|Number of scheduled and unscheduled visits|Percent of eyes with worsening diabetic retinopathy|Of eyes with non-proliferative diabetic retinopathy or proliferative diabetic retinopathy (PDR) at randomization, percent with improvement in diabetic retinopathy|Of eyes with PDR at randomization, proportion of eyes avoiding vitreous hemorrhage or panretinal photocoagulation (PRP) or vitrectomy for PDR|Mean change in low-contrast visual acuity on Electronic Visual Acuity Tester|Total cost of follow-up and treatment|For eyes randomized to deferred anti-VEGF, the percentage of eyes needing anti-VEGF treatment.	https://ClinicalTrials.gov/show/NCT01909791
287	NCT01788475	Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery	Withdrawn	No Results Available	Diabetic Macular Edema	Drug: Dexamethasone	Lahey Clinic	Both	Adult|Senior		0	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	2012-031	February 7, 2013	December 2012	November 2014	September 1, 2015	September 2015	No Study Results Posted	null	November 2014	Visual Acuity Gain|Central retinal Thickness Reduction	https://ClinicalTrials.gov/show/NCT01788475
288	NCT01945866	Phase II Combination Steroid and Anti-VEGF for Persistent DME	Recruiting	No Results Available	Diabetic Macular Edema	Drug: intravitreal ranibizumab 0.3 mg|Drug: dexamethasone intravitreal implant|Procedure: Sham injection	Diabetic Retinopathy Clinical Research Network|Allergan|Genentech, Inc.	Both	Adult|Senior	Phase 2	125	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)	DRCR.net Protocol U	September 12, 2013	February 2014	January 2016	June 9, 2015	June 2015	No Study Results Posted	null	January 2016	Mean change in visual acuity letter score|At 24 weeks after randomization, percent of eyes with at least 10 and at least 15 letter gain (increase) or loss (decrease) in E-ETDRS letter score visual acuity.|Visual acuity area under the curve (AUC) between randomization and 24 weeks|Mean change in OCT CSF thickness, adjusted for thickness at time of randomization|Percent of eyes with ≥1 and ≥2 logOCT step gain or loss in CSF thickness|Percent of eyes with OCT CSF thickness < the gender-specific spectral domain OCT equivalent of 250 microns on Zeiss Stratus|OCT CSF thickness area under the curve between randomization and 24 weeks|Percent of eyes with worsening or improvement of diabetic retinopathy on clinical exam	https://ClinicalTrials.gov/show/NCT01945866
289	NCT02193113	A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME	Active, not recruiting	No Results Available	Diabetic Macular Edema	Drug: KVD001 Injection	KalVista Pharmaceuticals, Ltd.|Juvenile Diabetes Research Foundation	Both	Adult|Senior	Phase 1	17	Industry|Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	KVD001-001	July 9, 2014	July 2014	July 2015	March 30, 2015	March 2015	No Study Results Posted	null	June 2015	Number of participants with Adverse Events as a measure of safety and tolerability|Measurement of KVD001 plasma levels over time following intravitreal injection (with calculation of Tmax, Cmax, AUC and t1/2)|Best Corrected Visual Acuity as measured by ETDRS EVA	https://ClinicalTrials.gov/show/NCT02193113
290	NCT01892163	Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone	Recruiting	No Results Available	Diabetic Macular Edema	Device: Ozurdex	Moorfields Eye Hospital NHS Foundation Trust|The Royal Wolverhampton Hospitals NHS Trust|Frimley Park Hospital NHS Trust|Brighton and Sussex University Hospitals NHS Trust|University Hospitals Bristol NHS Foundation Trust	Both	Adult|Senior	Phase 3	100	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	SIVS1007	June 25, 2013	March 2013	December 2014	July 3, 2013	June 2013	No Study Results Posted	OZDRY	December 2014	The difference between arms in the change from baseline in best corrected visual acuity at 12 months|Difference between arms in change from baseline in each domain and composite scores of the National Eye Institute Visual function questionnaire (VFQ-25).|Difference between arms in change in central subfield thickness.|Proportion of patients with ocular and systemic serious adverse events	https://ClinicalTrials.gov/show/NCT01892163
291	NCT02262260	Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Labeled regime arm|Drug: Wait and Extend regime arm	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 3	104	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	CRFB002DTR01	August 27, 2014	December 2014	December 2016	June 2, 2015	June 2015	No Study Results Posted	SALUTE-D	December 2016	Mean change in Best-corrected visual acuity (BCVA)|Mean change in Central Retinal Thickness (CRT)|Mean number of injections|Mean number of visits|Proportion of patients who gained ≥0 letters|Proportion of patients who gained ≥5 letters|Proportion of patients who gained ≥10 letters|Proportion of patients who gained ≥15 letters|Incidence of adverse events (AEs) and serious AEs	https://ClinicalTrials.gov/show/NCT02262260
292	NCT02259088	A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese DME Patients	Recruiting	No Results Available	Vision Impairment Due to Diabetic Macular Edema	Drug: ranibizumab|Procedure: laser	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 3	380	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	CRFB002D2305	October 3, 2014	November 2014	March 2017	June 2, 2015	June 2015	No Study Results Posted	null	March 2017	Mean average BCVA change|Mean BCVA change by visit|Mean change in Central subfield Thickness (CSFT)|BCVA improvement of ≥ 10 and ≥ 15 letters|BCVA loss of < 10 and < 15 letters|Visual acuity ≥ 73 letters|Mean average BCVA change after month 3|Mean change in patient reported visual functioning scale|Adverse events|Evaluation of treatment patterns	https://ClinicalTrials.gov/show/NCT02259088
293	NCT02186119	A Study of Abicipar Pegol in Patients With Diabetic Macular Edema	Completed	No Results Available	Macular Edema	Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure	Allergan	Both	Adult|Senior	Phase 2	151	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	150998-004|PALM	July 8, 2014	July 2014	June 2015	July 10, 2015	July 2015	No Study Results Posted	null	June 2015	Change from Baseline in Best Corrected Visual Acuity (BCVA)|Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale|Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye|Percentage of Patients with a BCVA of ≥70 Letters|Percentage of Patients with Resolution of Macular Edema	https://ClinicalTrials.gov/show/NCT02186119
294	NCT02188173	An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)	Active, not recruiting	No Results Available	Macular Edema	Drug: dexamethasone 700 ㎍ intravitreal implant	Allergan	Both	Adult|Senior		201	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	GMA-US-EYE-0272|REINFORCE	July 10, 2014	July 2014	May 2016	September 10, 2015	September 2015	No Study Results Posted	null	May 2016	Maximum Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Percentage of Patients with a BCVA Improvement of ≥15 Letters in the Study Eye|Average Change from Baseline in BCVA in the Study Eye|Percentage of Patients with an Increase from Baseline of ≥2 Lines in BCVA in the Study Eye|Percentage of Patients with an Increase from Baseline of ≥3 Lines in BCVA in the Study Eye|Percentage of Patients with BCVA of 20/40 or Better in the Study Eye|Mean Number of Ozurdex Injections in the Study Eye|Mean Time Between Ozurdex Injections in the Study Eye|Change from Baseline in Central Retinal Subfield Thickness (CRT) in the Study Eye	https://ClinicalTrials.gov/show/NCT02188173
295	NCT01805323	A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema	Completed	Has Results	Macular Edema	Drug: Dexamethasone Intravitreal Implant	Allergan	Both	Child|Adult|Senior		101	Industry	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	CMA-OZU-12-001	March 5, 2013	September 2012	April 2013	April 28, 2014	April 2014	April 28, 2014	null	April 2013	Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)|Peak Mean Change From Baseline in Central Retinal Thickness (CRT)	https://ClinicalTrials.gov/show/NCT01805323
296	NCT02181530	Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®	Completed	Has Results	Macular Edema|Retinal Vein Occlusion	Other: No Intervention	Allergan	Both	Child|Adult|Senior		43	Industry	Observational	Observational Model: Cohort|Time Perspective: Retrospective	MAF/AGN/OPH/RET/016	July 2, 2014	July 2014	October 2014	May 21, 2015	May 2015	April 10, 2015	null	October 2014	Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Percentage of Patients With an Increase of 2 Lines or More in BCVA in the Study Eye|Percentage of Patients With an Increase of 3 Lines or More in BCVA in the Study Eye|Change From Baseline in Retinal Thickness as Measured by Optical Coherence Tomography (OCT)|Time to Improvement of 2 Lines or More in BCVA in the Study Eye|Time to Improvement of 3 Lines or More in BCVA in the Study Eye|Time to OZURDEX® Re-Injection in the Study Eye	https://ClinicalTrials.gov/show/NCT02181530
297	NCT01903720	A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion	Completed	No Results Available	Macular Edema|Retinal Vein Occlusion	Drug: dexamethasone implant	Allergan	Both	Adult|Senior	Phase 4	71	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	APMA-OZU-01-01	July 16, 2013	July 2013	March 2015	August 31, 2015	August 2015	No Study Results Posted	COBALT	September 2014	Change from Baseline in Best Corrected Visual Acuity (BCVA)|Change from Baseline in Central Retinal Thickness (CRT)|Change from Baseline in BCVA|Change from Baseline in CRT|Percentage of Subjects with a Change from Baseline of 15 or More Letters in BCVA|Percentage of Subjects Receiving a Second Injection|Percentage of Subjects Receiving a Third Injection|Time to Second Injection|Time to Third Injection|Number of Laser Treatments	https://ClinicalTrials.gov/show/NCT01903720
298	NCT02121262	A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Patients With Diabetic Macular Edema	Withdrawn	No Results Available	Macular Edema	Drug: 700 μg dexamethasone|Procedure: Laser Photocoagulation	Allergan	Both	Adult|Senior	Phase 3	0	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	206207-026	April 22, 2014	April 2014	February 2017	July 9, 2014	July 2014	No Study Results Posted	null	February 2017	Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye|Percentage of Patients with BCVA Improvement ≥15 Letters from Baseline in the Study Eye|Change from Baseline in Central Retinal Thickness by Optical Coherence Tomography (OCT) in the Study Eye|Change from Baseline in Total Macular Leakage Area by Fluorescein Angiography (FA) in the Study Eye	https://ClinicalTrials.gov/show/NCT02121262
299	NCT01918371	A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema	Completed	No Results Available	Retinal Vein Occlusion|Macular Edema	Drug: Anti-VEGF	Allergan	Both	Adult|Senior		324	Industry	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	GMA-OZU-13-598	August 5, 2013	August 2013	July 2014	July 17, 2014	July 2014	No Study Results Posted	null	May 2014	Percentage of Patients with Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT in the Study Eye|Percentage of Patients with BCVA of 20/40 or Better in the Study Eye|Percentage of Patients with CTR of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye|Percentage of Patients with Both BCVA 20/40 or Better or CTR ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye|Percentage of Patients with BCVA 20/40 or Worse or CRT ≥250 µm on TD OCT or ≥300 µm on SD OCT AND, Compared with the Visit 3 Months Before the Current Visit, Patient had a Gain of <1 Line in BCVA or a Decrease of <50 µm in CRT in the Study Eye|Mean BCVA in the Study Eye|Change from Baseline in BCVA in the Study Eye|Percentage of Patients with an Increase from Baseline of ≥2 Lines in BCVA in the Study Eye|Percentage of Patients with an Increase from Baseline of ≥3 Lines in BCVA in the Study Eye|Change from Baseline in CRT in the Study Eye|Time to Improvement of ≥2 Lines in BCVA in the Study Eye|Time to Improvement of ≥3 Lines in BCVA in the Study Eye|Time to Improvement in BCVA to 20/40 or Better in the Study Eye|Time to Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye|Time to Improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye|Time Between Anti-VEGF Injections in the Study Eye|Number of Anti-VEGF Injections in the Study Eye|Change in BCVA Following the Last Anti-VEGF Injection in the Study Eye|Percentage of Patients switching to a 2nd or 3rd Anti-VEGF After the First Injection in the Study Eye|Percentage of Patients Switching Among Different Anti-VEGFs in the Study Eye|Percentage of Patients with Focal Laser in the Study Eye|Percentage of Patients with Panretinal Photocoagulation (PRP) in the Study Eye|Percentage of Patients Using Corticosteroids in the Study Eye|Percentage of Patients with a Loss, Gain and No Change from Baseline in BCVA by ≥1 Line in the Study Eye|Percentage of Patients with Glaucoma Laser Surgery in the Study Eye|Percentage of Patients with Incisional Glaucoma Surgery in the Study Eye|Percentage of Phakic Patients with Cataract Surgery in the Study Eye	https://ClinicalTrials.gov/show/NCT01918371
300	NCT01823081	Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Intravitreal injection of bevacizumab (Avastin)|Drug: Intravitreal injection of fasudil and bevacizumab (Avastin)	Shahid Beheshti Medical University	Both	Child|Adult|Senior	Phase 3	74	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	91128	March 21, 2013	January 2013	null	March 28, 2013	July 2012	No Study Results Posted	null	June 2013	Best corrected visual acuity|central macular thickness|Status of macular perfusion|intraocular inflammation	https://ClinicalTrials.gov/show/NCT01823081
301	NCT02194634	Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Conbercept|Other: Sham injection|Procedure: Laser|Other: Sham laser	Chengdu Kanghong Biotech Co.,Ltd.	Both	Adult|Senior	Phase 3	248	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	KHSWKH902010	July 14, 2014	July 2014	September 2017	June 8, 2015	June 2015	No Study Results Posted	null	December 2016	Mean change from baseline in best corrected visual acuity (BCVA) at month 12|Mean change from baseline in central retinal thickness (CRT) between two groups|Safety (e.g. incidence of adverse events) of Conbercept ophthalmic injection	https://ClinicalTrials.gov/show/NCT02194634
302	NCT01769599	Comparison of Initial Treatment in With Laser Grid in Diabetic Macular Edema to Intra Vitreal Avastin Injections	Recruiting	No Results Available	Diabetic Macular Edema|Diabetus Mellitus		Ziv Hospital	Both	Adult|Senior		60	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	0108-12-ZIV	January 14, 2013	January 2013	April 2014	January 14, 2013	January 2013	No Study Results Posted	null	January 2014	Macular thickness	https://ClinicalTrials.gov/show/NCT01769599
303	NCT01823965	Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment	Recruiting	No Results Available	Diabetic Macular Edema	Drug: ranibizumab	Poitiers University Hospital	Both	Adult|Senior	Phase 2	null	Other	Interventional		LLOMD	March 27, 2013	null	null	April 3, 2013	March 2013	No Study Results Posted	null	December 2013	Number of intravitreal injections of ranibizumab|best-corrected visual acuity	https://ClinicalTrials.gov/show/NCT01823965
304	NCT01792141	Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment	Completed	No Results Available	Macular Edema		Retina Institute of Hawaii	Both	Adult|Senior		50	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	RIH 1010	February 11, 2013	January 2011	December 2012	February 12, 2013	February 2013	No Study Results Posted	null	June 2012	Primary objective is to assess the effectiveness of FA-ICG guided focal laser therapy for the treatment CSME by means of serial FA-1CGs before and every 3 months after treatment.	https://ClinicalTrials.gov/show/NCT01792141
305	NCT02472366	A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy	Completed	Has Results	Chronic Diabetic Macular Edema	Drug: ILUVIEN	Alimera Sciences	Both	Adult|Senior	Phase 4	16	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	M-01-13-002	June 10, 2015	January 2014	May 2015	August 14, 2015	August 2015	June 23, 2015	null	March 2015	Changes in Best Corrected Visual Acuity From Baseline|Changes in Intraocular Pressure (IOP)|Changes in Central Subfield Thickness|Changes in Macular Volume	https://ClinicalTrials.gov/show/NCT02472366
306	NCT02511067	Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study	Not yet recruiting	No Results Available	Diabetic Macular Edema	Drug: Tocilizumab|Drug: Ranibizumab	University of Nebraska|Genentech, Inc.	Both	Adult|Senior	Phase 2	66	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label	ML29813	July 27, 2015	October 2015	October 2017	July 27, 2015	July 2015	No Study Results Posted	READ-4	April 2017	Adverse Events|Anatomic Retinal Changes|Visual Acuity|Rescue Therapy	https://ClinicalTrials.gov/show/NCT02511067
307	NCT01876914	Pilot Study of OCT Versus Fluorescein Angiography in DME	Active, not recruiting	No Results Available	Diabetic Macular Edema		Oregon Health and Science University|Oregon Clinical & Translational Research Institute	Both	Adult|Senior		28	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	OHSU IRB #9361|8UL1TR000128-07	June 6, 2013	June 2013	June 2015	April 21, 2015	April 2015	No Study Results Posted	OCT and DME	June 2015	Total retinal blood flow & visual acuity|Macular ischemic areas and microaneurysms, as identified by FA vs. OCT|The degree of parafoveal ischemia as identified by OCT and visual acuity	https://ClinicalTrials.gov/show/NCT01876914
308	NCT02299336	Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial	Active, not recruiting	No Results Available	Diabetic Macular Edema	Drug: Aflibercept|Procedure: Focal Laser	Greater Houston Retina Research|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 4	35	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	The Endurance 1 Trial	October 15, 2014	October 2014	January 2016	June 22, 2015	June 2015	No Study Results Posted	null	January 2016	Need for ongoing intravitreal aflibercept injections for subjects who were enrolled and completed the 3-year VISTA DME (VGFT-OD-1009) trial|Measure longer-term efficacy of intravitreal aflibercept injections in the management of DME|Measure the role of focal laser treatment (fluorescein angiography-guided, if applicable) in decreasing the treatment burden among subjects who require ongoing aflibercept treatment in the management of DME|Measure the role of (ultrawide-field, if available) baseline vs 52 week fluorescein angiography-determined retinal ischemia in predicting past and future anti-VEGF treatment burden, anatomic and visual outcomes:	https://ClinicalTrials.gov/show/NCT02299336
309	NCT02107131	Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab	Recruiting	No Results Available	Diabetic Macular Edema	Drug: Intravitreal ranibizumab 0.3mg	California Retina Consultants	Both	Adult|Senior	Phase 2|Phase 3	60	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ML29184s	April 2, 2014	May 2014	null	July 28, 2015	July 2015	No Study Results Posted	ERASER	December 2016	Maximum Reading Speed|Change in work productivity|Change in visual acuity|Change in contrast sensitivity	https://ClinicalTrials.gov/show/NCT02107131
310	NCT02297204	The Endurance 1 Trial	Enrolling by invitation	No Results Available	Diabetic Macular Edema	Procedure: Focal Laser Treatment|Drug: aflibercept 2.0 mg	Northern California Retina Vitreous Associates|Regeneron Pharmaceuticals	Female	Adult|Senior	Phase 4	10	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label	REG-2014-11-006	November 14, 2014	November 2014	March 2016	November 20, 2014	November 2014	No Study Results Posted	Endurance	January 2016	Need for ongoing intravitreal aflibercept injections in the management of DME|Vision change|Vision loss|Change in central retinal thickness|Development of clinically relevant diabetic macular edema|Role of focal laser treatment in management of DME (Proportion of subjects that receive focal laser treatment and mean number of intravitreal aflibercept injections before and after receiving focal laser treatment.)|Evaluation of Diabetic Retinopathy (Proportion of subjects with stable, worsened, or improved diabetic retinopathy as identified by eye examination and imaging.)|Ocular and systemic adverse events	https://ClinicalTrials.gov/show/NCT02297204
311	NCT02325271	Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers	Recruiting	No Results Available	Diabetic Macular Edema	Other: Frequent blood and urine sampling and blood pressure measurement	GWT-TUD GmbH|Novartis	Both	Adult|Senior		40	Other|Industry	Observational	Observational Model: Case Control|Time Perspective: Prospective	VEGF Bio	December 19, 2014	February 2015	December 2015	February 24, 2015	February 2015	No Study Results Posted	null	August 2015	VEGF-A|VEGF-B|VEGF-C|Placental growth factor|Glycated hemoglobin (HbA1c)|High-sensitivity C-reactive protein (hCRP)|Matrix metallopeptidase 9 (MMP-9)|MMP-9|Adiponectin|Cystatin C|Albumin|Creatinine|Blood pressure	https://ClinicalTrials.gov/show/NCT02325271
312	NCT01767545	Dexamethasone-implant for the Treatment of RVO	Completed	No Results Available	Macular Edema Caused by Retinal Vein Occlusion	Drug: Dexamethasone implant|Drug: Bevacizumab	Ludwig-Maximilians - University of Munich	Both	Adult|Senior	Phase 4	64	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label	Mayer-DEX-001	January 9, 2013	September 2010	February 2012	January 10, 2013	January 2013	No Study Results Posted	null	January 2011	The primary clinical endpoint was BCVA twelve months after the first intravitreal treatment.|Central retinal thickness|Lens opacity|Saftey of procedure	https://ClinicalTrials.gov/show/NCT01767545
313	NCT02080091	Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies	Terminated	Has Results	Diabetic Macular Edema (DME)		Alimera Sciences	Both	Adult|Senior		25	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	M-01-13-003	March 3, 2014	December 2013	April 2015	August 14, 2015	August 2015	July 15, 2015	ILUMINATE	March 2015	Visual Acuity|Number of Patients With Ocular Adverse Events|Retinal Center Subfield Thickness	https://ClinicalTrials.gov/show/NCT02080091
314	NCT02555956	Grid Laser for Diffuse Diabetic Maculopathy	Completed	No Results Available	Diabetic Macular Edema		Dow University of Health Sciences	Both	Adult|Senior		50	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	Macular Grid Laser	August 6, 2015	April 2012	December 2014	September 20, 2015	September 2015	No Study Results Posted	MMG	December 2014	Improvement of visual acuity after grid laser|Complication	https://ClinicalTrials.gov/show/NCT02555956
315	NCT01945892	Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome	Completed	No Results Available	Macular Edema|Visual Acuity	Drug: Ozurdex	Ludwig-Maximilians - University of Munich|Allergan	Both	Adult|Senior		23	Other|Industry	Observational	Observational Model: Case Control|Time Perspective: Prospective	MAF/ISS/OPH/RET/011	September 16, 2013	November 2011	July 2013	September 18, 2013	September 2013	No Study Results Posted	null	June 2013	Visual acuity|Retinal Thickness|Intraocular pressure	https://ClinicalTrials.gov/show/NCT01945892
316	NCT02207712	Noctura400 Treatment for Diabetic Retinopathy (CANDLE)	Not yet recruiting	No Results Available	Diabetic Macular Oedema	Device: Noctura 400 Eye Mask|Drug: Ranibizumab	PolyPhotonix Medical	Both	Adult|Senior		240	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	2014RM02	July 24, 2014	September 2014	September 2016	July 31, 2014	July 2014	No Study Results Posted	CANDLE	February 2016	The mean difference between trial arms in the number of intravitreal injections of ranibizumab required by each study eye at 48 weeks|Mean difference between treatment arms in change from baseline Central sub-field thickness at 48 Weeks|Mean difference between treatment arms in change from baseline best corrected visual acuity at 48 weeks.|Mean difference between treatment arms in utility (quality of life) as assessed by EQ-5D.|Mean difference between treatment arms in the number of ranibizumab injections required|Change in Central sub-field thickness over time|Pattern of injections given over the period of 48 weeks in both arms.|Adverse events rates	https://ClinicalTrials.gov/show/NCT02207712
317	NCT02337972	Conjunctival Flora Patterns After Serial Intravitreal Injections in Diabetic Patients	Recruiting	No Results Available	Diabetic Retinopathy|Diabetic Macular Edema	Drug: povidone-iodine 4%	Sheba Medical Center|Assaf-Harofeh Medical Center	Both	Adult|Senior		50	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	Sheba_Medical_Center	January 1, 2015	January 2015	January 2016	February 19, 2015	February 2015	No Study Results Posted	null	December 2015	Change of conjunctival flora and bacterial resistance	https://ClinicalTrials.gov/show/NCT02337972
318	NCT01827722	Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion	Recruiting	No Results Available	Macular Edema Following Central Retinal Vein Occlusion	Drug: Ozurdex|Drug: Ranibizumab|Drug: Combination Ozurdex with Ranibizumab PRN	Valley Retina Institute	Both	Adult|Senior	Phase 4	45	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	ORION	April 4, 2013	May 2013	null	July 5, 2013	July 2013	No Study Results Posted	ORION	May 2014	Best Corrected Visual Acuity	https://ClinicalTrials.gov/show/NCT01827722
319	NCT02140164	Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa	Recruiting	No Results Available	Retinitis Pigmentosa	Drug: Minocycline	National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)	Both	Child|Adult|Senior	Phase 1|Phase 2	10	NIH	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	140108|14-EI-0108	May 14, 2014	May 2014	May 2016	March 31, 2015	March 2015	No Study Results Posted	null	May 2016	Change in CME based on OCT measurements in the study eye at 6 months compared to pre-treatment values|The number and severity of AEs. Ocular safety outcomes will be changes not consistent with the natural progression of RP.|Changes in OCT, ERG, microperimetry and HVF 30-2. Pre-treatment measurements will be analyzed to measure the natural variability of the CME as well as the functional testing.	https://ClinicalTrials.gov/show/NCT02140164
320	NCT02478515	Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion	Recruiting	No Results Available	Branch Retinal Vein Occlusion	Drug: Ranibizumab	Nagoya City University|Novartis	Both	Adult|Senior	Phase 4	30	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	PRNNCU001	January 26, 2015	January 2014	September 2017	June 18, 2015	June 2015	No Study Results Posted	null	September 2016	Visual acuity|central foveal thickness	https://ClinicalTrials.gov/show/NCT02478515
321	NCT01857544	Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy	Active, not recruiting	No Results Available	Retinal Vein Occlusion	Drug: Aflibercept	Tennessee Retina|Regeneron Pharmaceuticals	Both	Adult|Senior	Phase 4	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	VGFT-OD-1313	May 16, 2013	June 2013	March 2016	October 27, 2014	October 2014	No Study Results Posted	null	January 2016	Complete anatomic resolution of macular edema following central retinal vein occlusion (CRVO) as measured by Optical Coherence Tomography (OCT)|Extent of reduction in macular thickness|Extent of reduction in macular volume|Mean change in best-corrected visual acuity (BCVA)|Proportion of patients with gain or loss of 5, 10, and 15 letters in BCVA|Number and severity of adverse events	https://ClinicalTrials.gov/show/NCT01857544
322	NCT01908816	An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.	Recruiting	No Results Available	Choroidal Neovascularization|Macular Edema|Glaucoma, Neovascular|Diabetic Retinopathy	Drug: ranibizumab	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 3	500	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CRFB002GFR02	July 20, 2013	September 2013	September 2017	June 2, 2015	June 2015	No Study Results Posted	ECLIPSE	September 2017	Rate and severity of serious and non-serious, ocular and non-ocular adverse events|Average change of BCVA for patients with CNV and ME|Average change of neovascularization extension for patients with neovascular glaucoma|Proportion of patient with Vitreous Cavity Hemorrhage occurrence for patient with proliferative retinopathy	https://ClinicalTrials.gov/show/NCT01908816
323	NCT01968616	Ranibizumab Treatment for Retinal Vein Occlusion	Recruiting	No Results Available	Macular Edema Due to BRVO/CRVO	Drug: Ranibizumab, 0.5mg, Intravitreal	Kyoto University, Graduate School of Medicine|Novartis	Both	Adult|Senior		100	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	KY-RV-R	October 20, 2013	September 2013	null	September 1, 2015	September 2015	No Study Results Posted	null	September 2016	Mean foveal thickness measured by SD-OCT	https://ClinicalTrials.gov/show/NCT01968616
324	NCT01978015	Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG	Completed	No Results Available	Uveitis, Anterior|Cystoid Macular Edema	Drug: travoprost and timolol maleate fixed combination|Drug: latanoprost and maleate timolol fixed combination|Drug: bimatoprost and timolol maleate fixed combination|Drug: dextran and hypromellose	University of Campinas, Brazil	Both	Adult|Senior	Phase 4	69	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	CEP424/2010|CAAE0319014600010	October 25, 2013	October 2011	January 2013	October 31, 2013	October 2013	No Study Results Posted	null	July 2012	Change of mean flare values from baseline at 6 months|Change of mean macular thickness values from baseline at 6 months	https://ClinicalTrials.gov/show/NCT01978015
325	NCT02232503	Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia	Not yet recruiting	No Results Available	Diabetic Retinopathy|Diabetic Macular Edema|Diabetes Mellitus	Genetic: Studied cohort	Novartis Slovakia, s.r.o.|Medirex Group Academy|Slovak Technical University|Faculty of Natural Sciences of Comenius University	Both	Adult|Senior		5000	Industry|Other	Observational	Time Perspective: Cross-Sectional	CRFB002DSK01	September 3, 2014	September 2014	September 2015	September 9, 2014	September 2014	No Study Results Posted	DIARET SK	March 2015	The prevalence of diabetic retinopathy as the proportion of patients with DR (any stage) in a given subgroup according to DM duration|Evaluate the prevalence and individual stages of Diabetic Retinopathy in patients with type 1 and type 2 DM verified based on complex ophthalmologic measurements|Evaluate the prevalence and individual stages of Diabetic Macular Edema (DME) in patients with type 1 and type 2 DM verified based on complex ophthalmologic measurements|Evaluate the impact of risk factors on the prevalence of Diabetic Retinopathy and Diabetic Macular Edema	https://ClinicalTrials.gov/show/NCT02232503
326	NCT02000102	Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab	Completed	No Results Available	Diabetic Macular Edema	Drug: Intravitreal Injection of Aflibercept	Stanford University	Both	Adult|Senior		14	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	28279	November 26, 2013	September 2013	September 2014	November 17, 2014	November 2014	No Study Results Posted	null	September 2014	Visual Acuity|Central Subfield Thickness on Optical Coherence Tomography	https://ClinicalTrials.gov/show/NCT02000102
327	NCT01832077	Uptake of Telemedicine System Trial in Rual Canton	Active, not recruiting	No Results Available	Diabetes Retinopathy|Diabetes Macular Edema	Device: 90 D|Device: fundus camera and grader	Sun Yat-sen University|Orbis|The World Diabetes Foundation	Both	Adult|Senior		5000	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	ZOC-WDF-Telemedicine	April 11, 2013	April 2013	August 2015	May 20, 2013	May 2013	No Study Results Posted	null	May 2015	Accuracy of trained doctors in diagnosing DR/DME versus photo grading and automated grading|cost-effectiveness|Frequency of comprehensive eye examination taken by rural doctors|comprehensive eye examination rate among patients in rural hospitals|the usage rate of Electric-Record|Cost-effectiveness of van	https://ClinicalTrials.gov/show/NCT01832077
328	NCT01988246	Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery	Recruiting	No Results Available	Diabetic Retinopathy	Drug: Aflibercept|Drug: Sham	Rishi Singh|Regeneron Pharmaceuticals|The Cleveland Clinic	Both	Adult|Senior	Phase 1|Phase 2	30	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject)	PROMISE Trial	October 30, 2013	December 2013	September 2016	August 31, 2015	August 2015	No Study Results Posted	PROMISE	June 2016	Safety and Efficacy|Visual Acuity	https://ClinicalTrials.gov/show/NCT01988246
329	NCT02424019	Phase 4 IOP Signals Associated With ILUVIEN®	Recruiting	No Results Available	Diabetic Macular Edema (DME)	Drug: ILUVIEN®	Alimera Sciences	Both	Child|Adult|Senior	Phase 4	300	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	M-01-15-004	April 18, 2015	April 2015	April 2019	October 19, 2015	October 2015	No Study Results Posted	PALADIN	April 2019	Intraocular Pressure	https://ClinicalTrials.gov/show/NCT02424019
330	NCT02425501	Special Drug Use Investigation of EYLEA for Diabetic Macular Edema	Recruiting	No Results Available	Choroidal Neovascularization	Drug: Aflibercept (Eylea, BAY86-5321)	Bayer	Both	Child|Adult|Senior		600	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	17544|EY1510JP	April 21, 2015	January 2015	May 2019	October 14, 2015	October 2015	No Study Results Posted	null	May 2019	Number of participants of Adverse Events|Number of participants of Serious Adverse Events|Mean change in visual acuity from baseline to 12 months|Mean change in retina thickness from baseline to 12 months	https://ClinicalTrials.gov/show/NCT02425501
331	NCT01766362	Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.	Recruiting	No Results Available	Diabetes Type 1 or 2 With Diabetic Retinopathy.	Procedure: PRPC using Pascal laser	Centre Hospitalier Universitaire Dijon	Both	Adult|Senior	Phase 3	90	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	Creuzot Innov 2010	January 10, 2013	October 2011	null	January 10, 2013	January 2013	No Study Results Posted	Pascal	October 2013	Macular thickness	https://ClinicalTrials.gov/show/NCT01766362
332	NCT02091505	Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO	Recruiting	No Results Available	Central Retinal Vein Occlusion	Drug: Ranibizumab	Mie University	Both	Adult|Senior		30	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	MKONDO-CRVO	March 16, 2014	December 2013	null	March 17, 2014	March 2014	No Study Results Posted	CRVO	May 2016	Best-corrected visual acuity	https://ClinicalTrials.gov/show/NCT02091505
333	NCT02032238	Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema	Completed	No Results Available	Clinically Significant Macular Edema	Device: Navigated laser|Drug: Anti-VEGF Injections	OD-OS GmbH	Both	Adult|Senior		12	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	CAVNAV-2	January 8, 2014	March 2013	June 2015	June 29, 2015	June 2015	No Study Results Posted	null	June 2015	Percentage of eyes that received retreatment	https://ClinicalTrials.gov/show/NCT02032238
334	NCT02349516	Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)	Withdrawn	No Results Available	Diabetic Retinopathy	Drug: Squalamine Lactate Ophthalmic Solution 0.2%	Starr Muscle|Ohr Pharmaceutical Inc.|NJ Retina	Both	Adult|Senior	Phase 2	0	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	Ohr-005	June 2, 2014	February 2015	September 2015	September 28, 2015	September 2015	No Study Results Posted	null	September 2015	To explore the effect of Squalamine Lactate eye drops on Best Corrected Visual Acuity in subjects with diabetic macular edema|To assess the change in Central Retinal Thickness|To assess need for rescue injections of Ranibizumab 0.3mg|To assess the safety and tolerability of Squalamine Eye Drops, measured by ophthalmic examination, the recording and evaluation of clinical AEs	https://ClinicalTrials.gov/show/NCT02349516
335	NCT02140411	Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.	Not yet recruiting	No Results Available	Efficacy and Safety of Ranibizumab (Lucentis)	Drug: Lucentis Intravitreal injections	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 4	60	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CRFB002DCL01	May 14, 2014	June 2014	April 2015	April 13, 2015	April 2015	No Study Results Posted	null	April 2015	Mean Change from baseline in Best Correct Visual Acuity (BCVA)|National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) composite score	https://ClinicalTrials.gov/show/NCT02140411
336	NCT02462304	To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema	Recruiting	No Results Available	Diabetic Macula Edema	Procedure: End-Point-Management grid laser|Drug: ranibizumab|Drug: Bevacizumab	The University of Hong Kong|Nagoya City University|Asahikawa Medical College|University of Fukui|Eguchi Eye Clinic|Kyoto University|Nagasaki University|Osaka Medical College|Kyushu University|Tokyo Medical University Hachioji Medical Centre|Hokkaido University|Kyorin University|Inje University|Pusan National University School of Medicine|Kyungpook National University|Chungnam National University Hospital|Sun Cheon Hyang University              |Kyunghee University|Yeungnam University|Korea University|National University Hospital, Singapore|Yamagata University	Both	Adult|Senior	Phase 4	60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	END-DME1	March 23, 2015	June 2015	May 2016	June 15, 2015	June 2015	No Study Results Posted	END-DME	December 2015	Difference in number of anti-VEGF required|Change in best corrected visual acuity|Central retinal thickness|Treatment related complications|Recurrence of macular edema	https://ClinicalTrials.gov/show/NCT02462304
337	NCT02522897	Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas	Not yet recruiting	No Results Available	Central Retinal Vein Occlusion With Macular Edema	Drug: Ranibizumab|Device: Laser	PD. Dr. med. Armin Wolf|University Hospital, Bonn|Ludwig-Maximilians - University of Munich	Both	Adult|Senior	Phase 4	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	EXT-201302-Pearl	August 4, 2015	August 2015	January 2018	August 11, 2015	August 2015	No Study Results Posted	PEARL	January 2018	Differences in the length of the treatment-free interval in patients with or without panretinal photocoagulation|Number of Injections|Retinal thickness in µm measured by spectral domain (SD)-Optical coherence tomography (OCT) at end-of-study visit|Visus at end-of-study visit|Percentage of patients with retinal thickness of more than 220 µm in the OCT examination at the end-of-study visit	https://ClinicalTrials.gov/show/NCT02522897
338	NCT01998412	Iluvien Registry Safety Study	Recruiting	No Results Available	Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies.		Alimera Sciences	Both	Child|Adult|Senior		800	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	M-01-12-001	November 20, 2013	December 2013	null	August 19, 2015	August 2015	No Study Results Posted	IRISS	December 2018	Number of participants with adverse events.	https://ClinicalTrials.gov/show/NCT01998412
339	NCT02194803	Observation of Treatment Patterns With Lucentis in Approved Indications	Recruiting	No Results Available	Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV		Novartis Pharmaceuticals|Novartis	Both	Adult|Senior		4500	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	CRFB002ADE18	June 11, 2014	December 2011	December 2016	June 2, 2015	June 2015	No Study Results Posted	OCEAN	December 2016	Change from Baseline in Visual Acuity (VA) to Month 12|Change from Baseline in Visual Acuity (VA) to Month 24	https://ClinicalTrials.gov/show/NCT02194803
340	NCT02515942	CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)	Recruiting	No Results Available	Geographic Atrophy	Drug: CLG561|Drug: LFG316|Drug: Sham injection	Alcon Research|Novartis Institutes for BioMedical Research (NIBR)	Both	Adult|Senior	Phase 2	114	Industry|Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	CLG561-2201|CCLG561X2201	August 3, 2015	September 2015	June 2018	September 28, 2015	September 2015	No Study Results Posted	null	June 2018	Number of subjects with a serious adverse event that, in the opinion of the investigator, is related to the study drug|Number of subjects experiencing a non-serious adverse event|Change in GA lesion size from baseline to Day 337 as measured by fundus autoflorescence (FAF)|Frequency of serum total CLG561 concentrations below the lower limit of quantification (LLOQ)|Frequency of subjects with anti-CLG561 and anti-LFG316 antibodies|Percent change from baseline in serum total properdin and total C5|Percent change from baseline in serum complement activity|Change in GA lesion size from baseline to Day 85, 169, 253, and 421 as measured by FAF|Change in GA lesion size from baseline to Days 169 and 337 as measured in the study eye and the fellow eye by FAF|Change in Best Corrected Visual Acuity (BCVA)/low luminance visual acuity/low luminance visual acuity deficit from baseline by visit up to Day 337 as measured by early treatment diabetic retinopathy study (ETDRS)|Change in BCVA/low luminance visual acuity/low luminance visual acuity deficit from baseline by visit up to Day 337 as measured in the study eye and the fellow eye by ETDRS|Proportion of subjects with letter change in BCVA from baseline up to Day 337 as measured by ETDRS|Proportion of subjects with letter change in BCVA from baseline up to Day 337 as measured in the study eye and fellow eye by ETDRS	https://ClinicalTrials.gov/show/NCT02515942
341	NCT02503332	Study of of APL-2 Therapy in Patients Geographic Atrophy	Recruiting	No Results Available	Geographic Atrophy	Drug: APL-2|Other: Sham Procedure	Apellis Pharmaceuticals, Inc.	Both	Adult|Senior	Phase 2	240	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	POT-CP121614	July 14, 2015	September 2015	null	October 14, 2015	October 2015	No Study Results Posted	FILLY	September 2016	Primary Efficacy Endpoint: The primary endpoint is the change in square root geographic atrophy (GA) lesion size from baseline at month 12 as measured by FAF.|Primary Safety Endpoint: Number of local and systemic treatment emergent averse events (TEAE).|Primary Safety Endpoint: Severity of local and systemic treatment emergent averse events (TEAE).	https://ClinicalTrials.gov/show/NCT02503332
342	NCT02288559	A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy	Recruiting	No Results Available	Geographic Atrophy	Other: Sham|Drug: lampalizumab	Genentech, Inc.	Both	Adult|Senior	Phase 2	90	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	GX29455	November 7, 2014	March 2015	July 2016	October 1, 2015	October 2015	No Study Results Posted	null	July 2016	Efficacy: Mean change in GA area, as measured by FAF|Safety (composite outcome measure): Incidence and severity of ocular and non-ocular (systemic) adverse events|Pharmacokinetic profile derived from the serum concentration-time data following administration of lampalizumab	https://ClinicalTrials.gov/show/NCT02288559
343	NCT02033668	Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers	Completed	No Results Available	Atrophy, Geographic	Drug: GSK933776 for SQ administration|Drug: GSK933776 for IM administration|Drug: GSK933776 for IV administration	GlaxoSmithKline|Quintiles	Both	Adult	Phase 1	36	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	116891	January 9, 2014	January 2014	July 2014	July 24, 2014	July 2014	No Study Results Posted	null	July 2014	Relative bioavailability of GSK933776 after single dose SQ or IM administration as compared to IV infusion|Relative bioavailability of GSK933776 after repeat dose SQ administration as compared to IV infusion|Composite of PK parameters of GSK933776 following single dose IM and SQ administration as compared to IV administration|Composite of PK parameters of GSK933776 following repeat dose SQ administration as compared to IV administration|Number of participants with adverse events as a measure of safety and tolerability following single dose administration|Clinical observation following IV, SQ and IM single dose administration as a measure of safety and tolerability|Clinical observation following IV, SQ and IM repeat dose administration as a measure of safety and tolerability|Vital sign measurement following single dose administration as a measure of safety and tolerability|Vital sign measurement following repeat dose administration as a measure of safety and tolerability|Electrocardiogram (ECG) measurement following single dose administration to assess safety and tolerability|ECG measurement following repeat dose administration to assess safety and tolerability|Clinical laboratory parameters assessment following single dose administration as a measure of safety and tolerability|Clinical laboratory parameters assessment following repeat dose administration as a measure of safety and tolerability|Plasma concentrations of GSK933776, total amyloid beta (AB), total AB fragments, as well as unbound concentrations of AB, fragments containing the epitope 1-22, as data permit following single dose administrationof GSK933776|Plasma concentration of GSK933776, AB, total AB fragments, as well as unbound concentrations of AB, fragments containing the epitope 1-22, as data permit following repeat dose administration|Presence of antibodies to GSK933776 in serum samples following single dose administration of GSK933776|Presence of antibodies to GSK933776 in serum samples following repeat dose administration	https://ClinicalTrials.gov/show/NCT02033668
344	NCT01890187	Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium	Completed	No Results Available	Advanced Dry AMD With Geographic Atrophy		Carl Zeiss Meditec, Inc.|DataMed Devices Inc.	Both	Adult|Senior		85	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	HD-OCT-GA-2010-2	June 24, 2013	November 2010	February 2011	June 27, 2013	June 2013	No Study Results Posted	null	February 2011	Coefficient of variation for area of increased illumination under the RPE (mm^2)|Coefficient of variation of the closest distance to fovea	https://ClinicalTrials.gov/show/NCT01890187
345	NCT01853930	Translation of Eye Movement Reading Training to Clinical Practice	Recruiting	No Results Available	Macular Disease	Behavioral: PAECT (Platform for Administering Eye movement Control Training).	VA Office of Research and Development	Both	Adult|Senior	Phase 1	70	U.S. Fed	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	C0849-R	May 2, 2013	January 2014	June 2017	June 22, 2015	June 2015	No Study Results Posted	null	February 2017	Change in reading performance and accuracy using MNREAD and VIEWSENTANCES test	https://ClinicalTrials.gov/show/NCT01853930
346	NCT02103738	Canadian Treat and Extend Analysis Trial With Ranibizumab	Recruiting	No Results Available	wetAMD	Other: 0.5 mg Ranibizumab intravitreal injections	Novartis Pharmaceuticals|Novartis	Both	Adult		580	Industry	Observational	Time Perspective: Prospective	CRFB002ACA06	February 18, 2014	May 2013	May 2017	June 2, 2015	June 2015	No Study Results Posted	CAN-TREAT	May 2017	Mean Change in Visual Acuity|Proportion of patients with a gain of equal or more than 5, 10, and 15 letters between the 2 treatment arms.|Proportion of patients with a loss of less than 5, 10, and 15 letters between the 2 treatment arms from baseline to Month 12 and from baseline to Month 24.|Proportion of patients with a loss of less than 5, 10, and 15 letters between the 2 treatment arms.|Mean change in BCVA ETDRS between the 2 treatment arms at Month 12 compared to Month 3.|Mean change in BCVA ETDRS between the 2 treatment arms.|Number of injections performed in each treatment arms.	https://ClinicalTrials.gov/show/NCT02103738
347	NCT01959724	Macular Detachment Associated With Intrachoroidal Cavitation	Completed	No Results Available	Macular Detachment|Macular Retinoschisis|Intrachoroidal Cavitation	Other: Vitrectomy	Kyorin University	Both	Child|Adult|Senior		69	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Kyorineye012|Kyorineye12	October 7, 2013	April 2007	September 2013	October 8, 2013	October 2013	No Study Results Posted	null	March 2013	Visual acuity|Optical coherence tomography	https://ClinicalTrials.gov/show/NCT01959724
348	NCT01862627	Macular Retinoschisis and Detachment Associated With Glaucomatous Optic Neuropathy	Completed	No Results Available	Macular Retinoschisis|Macular Detachment|Normal Tension Glaucoma	Procedure: Optical coherence tomography	Kyorin University	Both	Child|Adult|Senior		11	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	Kyorineye011	May 15, 2013	December 2004	null	August 18, 2014	August 2014	No Study Results Posted	null	April 2013	Optical coherence tomography|Visual recovery	https://ClinicalTrials.gov/show/NCT01862627
